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1.1 Epidemiology and clinical presentation of psoriasis
1.1.1 Epidemiology
Psoriasis vulgaris (also known as (a.k.a.) psoriasis when mentioned in the 
rest of this thesis) was erroneously recognized and described as a variant 
of leprosy in ancient times. However in 1841 Ferdinand von Hebra deﬁned
psoriasis as it is known nowadays.1 Psoriasis is a common, inﬂammatory,
chronic, relapsing skin disorder aﬀecting 1-3 % of the worldwide Cauca-
sian population.2-4 Despite this roughly estimated prevalence of psoriasis 
in the general Caucasian population, ethnic factors and geographical re-
gions seem to inﬂuence the prevalence as signiﬁcant diﬀerences are ob-
served among Japanese, West-Africans, Samoans, North American blacks 
and  Native Americans.5-7 Men and women are equally aﬀected.7 Psoriasis 
can present at any age. Nevertheless a bimodal age of onset has been rec-
ognized in several large studies distinguishing a mean age of onset on or 
before the age of 40 years (type I psoriasis) or beginning after the age of 40 
years with a peak occurring at 55-60 years (type II psoriasis).8-10 Type I dis-
ease accounts for more than 75% of cases and demonstrates a strong asso-
ciation with HLA-Cw6 as a genetic marker. Patients with late-onset psoriasis 
often have less severe skin involvement.8;9;11 In general, patients frequently 
report a family history of psoriasis.
Genetic disposition appears to play an important role in the susceptibility 
to develop psoriasis. Population studies have shown that the incidence of 
psoriasis is greater in ﬁrst and second degree relatives of patients than in
the general population. Moreover, as brieﬂy mentioned above, several HLA-
types are associated with psoriasis.12 There is evidence that multiple genes 
are involved and this has led to the identiﬁcation of diﬀerent psoriasis-sus-
ceptibility loci. The exact locations of the genes involved however, remain 
to be deﬁnitely identiﬁed.3;13
1.1.2 Clinical features and presentations 
Psoriasis is a skin disease with variable distribution, severity, course and 
morphology as the psoriatic phenotype has a changing spectrum of dis-
ease expression.  
The commonest type of psoriasis is psoriasis vulgaris, also designated as 
chronic plaque psoriasis, and accounts for approximately 90% of all cases. 
It is a papulosquamous disease in which the lesions have a red or salmon 
pink colour covered by dry white or silvery scales and are well-delineated 
from surrounding normal skin (ﬁgure 1). The amount of scaling and indu-
ration of plaques varies among patients and at diﬀerent sites on a patient.
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The lesions may initially begin as erythematous macules or papules and 
coalesce to form plaques of one to several centimeters in diameter. Fre-
quently, lesions are slightly raised and most active at the edge as they are 
known to expand centrifugally. The scales are only lightly attached and can 
be easily peeled. Upon peeling several layers at once, point bleeding can 
occur in the dermal papillae named “Auspitz’ sign”.
The distribution is typical as the lesions are predominantly located sym-
metrically on the extensor side of the extremities, the lumbosacral region, 
umbilicus and the scalp. This thesis focuses on this type of psoriasis.
Psoriasis guttata, from the Greek word ‘gutta’ meaning a droplet, describes 
the acute onset of these droplet-like lesions disseminated over the body. 
Classically, guttate psoriasis occurs shortly after an acute group B haemo-
lytic streptococcal infection or viral infection of the pharynx or tonsils14-16 
and can be the presenting episode of psoriasis, mainly in children.11 In 
adults guttate ﬂares may complicate chronic plaque type psoriasis, some-
times triggered by a sudden cessation of an anti-psoriatic treatment. Gut-
tate psoriasis is known to be self-limiting, resolving within 3-4 months of 
onset.12
Psoriasis inversa (inverse psoriasis) appears as shiny, red plaques in inter-
triginous areas, particularly infra- and submammary, perineal and axillary, 
where scaling is minimal (ﬁgure 2). Occasionally these lesions are com-
bined with candidal, intertrigo and dermatophyte infections. 
In psoriatic erythroderma, the whole body surface is aﬀected by psoriasis,
which can lead to hypothermia, hypoalbuminaemia and high output car-
diac failure eventually rendering it a possible life-threatening condition. On 
one hand chronic plaque psoriasis can progress as plaques become conﬂu-
ent and extensive, on the other hand erythroderma may be a manifestation 
of unstable psoriasis precipitated by infection, drugs or withdrawal of anti-
psoriatic therapies.
Generalized pustular psoriasis, also known as Von Zumbusch psoriasis, is an 
acute rare form in which small, monomorphic sterile pustules develop in 
painful inﬂamed skin and can coalesce to form large aﬀected areas ﬁlled
with pus. Precipitants include intercurrent infection and acute withdrawal 
of systemic and, on occasion, ultrapotent topical corticosteroids.17  Local-
ized forms include palmoplantar pustulosis (a.k.a morbus Andrews-Barber) 
and acrodermatitis continua of Hallopeau, consisting of yellow-brown, ster-
ile pustules on a background of erythema and scaling aﬀecting the palms
and / or soles (ﬁgure 2). Approximately 25% of cases are associated with 
classic psoriasis vulgaris but genetic analysis has implied they can have dif-
ferent causes.18 The demographics are markedly diﬀerent from those of the
classic variant in that it more commonly aﬀects women (9:1), onset occurs
in the 4th or 5th decade and has a strong association with smoking either 
current or past.19
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Psoriasis is not only limited to the skin. Extracutaneous manifestations can 
aﬀect patients considerably in their daily activities. About 10-50% of psori-
atic patients have distinctive nail changes related to psoriasis. Fingernails 
are more commonly aﬀected than toenails.20;21 The commonest ﬁndings in
nail psoriasis, or psoriasis unguium, are small pits in the nail plate, nail plate 
separation at its distal or lateral attachments (onycholysis), orange-yellow 
sub-ungual discolouration (oil spots) and thickening of a dystrophic nail 
(ﬁgure 2). In addition, yellow, keratinous material may collect under the 
nail plate and is known as subungual hyperkeratosis.12;20;21
Psoriatic arthritis (PsA) is a seronegative inﬂammatory arthritis that can oc-
cur in the presence of psoriasis.12 The presence of inﬂammatory arthritis
in patients with psoriasis varies between 5% and 42%.22-24 Around 15% of 
patients with PsA have an onset of arthritis before the onset of psoriasis. 
Classiﬁcation Criteria for Psoriatic Arhritis25 have recently been developed 
reﬂecting a diverse range of clinical patterns that can change by time and
by the inﬂuence of therapy. In general the classical psoriatic arthritis con-
sists of oligoarthritis, distal interphalangeal joint involvement, dactylitis 
and calcaneal enthesitis.26 A classical radiological hallmark of PsA are mar-
ginal erosions with adjacent proliferation of bone, joint-space narrowing 
and periostitis.27 No serologic markers exist for the diagnosis. There are 
conﬂicting data addressing the question whether PsA is as destructive as
rheumatoid arthritis. Nevertheless, the quality of life and functionality are 
signiﬁcantly reduced in PsA patients.24 
Moreover, psoriasis deeply aﬀects well-being and has emotional and rela-
tional consequences that go far beyond the skin.28;29 The impact of psoriasis 
on quality of life can even be considered similar as compared to other ma-
jor medical diseases such as cancer, depression, heart disease, diabetes and 
hypertension.30
Figure 1 Typical clinical presentation of psoriasis vulgaris with sharply delineated ery-
thematous plaques covered by silvery white scales.
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1.1.3 Clinical course and triggering factors
The course of psoriasis is as ﬂuctuating as its distribution and morphology.
Every patient has a unique typical disease history, although usually char-
acterized by exacerbations and remissions. On the one hand, the disease 
process can remain changeless over years, on the other hand worsening 
and ﬂares can surprise the patient and dermatologist adventitiously. The
ﬂuctuating course can be inﬂuenced by triggering factors. For many pa-
tients, the symptoms of psoriasis are subject to environmental factors as 
they frequently improve in the summer and worsen in the winter. Physi-
cal trauma may trigger psoriatic lesions at sites of injury, a.k.a. Koebner’s 
phenomenon.6 A positive Koebner reaction predicts subsequent disease 
activity.31 Drug-induced ﬂares are well-known to induce exacerbations, e.g.
Chapter 1
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β-receptor blockers, lithium, chloroquine, non-steroidal anti-inﬂammatory
agents, tetracyclines and interferons.14;32 In addition, psychogenic stress has 
been reported to be a triggering factor in patients with psoriasis. As men-
tioned before, infections, in particular streptococcal infections of the upper 
respiratory tract, have been recognized as triggers of psoriasis as well.14-16
1.1.4 Associated diseases
Awareness is increasing that psoriasis as a disease is more than skin deep.33 
Psoriasis can be associated with other diseases, which have a major impact 
on patients. Not only psoriatic arthritis is included herein, but more recently 
epidemiological investigations have documented that diabetes, hyperten-
sion, hyperlipidemia, alcohol consumption, smoking and increased BMI 
are associated with both mild and severe psoriasis.34-38 These ﬁndings sug-
gest that psoriasis is associated with the complex disorder of metabolic 
syndrome which incorporates hypertension, dyslipidemia, central obesity 
and impaired glucose tolerance.36;39;40 This association is stronger in patients 
with severe psoriasis compared with those with mild psoriasis. The meta-
bolic syndrome is a strong predictor of cardiovascular diseases, diabetes 
and stroke.41-43 Even severe, but not mild, psoriasis was recently associated 
with an increased risk of death.44
Other associated disorders include Crohn’s disease45;46, depression40 and 
cancer. For the latter it is unclear whether cancers, particularly lymphoma47 
and skin cancer48, are related to psoriasis or to its treatment.12
1.2 Histopathological features of the psoriatic plaque
In order to understand the histopathology of psoriatic skin, an understand-
ing of the basic normal histology of the skin is essential. The skin can be 
divided in two seemingly separate layers: the epidermis and dermis. The 
epidermal layer is composed primarily of keratinocytes with minority pop-
ulations of Langerhans cells, melanocytes, neuroendocrine cells and un-
myelinated axons. As the keratinocytes diﬀerentiate into horny cells, they
are arranged in four layers: the basal cell layer (stratum basalis), the sq-
uamous cell layer (stratum spinosum), the granular layer (stratum granu-
losum) and the horny layer (stratum corneum). An additional layer, the 
stratum lucidum, can be recognized in areas that have a thick stratum gran-
ulosum and corneum forming the lowest portion of the stratum corneum, 
especially on the palms and soles.49 The undersurface of the epidermis is 
undulant with downward invaginations termed rete, and interdigitating 
mesenchymal cones termed dermal papillae. The epidermis is separated 
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from the dermis by the basement membrane zone. The dermis consists of 
endothelial and neural cells and supporting elements, ﬁbroblasts, mono-
cytes and macrophages and mast cells enveloped within a matrix of col-
lagen and glycosaminoglycan. Adnexa extend from the epidermis into the 
dermis and consist of specialized cells for hair growth, epithelial renewal 
and temperature regulation. The subcutis is an underlying cushion formed 
by cells engorged with lipid and cultivated by vessels that grow within thin 
intervening septa.49 The diagnosis of psoriasis relies almost entirely on the 
reviewed characteristic clinical features, and skin biopsy for histopathologic 
review is usually not required. However, the histopathology is characteristi-
cally conﬁrmative and of additional value to correlate the clinical signs and
symptoms with histopathologic changes.
As a consequence of the course of remissions and exacerbations of psoria-
sis, the histopathologic ﬁndings can vary with the age of the lesions.50-52 
In general, psoriasis has three main histopathological features (ﬁgure 3):
     1. epidermal hyperplasia with epidermal thickening
     2. dilated, elongated and increased prominent superﬁcial capillaries  
 in the dermis
     3. a predominantly intra-dermal inﬂammatory inﬁltrate of mainly T-cells
Hyperproliferation of keratinocytes in the epidermis is a prominent feature 
in the psoriatic plaque. Basal keratinocytes maintain expression of Keratin 
5 and Keratin 14 (the keratins typical of basal keratinocytes in normal skin), 
whereas Keratin 1 and Keratin 10 (the keratins typical of suprabasal cells in 
normal skin) are replaced by so-called hyperproliferation-associated keratins 
Keratin 6 and Keratin 16, in addition to Keratin 17.53-57 The mitotic activity of 
basal keratinocytes is increased by a factor 50 in psoriatic skin. As a result, 
keratinocytes only need 3-5 days in order to move from the basal layer to 
the corniﬁed layer as opposed to the normal of 28-30 days. This increased
recruitment of keratinocytes becoming cyclic in the psoriatic epidermis can 
be visualized by staining the Ki67 nuclear antigen. Ki67 is an representative 
marker to determine the growth fraction of the keratinocytes.58
Due to the increased proliferation of keratinocytes, epidermal rete ridges 
become very elongated and form long, thin downward projections into the 
dermis.59 Consequently, the epidermis that lies immediately above the der-
mal papillae is thinned (suprapapillary plate thinning). 
The signiﬁcant reduced transition time of keratinocytes is accompanied
by altered diﬀerentiation, reﬂected by the focal reduction or absence of
the granular layer of the epidermis and parakeratosis.6 The terminally dif-
ferentiated keratinocytes fail to stack normally and adhere to each other 
causing the typical psoriatic scaling. Besides being in a hyperproliferative 
state, keratinocytes are also described to be highly immunologically active 
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participating in and modulating immune reactions in the skin e.g. through 
production of cytokines.
Compared to the abnormalities in psoriatic vasculature, in normal skin the 
superﬁcial micro-vasculature is composed of capillary loops which arise
from terminal arterioles in the upper horizontal dermal vascular plexus, 
pass up into the dermal papillae and arch back to connect with the post-
capillary venules in the horizontal plexus.60 In psoriasis, each papilla con-
tinues to be served by a single capillary loop, but the limbs of the loop are 
twisted along their axis.61;62 There is a fourfold increase in the endothelium 
of the superﬁcial micro-vasculature in lesional skin, but not in the deeper
vasculature indicating that micro-vascular expansion is restricted to the 
upper plexus.63 These papillary vessel changes are uniformly distributed 
throughout clinical lesion.64 Blood ﬂow in plaque skin is also substantially
elevated compared with clinically uninvolved skin and the normal skin.61;65 
This increased vascularity in the psoriatic dermis causes the visible redness 
of psoriatic skin lesions. The vascular abnormalities are probably the most 
neglected feature in the psoriatic pathogenesis (see also paragraph 1.5.4).
The psoriatic inﬁltrate in the dermis varies in density depending on the ex-
tent of activity and involvement of immunecompetent cells. It has a mixed 
Figure 3 Histopathological characteristics of psoriasis. Top left: normal skin of healthy
volunteer, Top right: psoriatic skin (both HE-staining). Bottom left: T-cell inﬁltrate in psoriasis
(CD3; red stained), Bottom right: Prominent vasculature in psoriasis (CD31; red stained).
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composition of cell-types, however the T-cell dominates this composition. 
In the mid-nineties the T-cells gained ground as primary players in the 
pathogenesis.66-71(see also paragraph 1.3)
This thesis touches upon the above-mentioned three main histopathologi-
cal aspects of the pathogenesis of psoriasis in one or the other way. Other 
prominent histological features of psoriasis comprises the polymorphonu-
clear leukocytes / neutrophilic granulocytes, dendritic cells and mast cells. 
Collections of neutrophils within the stratum corneum, the so-called Mun-
ro’s micro abscesses, are present in approximately 75% of the cases. When 
present in the spinous layer they form very characteristic spongiform micro 
pustules of Kogoj.52;72;73 
In psoriasis, antigen-presenting cells (APCs) are of importance for activation 
of T-cells by presenting antigens to the CD4+ and CD8+ T-cells (see para-
graph 1.3.2). Epidermal Langerhans cells (CD1a+, HLA-DR+), dermal den-
dritic cells (CD1a-, HLA-DR+), HLA-DR+ keratinocytes and dermal dendro-
cytes are all APCs relevant in the psoriatic pathogenesis.74
Mast cells are described to inﬁltrate developing psoriatic plaques before
macrophages, T-lymphocytes or neutrophils. Mast cells can produce large 
amounts of TNF, IFN-γ, IL-8 and multiple other mediators.75;76
1.3 Cellular aspects of the immunopathogenesis of
 psoriasis 
Hypotheses of the psoriatic pathogenesis have changed over the decades. 
As the massive epidermal changes have been impressive from the ﬁrst time
researchers examined histological sections of involved psoriatic skin, no 
wonder the investigations were initially concentrated on the keratinocytes.77 
Since then numerous groups have studied and revealed the abnormalities 
in the proliferation and diﬀerentiation of keratinocytes in detail. At the end
of the 1970s an observation was made that shed a completely new light 
onto the explanation of the pathogenesis of psoriasis. Physicians observed 
a clear improvement of psoriasis in patients who were treated with cy-
closporin A (CsA) because of a kidney transplantation.78  The clinical eﬃcacy
was proved in a double-blind placebo-controlled trial of CsA in psoriasis79;80 
and evidence accumulated that the primary mode of action of CsA inhibits 
the proliferation of T-cells and their cytokine production. For this reason, 
these observations were at the basis of a shift in pathogenic hypotheses 
as psoriasis became viewed as an epidermal (keratinocyte) response to im-
munocompetent cell-types. To date, many investigations focus on the T-cell 
mediated pathology and have created an understanding of the biology of 
many aspects of the T-cells. 
Presumably, pathologic activation of both innate and adaptive (T-cells) im-
Chapter 1
General Introduction
27
munity pathways in response to a yet unknown trigger, seems to comprise 
the main principles of the complex immunopathogenesis of psoriasis. Re-
cently, studies have involved the role of innate immunity81-86 and IL-17 me-
diated immune responses87;88 as novel pathogenic insights. However, it is 
beyond the scope of this thesis to fully elaborate on these topics. 
In this thesis, the adaptive immunity response system will be highlighted 
addressing the basic aspects and components of the immunopathogenesis 
of psoriasis in the following paragraphs. 
1.3.1 T-cell subsets 
The range of T-cell subsets can be distinguished by use of the ‘cluster of diﬀer-
entiation’ antigens, a.k.a. CD-markers. The nomenclature is used for the iden-
tiﬁcation and investigation of in particular cell surface molecules on leuko-
cytes. Cell populations are usually deﬁned using a ‘+’ or ‘-‘ symbol to indicate 
whether a certain cell fraction expresses or lacks a CD molecule.89-91 In gen-
eral T-cells are characterized by expression of CD3, the pan T-cell marker.
The psoriatic lesion
In fully developed psoriatic skin lesions, there is a mixture of innate immune 
cells (neutrophils, mast cells, dendritic APCs and NKT cells) and adaptive im-
mune cells (both CD4+ and CD8+ T-lymphocytes) composing and in pres-
ence of the inﬂammatory inﬁltrate. Signals derived from immune cells are
able to stimulate keratinocyte proliferation and inversely keratinocytes may 
activate immune cells through surface receptors and cytokines.92 Laborato-
ry and clinical evidence has led to the statement that Th1- cytokines (IL-12, 
IFN-γ, IL-2) and –T cells predominate in psoriatic plaques.93;94(see paragraph 
1.3.3)
The majority of T-cells that localize to the dermis are of the CD4+ helper 
type, while those that migrate to the epidermis are predominantly of the 
CD8+ cytotoxic type.72;95 In fact the memory eﬀector (CD45RO+) T-cells are
the subtype of T-cells which migrate into skin rather than the CD45RA+ (na-
ive) population.96 Most are positive for cutaneous lymphocyte-associated 
antigen (CLA), a marker for skin-homing leukocytes.95 The epidermal CD8+ 
T-cells express CD103, a β7integrin that characterizes intra-epithelial T-cells 
and facilitates their migration into the epidermis.97 Subsequently, studies 
have shown that both CD4+ and CD8+ T-cells have markers of persistent 
activation such as HLA-DR98 and CD69 surface molecules and the costimu-
latory receptor CD2.99;100 Thus, the major populations of T-cells in the psori-
atic plaque are mature, skin-homing, activated memory cells.
The so-called natural killer (T-)cells (NKT) are part of the innate immune 
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system and have been implicated in the pathogenesis of a variety of auto-
immune diseases such as multiple sclerosis101, type I diabetes mellitus102, in-
ﬂammatory bowel disease103, autoimmune hepatitis104 and systemic lupus 
erythematosus.105;106 In line, natural killer and natural killer T-cells are part of 
the cutaneous inﬂammation in psoriasis.107;108 CD94 receptors are expressed 
on most NK cells and some T-cells, whereas CD161 is an obligate NKT-cell 
receptor.74;109 It has been suggested that NKT cells interact with CD1d, ex-
pressed on keratinocytes in psoriasis, leading to the production of IFN-γ by 
these NKT cells.110 In psoriasis, a signiﬁcant higher number of NKT cells is
present in the psoriatic lesion in comparison with uninvolved and normal 
skin.111 Because of the ability to secrete cytokines such as IFN-γ or IL-4/IL-
13, NKTcells are thought to be important in immunoregulation of mature 
Th1- and Th2-lymphocyte mediated immune responses. The exact function 
in the psoriatic immunopathogenesis of these cells however to date is still 
unclear. 
The past few years, there is mounting interest in T-cells with various im-
munoregulating functions that have been described as regulatory T-cells 
(Treg). These cells play a central role in inducing and maintaining immuno-
logic tolerance and in the termination of immune responses. Deﬁciency or
dysfunction of these cells may lead to auto-immune conditions or aggra-
vated pathogen-induced inﬂammation.112 Naturally arising Treg are CD4+ 
T-cells expressing CD25 (the IL-2 receptor α chain) and are associated with 
the expression of the transcription factor Foxp3.113-116 They have been linked 
to a number of autoimmune diseases, including psoriasis. It has been sug-
gested that these cells have aberrant suppressive capacities in peripheral 
blood and skin lesions of patients with psoriasis.112;115;116 
Peripheral blood
In line with the data on the local presence of several types of T-cell subsets 
in the psoriatic lesion, circulating T-cells have been point of study as well in 
order to investigate abnormalities in the peripheral blood of patients with 
psoriasis.111;117-119 Baker et al. suggested that circulating T-cells are activated 
and subsequently recruited from the circulation during the development 
of psoriatic plaques.98 Several subsets seem to play a primary role in the 
lesion, e.g. CD4+, CD8+, CD45RO+, CD45RA+ and CD25+. Increased per-
centages of these psoriasis-associated T-cell subsets in peripheral blood 
have been reported.98;118;120 In particular, more severe forms of psoriasis (de-
ﬁned by cut-oﬀ point of PASI 12, see paragraph 1.7.1) show signiﬁcantly
increased counts of CD4+, CD8+, CD45RO+, CD45RA+, CD94+ and CD161+ 
T-cells compared to mild psoriasis.119 Moreover, CLA+ T-cells were found to 
be increased in the peripheral blood of patients with acute psoriasis121 in 
contrast to NKT cells which are decreased in peripheral blood of psoriasis 
patients.120;122 As far as the Treg are considered, approximately 10% of CD4+ 
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lymphocytes in peripheral blood are found to be CD25+. Remarkably, simi-
lar proportions were found in psoriatic and normal blood115 despite the fact 
that the Treg cells showed some deﬁciency in their ability to suppress eﬀec-
tor CD4+ T-lymphocyte responses. This might point to a defective immu-
noregulatory activity in psoriasis that permits T-lymphocyte activation and 
cytokine production. The exact role though still needs clarifying.
For T-cells to gain access to skin, they must bind to endothelial cells and 
move out of the peripheral circulation and into the dermis. The correlation 
between T-cell subsets present in peripheral blood and the skin has been 
hypothesized in relation to clinical severity and therapeutic eﬀect.74 How-
ever, this alleged recompartmentalization of T-cells in psoriasis has not yet 
been point of focus in studies.
1.3.2 The cutaneous T-cell response3;92;123
In the course of a normal cutaneous immune reaction, antigen-reactive
T-cells enter the skin at sites that harbour residual antigen. Subsequently, 
the antigen would be eliminated by an immune mechanism appropriate 
to the inciting antigen. In psoriasis, the cutaneous immune reaction seems 
overstrained.
Antigen processing and presentation3 
Speciﬁc T-cell responses require activation of T-cells through antigen-pre-
senting cells. At the onset of psoriasis, the initial step comprises the rec-
ognition and uptake of (exogenous) antigen (Ag) by tissue-guarding DCs 
(Langerhans cells), the migration of these cells to the T-cell areas of local 
draining lymph nodes and the presentation of selected Ag fragments (pep-
tides) on the DCs’ cell surface to naïve T-cells. Naïve T-cells are cells that have 
not previously been activated by antigen in an immune response. After the 
Ag uptake, the DCs undergo a maturation process and reduce their capac-
ity to further absorb Ags. One question that remains crucial to the under-
standing of psoriasis refers to the responsible Ag for initial T-cell priming. 
Disease initiation is widely suggested to be mediated through DCs present-
ing foreign antigens or self-antigens to T-lymphocytes. Optionally, one of 
these antigens may be a self-peptide cross-reactive to streptococci as it is 
reported that streptococcal infections precede psoriasis in more than 90% 
of patients with type I psoriasis.15;124
Generation of eﬀector and memory T-cells3
The conversion from naïve to eﬀector memory T-cells in the secondary lym-
phatic organs is necessary for T-cells to obtain their functions according to 
the type of immune response that needs to be generated and their ability 
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to immigrate into tissues. Naïve T-cells constantly circulate between blood 
and secondary lymphatic organs, such as lymph nodes and tonsils. Naïve 
T-cells express high levels of L-selectin, allowing them to attach, or tether, 
and then roll on the surface of the high endothelial venules (HEV) within 
lymph nodes. After stimulation by an adhesion-triggering chemokine ex-
pressed on the luminal surface of the HEV, the rolling T-cells arrest and 
bind tightly through an integrin (LFA-1). Now, the T-cells can extravasate 
through the HEV into the lymph node. In T-cell areas of these organs, they 
congregate with mature DCs.123 At the heart of the antigenic activation of 
naïve T-cells is the recognition of an antigenic peptide bound to either class 
I or II major histocompatibility complex (MHC) molecules on dendritic APCs 
that have migrated from the skin via eﬀerent lymphatics to skin-draining
lymph nodes. Antigens are recognized, in turn, by the T-cell receptor (TCR) 
complex which is present on the surface of all T-cells. A naïve CD4+ T-cell 
(CD45RA+) whose TCR has a high enough aﬃnity for the respective MHC-II
peptide complex, attaches to the respective DC and forms a so-called im-
munological synapse. The CD8+ T-cell has aﬃnity for MHC class I bound
antigen. Subsequently, in order to become activated, the T-cell needs three 
signals: the ﬁrst signal has already been delivered by interaction between
TCR and MHC-I/II peptide-complex. The second signal is given by the so-
called co-stimulatory molecules. The third signal for T-cell activation is de-
livered by soluble mediators (cytokines).
Costimulation can be deﬁned as a stimulus necessary for optimal T-cell acti-
vation delivered jointly to T-cells along with the TCR signal.125 The most im-
portant co-stimulatory molecules expressed on DCs are: CD86, CD80, and 
CD40. CD86 and CD80 interact with the T-cell molecules CD28 and CD152 
(cytotoxic T-lymphocyte-associated protein 4, CTLA-4). CD86 is a major co-
stimulatory molecule in DCs as it is critical for full activation, particularly of 
naïve T-cells. Engagement of CD152 inhibits TCR- and CD28-mediated sig-
nal transduction, increases the threshold for activation of these cells and re-
presses the cell cycle. Therefore, it counteracts acute T-cell responses but is 
also essential for the formation of memory T-cells. The counterpart for CD40 
on T-cells is CD40-ligand (CD154). The immunological synapse is stabilized 
by adhesion molecules expressed between DCs and T-cells such as the in-
teraction between intercellular adhesion molecule 1 (ICAM-1; CD54)(DC) 
and lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18) (T-
cell) and the interaction between lymphocyte function-associated antigen 3 
(LFA-3; CD58) (DC) and CD2 (T-cell).
The third signal delivered to the T-cell is from the cytokines and essential-
ly inﬂuences the mode of action of the eﬀector and memory (CD45RO+)
T-cells, which evolve from these activated T-cells. Naïve T-cells can be po-
larized into diﬀerent Th-subsets of which the major classes are Th1, Th2,
Th17 and Treg. When IL-12 is present during activation of naïve T-cells, they 
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are polarized into Th1 cells through activation of the transcription factors 
STAT4 and T-bet. The generation of Th1 cells is supported by IFN-γ, which 
increases the expression of the speciﬁc receptor chain for IL-12. When IL-4
is present, naïve T-cells are polarized into Th2 cells through activation of 
Figure 4 A selected view on the cutaneous T-cell response with its diﬀerent polari-
zation pathways.
In order to generate a cutaneous T-cell response, a T-cell must interact with antigen-pre-
senting cells (mature Langerhans’ cells) which have taken up and processed auto-antigens. 
After the processing APCs migrate to the regional lymph nodes where they come in contact 
with naïve T-lymphocytes. It is in the immunological synapse that various molecular interac-
tions ultimately result in T-cell activation. Three sets of signals are required to achieve this. 
First the APCs present the processed antigen bound to MHC molecules, to the TCR. Second, 
additional so-called accessory signals are being transmitted through interactions between 
costimulatory molecules with their corresponding ligands. The immunological synapse is 
stabilized by adhesive interactions between integrins and their ligands as they transmit ad-
ditional signals. Following these activating signals, T-cells diﬀerentiate into memory T-cells
under inﬂuence of soluble mediators such as cytokines. Now they are activated they re-
enter the peripheral blood circulation and predominantly extravasate at sites of cutaneous 
inﬂammation where they can exert their eﬀector functions. In psoriasis, this cutaneous T-cell
response is chronic of nature. 
Naïve T-cells can be polarized into diﬀerent Th-subsets of which the major classes are Th1,
Th2, Th17 and Treg. The T-cell lineage is dependent on the cytokine milieu present during 
the T-cell activation (as explained in text).
(Modiﬁed from: Schön MP and Henning-Boehncke W. N Engl J Med 2005;352:1899-912 Sabat R, Philipp
S, Höﬂich C et al. Exp Dermatol 2007;16: 779-798.)
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the transcription factors STAT6 and GATA-3. These T-cells secrete IL-4, IL-5 
and IL-13 during repeated activation and have a regulatory role as high 
concentrations of type 2 cytokines suppress the actions of type 1 eﬀectors.
The activation of naïve T-cells with mature DCs in the presence of IL-6 and 
transforming growth factor β (TGF-β) upregulate the receptor for IL-23 and 
together with this cytokine induced Th17 cell development. The Th1-cell 
inducing cytokines IL-12 and IFN-γ actively suppress the development of 
Th2 and Th17 cells. Conversely, the Th2-cell inducing cytokine IL-4 inhibits 
the development of Th1 and Th17 cells.
Independent of its polarization into a Th1 or Th2 (or Treg / Th17) cell, a suc-
cessfully activated naïve T-cell develops into an eﬀector T-cell. The com-
munication between dendritic APCs and T-cells should be considered as a 
ﬂuent ongoing dialogue rather than a brief contact, enhancing the chronic
character of the psoriatic immune response. A schematic ﬁgure of the cuta-
neous T(h1)-cell response is reﬂected in ﬁgure 4.
Skin inﬁltration of T-cells and other immune cells3
Tissue invasion by activated T-cells from the periphery seems to be essen-
tial for the development and maintenance of psoriatic plaques. The pas-
sage of leukocytes from blood vessels into tissue occurs in ﬁve steps (ﬁgure 5). 
Endothelial cells play a central role in these processes.
1.      leukocytes roll along the blood vessel wall
Rolling reduces the ﬂow velocity of the leukocytes and is mediated by the
interaction between P-selectin and E-selectin expressed by endothelial cells 
and selectin ligands expressed by leukocytes. E-selectin is the endothelial 
ligand for CLA on memory T-cells. It is normally not expressed on endothe-
lial cells in cutaneous micro vessels but is upregulated during cutaneous 
inﬂammation.
2.      recognition of chemokines presented by the endothelial walls
The rolling immune cells along the vessel wall recognize chemokines pre-
sented by endothelial cells and become activated (triggering).
3.    formation of tight adhesions between endothelial cells and immune
         cells
This is achieved by integrins (and adhesion molecules) expressed on im-
mune cells and their ligands expressed on endothelial cells. 
Chemokines induce this integrin-dependent adhesion. LFA-1(CD11a/CD18) 
seems to be an important integrin for skin-homing as the anti-psoriatic ef-
fect of efalizumab has become established, a monoclonal antibody directed 
(among other things) against LFA-.126-130(see paragraph 1.5.3)
4.      passage through the endothelial wall (diapedesis)
This is probably performed by pores between endothelial cells. 
5.      migration to the target tissue
Chapter 1
General Introduction
33
In contrast to the relatively well understood process of lymphocyte extrava-
sation, little is known about the exact subsequent migration through the 
cutaneous extracellular matrix and the processes determining the ultimate 
localization and arrest of lymphocytes within the (epi)dermal compart-
ment. Immigration is apparently initiated by trauma or invasion of a few 
micro-organisms that leads to the local activation of immune cells. Through 
the products of these cells and complement components, endothelial cells 
are activated, which then actively support the inﬁltration of immune cells
to the skin. Later, the immigrated immune cells activate each other so that 
the T-cells stimulate monocytes / macrophages and DCs through IFN-γ and 
these cells then activate the T-cells through IL-23 and IL-6. At the same time, 
keratinocytes are activated whereby they actively support the inﬁltration of
further immune cells through the production of chemokines. After migra-
tion into the skin, the immune cells may be activated by various types of 
APC populations or keratinocytes. T-cells may proliferate as a consequence 
of activation in the skin. 
As mentioned earlier, CD8+ T-cells primarily home to the epidermis in pso-
riasis whereas CD4+ T-cells are mainly present in the dermis. The reasons 
for this diﬀerent homing pattern may be caused by the varied expression
of chemokine receptors and integrins. Other immune cells such as NK-
cells, monocytes / macrophages and DCs also use a similar mechanism as
described above to migrate into the skin. However, diﬀerent chemotactic
factors are dominant as well as other adhesion molecules. It remains un-
clear however, in what way precisely the immigrated T-cells in the skin be-
come activated eventually.
Figure 5 Five steps in skin homing of leukocytes (Modiﬁed from Sabat R, Philipp S, Höﬂich C et
al. Exp Dermatol 2007;16: 779-798) 
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1.3.3 A tangled web of cytokines and chemokines
Inﬂammation or tissue damage initiates the production of cyto- and
chemokines and the recruitment of leukocytes. Once the leukocytes have 
crossed the endothelium and the basement membrane, their migration to 
the focus of inﬂammation is directed by a constant gradient of cyto- and
chemokines.
Cytokines are a large family of extracellular protein mediators including but 
not limited to chemokines, which can be deﬁned as chemoattractant cy-
tokines. They have pleiotropic eﬀects. Cytokines and chemokines are the
most important facilitators of leukocyte migration. Mosmann et al. were the 
ﬁrst to propose the T-helper (Th)1 and Th2 cytokine network theories.131;132 
In 1991, the cytokine network was further speciﬁed for psoriasis establish-
ing a paradigm for understanding these mediators of inﬂammation in the
psoriatic context.133 As brought up earlier, in the Th1 immune response, IL-2, 
IFN-γ and TNF represent the key cytokines contributing to a T-cell mediated 
reaction whereas in the Th2 immune response, IL-3, IL4, IL-5 and IL-10 con-
tribute to a humoral or B-cell mediated immune reaction.134 In psoriasis, the 
described immunocytes communicate with endothelial cells, ﬁbroblasts
and keratinocytes via the production of and interaction of Th1 cytokines 
and chemokines.93;94;100;135 Chemo- and cytokines interact with speciﬁc re-
ceptors and can inﬂuence cells in an autocrine, juxtacrine and paracrine
fashion.134 Functionally, cytokines are able to inﬂuence the proliferation, dif-
ferentiation or secretion of proinﬂammatory or anti-inﬂammatory factors
by resident and recruited cell types. The group of proteins referred to as 
cytokines include lymphokines, monokines, interleukins, interferons and 
growth factors. Chemokines may overlap the function of cytokines, but are 
primarily recognized biologically for their ability to modulate the move-
ment of cells either by promoting the entry or leaving of migratory (T-) 
cells.134;136 Beside the function in leukocyte chemotaxis, chemokines have 
an important function in integrin activation during the multistep process of 
leukocyte-endothelial cell interaction, stimulation of leukocyte degranula-
tion or release of inﬂammatory mediators and stimulation of angiogenesis.
In general, chemokines connect directly to classes of cytokines and eﬀector
leukocytes to orchestrate immune responses.136
Table 1 creates an overview of the cytokines and chemokines upregulated 
in the psoriatic lesion. Obviously, many cytokines and chemokines contrib-
ute to the initiation and maintenance of psoriatic plaques. Considering the 
wide variety of psoriasis-associated cytokines, it seems worthless to target 
only a single cytokine for therapeutic success. However, some cytokines 
seem of primary importance and some of secondary, as the use of high-
ly selective biological agents in the treatment of psoriasis has proven to 
be very eﬀective (anti-TNFα therapy: etanercept137-140, inﬂiximab141-144 and 
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adalimumab145-147) (see also paragraph 1.5.3). TNF-α is a key pro-inﬂamma-
tory cytokine taking part in the immune response, that merits some spe-
cial attention in this thesis, as three studies have addressed the eﬀect of an
anti-TNFα therapy in psoriasis. This cytokine is produced by macrophages, 
monocytes, mature DC (including Langerhans cells), polymorphonuclear 
cells, mast cells, NK cells, activated T-cells, keratinocytes and endothelial 
cells.148-150 High concentrations of TNF-α have been found in psoriatic le-
sions, but not in unaﬀected skin.151;152 Furthermore, serum levels of TNF-α 
have been shown to correlate with disease severity, i.e. increasing during 
worsening of psoriasis and decreasing after eﬀective therapy.153 TNF-α has 
a multitude of pro-inﬂammatory actions that could account for the signs
and symptoms of psoriatic plaques, as it is able to induce a cascade of other 
cytokines.154;155 
In addition, a novel therapeutic agent (targeting cytokines) that recently has 
led to great clinical responses in psoriasis, is the antibody that recognizes a 
shared subunit (p40) of the cytokines IL-12 and IL-23.156-161 IL-12 is produced 
by activated macrophages and dendritic cells and induces a Th1-type dif-
ferentiation response with naïve T-cells becoming IFN-γ producing T-cells. 
IL-23 is also produced by activated DCs leading to memory Th1-type T-cells. 
Both IL-12 and IL-23 inﬂuence the levels of cytokine IL-17 which has led to
a new paradigm in the cytokine network highlighted by the dominance of 
a Th17-type immune response.134;162 The Th17 response is an emerging ﬁeld
of interest in psoriasis; for the latest insights and understandings we refer to 
publications in journals of recent date.
Table 1 Cytokines and chemokines 
upregulated in psoriatic lesions
(From: Lew W, Bowcock Am, Krueger JG. 
Trends Immunol 2004; 25(6): 295-305 
Gaspari AA. J Am Acad Dermatol 2006; 
54: S67-80)
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The exact immunologic mechanisms that trigger the psoriatic phenotype 
are not proven, but basic elements in the psoriatic immunopathogenesis 
have been elucidated in the past decades, and touched upon in this para-
graph. It seems that a variety of speciﬁc and non-speciﬁc stimuli lead to
triggering of the cutaneous exaggerated adaptive immune response in 
genetically susceptible individuals to psoriasis. Although it remains open 
whether the primary defect leading to psoriasis is an inborn metabolic er-
ror of keratinocytes or a dysfunction in the innate and/or adaptive immu-
nity, in the end it would be diﬃcult to draw a T-cell independent model of
the psoriatic pathogenesis.
1.4 CD26 / Dipeptidyl peptidase IV (DPPIV)
CD26 / DPPIV is a 110 kDa cell surface glycoprotein which enjoys a great deal 
of interest in the ﬁelds of immunology and inﬂammation, glucose homeo-
stasis, neuroendocrinology and cancerology.163 In particular, it is described 
to interfere with the pathology of several auto-immune diseases. As a cell 
surface protease, it is expressed in many tissues where it can truncate sev-
eral chemokines, and can inﬂuence immune responses via modulation of
cell adhesion and T-cell activation. Consequently, this suggests a potential 
involvement of CD26 / DPPIV in the psoriatic immune response. Therefore, 
in this thesis we were triggered to map the expression of CD26 / DPPIV in 
psoriasis in order to investigate and create more insight into whether the 
expression of this protein could be of additional value and in the long run 
could possibly function as a supplementary marker correlating with disease 
severity in the psoriatic pathogenesis.
The following subparagraphs give insight in the known expression and 
functions of CD26 / DPPIV in the human body, chieﬂy in the ﬁeld of immu-
nology and inﬂammation.
1.4.1 Structural properties163
DPPIV was ﬁrst reported in 1966 as glycyl-prolyl-β-naphthylamide hydro-
lyzing enzyme164 and later was renamed as dipeptidyl aminopeptidase IV, 
post-proline dipeptidyl aminopeptidase and X-Pro dipeptidyl aminopepto-
dase. The present name is dipeptidyl peptidase IV. In the context of T-cells 
however, it is frequently referred to as CD26.165 CD26 / DPPIV is composed of 
a short cytoplasmatic domain of 6 amino acids, a transmembrane region of 
22 amino acids and an extracellular domain of 738 acids. The human CD26 / 
DPPIV gene has been located on the long arm of chromosome 2 (2q24.3). 
CD26 / DPPIV belongs to the serine proteases. Proteases are enzymes con-
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ducting proteolysis; the degradation of proteins. According to the character 
of their catalytic active site and conditions of action they can be classiﬁed
into four groups: serine, cysteine, aspartic, and metalloproteases. In gener-
al, proteases can be involved in a multitude of physiological reactions from 
simple digestion of food proteins to highly-regulated cascades as in immu-
nology and inﬂammation, which can result in rapid and eﬃcient ampliﬁca-
tion of an organism’s response to a physiological signal. By splitting long 
protein chains into short fragments, (amino)peptidases break the peptide 
bonds that link amino acid residues. Likewise, CD26 / DPPIV can selectively 
cleave the N-terminal dipeptide from peptides with proline or, to a lesser 
extent alanine, at the penultimate position166;167 (indicating the amino acid 
on the second position counting from the amino terminus).
1.4.2 Patterns of CD26 / DPPIV expression
CD26 / DPPIV has a widespread tissue distribution diﬀering in expression
level between tissues depending on cell-type, diﬀerentiation and activa-
tion status. Immunohistochemical analyses have detected CD26 / DPPIV in 
human tissue sections of the gastrointestinal tract, biliary tract, exocrine 
pancreas, kidney, uterus, placenta, prostate, the adrenal, parotid, sweat, 
salivary and mammary glands and on endothelia of all organs exam-
ined including liver, spleen, lungs and brain.168 In human skin, it has been 
shown that CD26 / DPPIV is expressed on the surface of keratinocytes169 as 
well as on sebocytes, the lipid-producing cells localized in the sebaceous 
glands.170;171 Dermal ﬁbroblasts also express the membrane-bound form of
CD26 / DPPIV.172  
By contrast, in immunological context the cell surface expression of CD26 
on human T-lymphocytes is known to be tightly regulated. As indicated in 
paragraph 1.3.2, the CD3/TCR complex plays a central role in T-cell activa-
tion and function. The signiﬁcance of CD26 / DPPIV in T-cell function is best
indicated by the enhancement of CD3 and CD2 dependent activation and 
proliferation by anti-CD26 antibodies.173-179 After T-cell stimulation, the ex-
pression levels of CD26 / DPPIV as well as the percentage of CD26+ T-cells are 
increased which makes it a suitable marker for activated T-cells.180 Further-
more, on resting B- and NK-cells in the circulation, CD26 / DPPIV is known to 
be absent but can be induced on their surface after stimulation.181;182
In general, CD26+ T-helper cells in the peripheral blood are for 76% CD4+ 
and for 16% CD8+.183  At the resting state in the peripheral blood, CD26 
is preferentially expressed on the helper/memory T-cell population(CD4+
CD45RO+).184 Moreover, a small subpopulation of T-cells in unstimulated 
mononuclear cells in the peripheral blood expresses CD26 at high densi-
ty on their surface, the so-called bright expression, which encompasses a 
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number of deﬁned phenotypic and functional characteristics. This rather
small CD26bright population belongs to the CD45RO+ T-cells and is re-
ported to be necessary for the proliferative response to recall antigens and 
alloantigen.185 It is also responsible for the induction of cytotoxic T- lym-
phocyte activity against alloantigen and the induction of B-cells to synthe-
size IgG.184 The speciﬁc capacity of CD26+ cells to migrate transendotheli-
ally and to inﬁltrate inﬂammatory sites186;187, is primarily exhibited by the 
CD26bright CD4+CD45RO+ T-cells.
The CD26 / DPPIV cell surface expression on CD4+ T-lymphocytes is cor-
related with the production of a Th1 like cytokine pattern.188 Th1 hallmarks 
such as IFN-γ, CCR5, CXCR4 and CXCR3 (IP-10, MIG, I-TAC) can all be proc-
essed by CD26 / DPPIV (see paragraph 1.4.4). Subsequently, processing of 
cyto- and chemokines by CD26 / DPPIV may constitute an important mech-
anism to reduce attraction of leukocytes in a Th1 response.183 In the end, 
CD26 / DPPIV can not be considered a truly speciﬁc and selective marker for
human Th1 cells, yet it can characterize the pathway of this speciﬁc immune
Figure 6 Various characteristics of T-cells 
in peripheral blood expressing high levels 
of CD26 on their surface, the CD26bright 
T-cells.
(Modiﬁed from De Meester I, Korom S, Van
Damme J et al. Immunology Today 1999: 20(8); 
367-75.)
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response. Figure 6 reﬂects an overview of the phenotypic and functional
characteristics of CD26bright T-cells.
Soluble CD26 / DPPIV (sCD26 / DPPIV) is similar to cell surface CD26 / 
DPPIV189;190 and can be detected at signiﬁcant levels in peripheral blood. It
is soluble because it lacks the transmembrane domain. The cellular origin(s) 
of the sCD26 / DPPIV is unclear. Nevertheless, it is hypothesized that sCD26 
/ DPPIV may derive from all CD26-expressing cells that contact blood and 
that it may help to inactivate (locally produced) bioactive substrates and 
thereby prevent possible systemic eﬀects.168 sCD26 / DPPIV can inﬂuence
T-cell proliferation in vitro but the underlying mechanisms are indistinct. 
Interestingly, altered levels of sCD26 / DPPIV are found in inﬂammatory dis-
ease conditions (see paragraph 1.4.5). 
A number of other molecules exhibiting DPPIV-like enzyme activity have 
been introduced and termed “DPP-IV activity and/or structure-homo-
logues” (DASH). This group comprises several proteases including attractin, 
ﬁbroblast activating protein α, DPP 8 and 9.191;192 DASH have potential abili-
ties to complement and/or associate to DPPIV on the level of its enzymatic 
activity. These homologues have been implicated in inﬂammatory condi-
tions as contributing factors193, although the exact contribution and role 
are still largely unestablished.
1.4.3 Functions of CD26 / DPPIV
A large array of functions has been attributed to CD26 / DPPIV. The two 
mainstays can be described as its ability to regulate the eﬀect of biological
factors through its enzymatic activity and its essential role in human T-cell 
physiology. 
Besides its proteolytic function (see paragraph 1.4.4), it has numerous other 
distinguishing functions as a receptor, a costimulatory protein, as an adhe-
sion molecule for collagen and ﬁbronectin and its involvement in apoptosis.
Due to this multifunctional character and its widespread expression, CD26 / 
DPPIV has a so-called moonlighting character referring to the diverse func-
tions separately regulated in time and context.183;194 The exact functions of 
CD26 / DPPIV in vivo however, have not yet been explored to the fullest.  
In 1993, CD26 / DPPIV was recognized as a receptor, i.e. as the binding pro-
tein for adenosine deaminase (ADA).195-198 Adenosine deaminase (ADA) is 
a soluble enzyme that catalyzes the degradation of adenosine and deoxy-
adenosine. It mainly occurs in the cytosol199 (90%), and to a lesser extent on
the cell membrane in many tissues. The highest expression is found on the 
surface of  (T- and B-) lymphocytes.200 Dong et al. found that ADA and CD26 
/ DPPIV only colocalize on the cell surface and not inside the cell, suggesting 
that ADA is not transported through the cell membrane by CD26 / DPPIV201 
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and the individual enzymatic activities of both molecules remains pre-
served. Despite its wide distribution, deﬁciency of ADA in humans causes
profound lymphopenia and results in severe impairment of cellular and hu-
moral immunity (severe combined immunodeﬁciency disease (SCID)). The
binding does not occur in rodents which implies interspecies variation.183 
Despite this alliance between ADA and CD26 / DPPIV on lymphocytes, no 
distinctive counter-receptor has been identiﬁed on the antigen presenting
cell.
The costimulatory properties of CD26 / DPPIV have been extensively stud-
ied in vitro.180;185;198;202;203 Important to note is that the proteolytic activity 
of CD26 / DPPIV is not a prerequisite for the costimulatory properties in 
vitro. In general, the activation of T-cells requires at least two signals. The 
ﬁrst is provided by stimulation of the TCR by speciﬁc peptide antigens. The
second can be delivered by triggering costimulatory molecules which can 
be provided by a number of accessory molecules expressed on the T-cell 
surface. The costimulatory characteristics of CD26 / DPPIV comprise that 
it augments T-cell responses to foreign antigen as it is able to transmit an 
activating signal to the T-cell180, initiates signal transduction, increases cy-
tokine secretion and proliferation, upregulates activation markers such as 
CD25, CD71 and CD69, induces diﬀerentiation into eﬀector cells and en-
hances provision of help to B-cells and cytotoxic T-cells.168;204;205 Yet, the spe-
ciﬁc triggering mechanism for the costimulatory activity of CD26 / DPPIV
has not been deﬁned. Biochemical and immunomodulation studies185 have 
provided evidence that CD26 as a costimulatory molecule on the T-cell sur-
face is able to induce cell proliferation via direct interaction with CD45.206 
However, the importance of this association is still to be elucidated. 
A role for CD26 / DPPIV in cell interactions with the extracellular matrix as 
an adhesive molecule has been described and speciﬁed to involve two ma-
jor constituents namely ﬁbronectin and collagen.207-209 
Lastly, CD26 / DPPIV is reported to be involved in apoptosis.210 Apoptosis 
is a form of programmed cell death crucial to ensure correct tissue func-
tion and to prevent inappropriate excessive growth. In vitro studies have 
showed that human keratinocytes derived from psoriatic plaques are resist-
ant to induced apoptosis when compared to keratinocytes derived from 
normal skin.211 Therefore, defects in apoptosis might play an important 
role in the pathogenesis of psoriasis. In line with this, UVB irradiation has 
proven to be an eﬀective treatment causing apoptosis in T-lymphocytes
and keratinocytes.212;213 When apoptotic mechanisms fail due to defects 
or mutations in apoptotic proteins (possibly CD26 / DPPIV), pathological 
mechanisms can take over as in psoriasis.
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1.4.4 Protease function and possible substrates
CD26 / DPPIV has an ecto-peptidase activity that catalyses the cleavage 
of N-terminal dipeptides from proteins containing proline or, to a lesser 
extent, alanine at the penultimate position. The rate of the CD26 / DPPIV 
catalyzed proteolysis is described to be inversely related with the chain 
length of the protein to be cleaved.214;215 Although the natural substrate(s) 
for CD26 / DPPIV remain(s) to be identiﬁed, CD26 / DPPIV participates in the
degradation of many pro-inﬂammatory molecules and  possible substrates
of CD26 / DPPIV include several cytokines, chemokines, hematopoetic 
growth factors, neuropeptides and hormones which all share the proline 
(or alanine) at their N-terminus. In particular, as many cytokines and chemo-
kines contain DPPIV-susceptible N-terminal sequences, the processing of 
cytokines and chemokines by CD26 / DPPIV has an important impact on 
the biological activity of the speciﬁc substrates eventually contributing to
the regulation of leukocyte migration. Activity of RANTES (regulated upon 
expression, normal T-cell expressed and secreted;CCL5) is altered by the en-
zymatic cleavage of CD26 / DPPIV as the processed form has a more than 
10 times lower chemotactic potency for monocytes and eosinophils. Acti-
vation of CCR5 by RANTES activates type 1 T-cells.123;216 In psoriatic lesional 
skin, RANTES is overexpressed.217
Other important chemokines that appear to be substrates of enzymatic 
activity of CD26 / DPPIV are CCL11 (eotaxin), CCL22(macrophage-derived 
chemokine), CXCL10 and CXCL11 (interferon inducible chemokines IP-10 
and I-TAC).218 Notably, the chemokines CXCL2 (MIP-2α), CCL2 and CCL7 
(MCP3) have penultimate prolines but are not hydrolyzed by DPP IV.168 
Table 2 Chemokines as substrates for CD26 / DPPIV 
(From Boonacker and Van Noorden, 2003, De Meester 1999, 
Gorrell 2001) 
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Table 2 reﬂects an overview of the substrates219-221 exhibiting altered chem-
otactic activity following CD26 / DPPIV-mediated truncation in inﬂamma-
tory processes. 
Natural substrates currently attracting interest include glucagon and gluca-
gon-like peptide (GLP-1/2) owing to the eﬀects on blood glucose toleration
and insulin productions.222-224 Interestingly, diﬀerent isoforms of CD26 / DPPIV 
may have diﬀerent substrate speciﬁcities.225 These aspects of substrate spe-
ciﬁcity of CD26 / DPPIV make it diﬃcult to predict which natural substrates
are eventually processed by which isoforms of CD26 / DPPIV.183;226
1.4.5 CD26 / DPPIV in auto-immune diseases
Aberrant soluble (serum) CD26 / DPPIV activity has been reported for a large 
array of diseases such as solid tumors, hematological malignancies and in-
fectious diseases (e.g. HIV and hepatitis C). In fact, several (auto)immune 
and inﬂammatory diseases have been related with altered plasma levels
of soluble CD26 / DPPIV as well (table 3). Reduced serum activity was also 
observed in patients with inﬂammatory bowel disease (Crohns disease and
ulcerative colitis).163;227 Also in psoriasis altered (decreased) levels of soluble 
CD26 / DPPIV activity in plasma have been found.228 
Regarding the levels of the membrane-bound form of CD26 / DPPIV in auto-
immune diseases, changed numbers of CD26+ T-cells have been found at 
inﬂammation sites as in patients with Graves’ disease and RA where in-
creased numbers of CD26+ T-cells in the thyroid and synovial ﬂuids were
described.187;229 In addition, enhancement of CD26 expression in these dis-
eases may correlate with disease severity.230;231 Referring to the subpopula-
tion of the CD26 bright cells, they are found to be increased during active 
phases of autoimmune diseases and reduced during immunosuppression 
as reﬂected in table 3.220   
In psoriasis, a signiﬁcant decrease of CD26 expression on CD8+ T-cells was
found in the peripheral blood of a cohort of thirty patients when compared 
to a control population. However, there was no correlation to disease sever-
ity as determined by the Psoriasis Area and Severity Index (PASI score).232 
With respect to psoriatic dermal inﬂammation, Novelli et al reported that
CD26 / DPPIV is expressed on human keratinocytes in variable amounts and 
in a group of patients with heterogeneous inﬂammatory dermatoses (i.e.
erythrodermic psoriasis, spongiotic dermatitis and lichen planus).169  CD26 
/ DPPIV expression is also found to be signiﬁcantly increased in ﬁbroblasts
derived from patients with psoriasis and lichen planus as compared to their 
normal counterparts.172 Unfortunately, little is known about the functional 
relevance of CD26 / DPPIV expression on these skin cells in animal models 
of psoriasis or normal or pathologic human skin.
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Clinical relevance of CD26 / DPPIV inhibitors
During the last decade the blocking eﬀects of CD26 / DPPIV on T-cell ac-
tivation and function were examined in several animal models of human 
auto-immune diseases including RA, MS, inﬂammatory bowel disease (IBD)
and transplantation.233-237 The in vivo observation that inhibitors of CD26 / 
DPPIV can suppress T-cell functions, suggests a potential use as therapeutic 
drugs in inﬂammatory diseases.238 To date no clinical studies have been re-
ported using CD26 / DPPIV inhibitors during auto-immune diseases except 
for non-insulin dependent diabetes mellitus (NIDDM). The CD26-mediated 
processing of GLP-1 is reported to enhance insulin secretion and improves 
glucose tolerance. Recently, DPPIV inhibitors have been successfully intro-
duced in the treatment of NIDDM.239;240
Concluding remarks on CD26 / DPPIV
Unraveling the complex nature of CD26 / DPPIV is continuing as much is 
still largely unknown about its precise properties and functions. In line, the 
exact picture of all biological functions of CD26 / DPPIV is diﬃcult to com-
pose but explicable due to its moonlighting properties as CD26 / DPPIV 
exerts its diﬀerent functions in diﬀerent cell types and thus in diﬀerent cel-
lular contexts. CD26 / DPPIV expression and activity measurement may be 
useful for the assessment of the severity of various inﬂammatory diseases,
the response to therapy and the prognosis.
Some believe that the psoriatic pathogenesis can be considered an auto-
Table 3 Altered levels of soluble CD26 and number of CD26brightT-cells in inﬂammatory
diseases (From Boonacker, van Noorden 2003, De Meester 1999, Gorrell 2001) 
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immune response against a yet undeﬁned antigen involving the activa-
tion of immune cells. CD26 / DPPIV has been shown to be expressed and 
variably upregulated on the surface of key-pathogenic immune competent 
cells in various auto-immune conditions. In addition, CD26 / DPPIV can ex-
ert a proteolytic function on cyto- and chemokines, potentially inﬂuencing
the complex network of interactions in the psoriatic immune cascade. Pos-
sessing properties as a T-cell activation molecule and costimulatory pro-
tein, CD26 / DPPIV has abilities to interfere with the heart of the psoriatic 
immune response. Schematically, the outlined position of CD26 / DPPIV in 
the psoriatic interplay of keratinocytes, T-cells and cytokines is illustrated in
ﬁgure 7. Targeting CD26 / DPPIV may possibly contribute to the clariﬁca-
tion of the pathophysiology of psoriasis and therapeutic means to treat 
psoriasis.
1.5 Therapies for psoriasis
In summary, psoriasis can be recognized by a disturbed proliferation and 
diﬀerentiation of keratinocytes accompanied by vascular alterations and
epidermal inﬁltration of activated Th1-type lymphocytes together with a
local Th1-type cytokine immune response. As a consequence of this diver-
Figure 7 Hypothesized position of CD26 / DPPIV in psoriasis
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sity in etiology, the understanding of a multifactorial pathogenesis of pso-
riasis has evolved into a remarkable number of therapeutic concepts.
Due to diverse presentations of psoriasis and individual needs and coexist-
ent factors, the choice of treatment must be individualized for each patient. 
A holistic approach to treatment, including education and psychological 
support, is needed for optimal care of psoriatic patients. Patients must un-
derstand the genetic, environmental and real-life implications of psoriasis 
and its treatment. Indications for treatment may arise from local symptoms 
(itch, pain), cosmetic problems or both.241 The main aim of treatment is to 
reduce the burden of disease over time by controlling symptoms, helping 
the patient to cope with the chronic nature of the disease, ultimately lim-
iting psychological and relational consequences, and preventing systemic 
complications and comorbidity.29 Even cost-beneﬁt matters should be in-
volved herein. Moreover, an evidence-based approach is essential in making
a choice between the many available treatments. Treatments currently 
available comprise topical agents, phototherapy and systemic agents in-
cluding the injectable biologicals. Other innovative treatments are con-
stantly emerging, but often not (yet) registered for psoriasis. This paragraph 
touches upon the registered treatments and some innovative treatments 
for psoriasis, with speciﬁc reference to the treatments which are the focus
of interest in the various manuscripts in this thesis. An overview of the avail-
able anti-psoriatic treatments and the corresponding “stepwise approach” 
is given in ﬁgure 8.
1.5.1 Topical therapy
Emollients and Keratolytics
Use of emollients can serve as important complementary therapeutic mo-
dality. In general, psoriatic patients should be advised to maintain adequate 
hydration of their skin with emollients such as lanette, petrolatum or pa-
raﬃne as their barrier function is disturbed. Speciﬁcally, they can soften the
often hyperkeratotic surface of the lesional psoriatic skin which creates a 
less tightening, soothening sometimes cooling sensation on the spot. In 
this way it can take part in improving the clinical signs and symptoms of 
psoriasis.242;243
Keratolytics can be considered excellent descaling agents as they promote 
the removal of the uppermost scaly layer of the epidermis, i.e. the stratum 
corneum. Salicylic acid is the most widely used and prescribed as an ad-
junctive treatment for psoriasis as the combination with a topical cortico-
steroid decreases the amount of scale and subsequently enhances the skin 
penetration of the steroidal agent.244 
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Vitamin D3 derivatives
These vitamin D3 derivatives were ﬁrst introduced in the topical treatment
of psoriasis in the early 1990s in Europe. Nowadays, they represent the 
ﬁrst choice of maintenance therapy for mild-to-moderate psoriasis. These
agents bind with vitamin D-selective receptors in various cell types and 
have been shown to inhibit the hyperproliferation and abnormal diﬀerenti-
ation of keratinocytes in psoriasis.245-248 The exact mode of action is not fully 
elucidated. The majority of available data is on calcipotriol (Daivonex™), in 
a lesser extent on calcitriol (the active metabolite of vitamin D; Silkis™) and 
tacalcitol. The latter is not registered in the Netherlands for the treatment of 
mild-to-moderate psoriasis. The clinical response with these preparations is 
good although slower than with higher potency corticosteroid agents. Cal-
cipotriol is more eﬀective than calcitriol and as eﬀective as potent, but not
ultrapotent, topical corticosteroids.249-251 The topical vitamin-D3 analogues 
are generally well-tolerated and practicable for the physician and the pa-
tient. It has minimal eﬀects on the calcium metabolism when used in their
respective dosage regimens and is safe up to 100 g per week. Temporary skin 
irritation may limit the use, especially on the face or the intertriginous areas.
A great beneﬁt of vitamin D3 derivatives is their value in combination
therapy.252 In the ﬁrst weeks of treatment, use together with topical cortico-
steroids is superior to monotherapy with respect to eﬃcacy and tolerance.253 
For moderate-to-severe psoriasis, a combination of topical vitamin D3-ana-
logues with UV phototherapy or a systemic therapy (ciclosporine, acitretin) 
can result in a synergistic eﬀect and therefore be recommended.252
Topical corticosteroids
Besides the group of vitamin D3 derivatives, corticosteroids compose the 
other cornerstone in the topical treatment for psoriasis. The anti-psoriatic 
eﬀect of corticosteroids is largely related to their eﬀects on gene transcrip-
tion that result in diminishing of inﬂammatory, proliferative and immuno-
logic responses.244;254 They are available in a variety of formulations, with po-
tencies categorized in the Stoughton-Cornell classiﬁcation which assigns
clinical eﬀectiveness to corticosteroids on the basis of their ability to induce
vasoconstriction, separated into four potency groups (classes I to IV).255 As 
a general rule, topical corticosteroid therapy is initiated with the lowest po-
tency agent expected to be eﬀective. Low potency agents are appropriate
for lesions aﬀecting the face or intertriginous areas and for small children.244 
Their potency can be enhanced by occlusion with a plastic dressing.256-258 
Care must be taken regarding the development of typical adverse corti-
costeroid eﬀects such as skin atrophy, teleangiectases, striae distensae and
purpura in cases of longer application and in particular at sensitive areas. 
Systemic eﬀects such as iatrogenic Cushing’s syndrome and hypothalamic-
pituitary-adrenal axis suppression are also seen with extensive treatment.259 
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These side-eﬀects are most likely with high potency corticosteroids. In order
to minimize such complications, the use of (ultra)potent corticosteroids is 
limited and various treatment regimens are being employed e.g. use in the 
weekends only, combination with non-steroidal agents and transition to 
products of weaker potency when initial clinical response is accomplished. 
In general, topical corticosteroids are not used as the primary treatment 
when more than 20% of the body surface is aﬀected by psoriatic lesions.
Calcipotriol/betamethasone 
Interest in the corticosteroid sparing ability of vitamin D3 derivatives has fa-
cilitated the development of a new single agent topical therapy for plaque 
psoriasis. Large well-controlled studies have established the superior eﬃca-
cy of a once-daily combination ointment containing calcipotriol 50µg.g-1 and 
betamethasone dipropionate 0.5 mg.g-1 (class III corticosteroid; Dovobet™) 
over use of either agent alone.260-263 Side-eﬀects of both active compounds
are minimized in clinical use for up to 1 year by use of this combination.252 In 
addition, both clinical and immunohistochemical studies have shown that 
the combination ointment of calcipotriol and betamethasone dipropionate 
is more eﬀective than the simultaneous use of each of the compounds once
daily.264;265 Moreover, in terms of quality of life, a once-daily application of 
Figure 8 Anti-psoriatic treatment ladder
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this  product is favourable when compared with twice-daily application of 
calcipotriol.266;267
Dithranol
Dithranol (anthralin, cignolin) is one of the oldest topical therapeutics for 
psoriasis. It induces a cascade of free radicals in the skin, resulting in an-
tiproliferative eﬀects and a modulation of inﬂammation in psoriasis pre-
sumably via a direct eﬀect on mitochondria.268;269 Although it is an eﬀec-
tive treatment for mild-to-moderate psoriasis, dithranol as monotherapy is 
less eﬀective than either topical corticosteroids or vitamin D3 derivatives.249 
The eﬃcacy can be increased further if either calcipotriol, intermittent high
potency topical corticosteroids or UVB phototherapy is combined with 
dithranol.252;270
The therapy is safe although skin irritations, burning, erythema and inter-
mittent brown discolorations of skin and clothing can frequently be ob-
served, which makes it best used in hospital or day care clinics. 
 
Coal tar
Coal tar is a mixture of thousands of compounds roughly comprising 48% 
hydrocarbons, 42% carbon and 10% water.268 Like dithranol it has anti-
proliferative eﬀects and can modulate inﬂammatory events in psoriasis.
Head-to-head comparative and placebo-controlled studies are sparse 
with respect to tar treatment. Skin irritation, folliculitis, allergic/phototoxic 
responses, staining and odour of clothing limit coal tar’s use as a routine 
outpatient treatment. Carcinogenicity following coal tar applications in
psoriatics remains unconﬁrmed.
 
Calcineurin inhibitors
The calcineurin inhibitors tacrolimus and pimecrolimus have both been 
assessed in the treatment for psoriasis, but were originally approved topical 
treatments for atopic dermatitis. They are immunosuppressant and inhibit
T-cell activation. Unlike corticosteroids, they do not cause skin atrophy. 
Their eﬃcacy is limited in the treatment of psoriasis because of poor
penetration unless they are used under occlusion or on the thinner skin of 
the face, intertriginous areas or genitals.252;271-274
Topical retinoids275
Tazarotene is the only topical retinoid (vitamin A derivative) available for 
the treatment of plaque psoriasis. It has been shown to have antiprolifera-
tive and anti-inﬂammatory eﬀects.
Tazarotene (0.05% or 0.1%) is available as gel and cream formulations, al-
though not in the Netherlands as it is not registered. It is most eﬀective
when used in combination with topical corticosteroids.
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Besides local adverse events such as pruritus, erythema and burning it is 
important to note that teratogenic aspects are only of concern when more 
than 20% of the body surface is treated.
1.5.2 Systemic therapy: classics 
In psoriatic patients with more than 20% of body surface area involved, 
topical therapy may be impractical and usually requires some form of pho-
totherapy or the use of systemic therapies. All these regimens cause toxic 
eﬀects in one or the other way, therefore the indication to treatment must
be considered repeatedly to avoid excessive risk in relation to beneﬁts.
Photo(chemo)therapy
Phototherapy is often a good treatment option when the psoriatic lesions 
are widespread covering a considerable body surface or when the lesions 
are resistant to various topical therapies. Therefore it can be considered a 
valuable option “in between” topical and systemic therapy. The interaction 
between UV radiation and chromophores in the skin induces a multitude of 
eﬀects such as induction of oxidative stress and activation of transcription
factors as well as induction of DNA damage.276 Phototherapy for psoriasis 
includes broadband UVB (290-320 nm), narrowband UVB (311-313 nm) and 
psoralen plus ultraviolet A light (PUVA) (320-400 nm plus pretreatment with 
photosensitizing psoralens). When comparing narrowband to broadband 
UVB, the most eﬀective wavelength for psoriasis is determined to be 311-
313 nm (narrowband range).277 Moreover, use of PUVA has been reduced 
because narrowband UVB is more convenient and possibly safer for pa-
tients.
In using UVB phototherapy, the minimal erythema dose (MED) is deter-
mined ﬁrst on the basis of individual patients’ Fitzpatrick skin type I-IV and
the metered output of the UVB unit before beginning treatment.252;278 UVB 
therapy is initially most common used two to three times a week with cau-
tious dose escalation and reduction in correspondence with the clinical 
response.279 The onset of the clinical eﬀects is usually within 2 weeks.
Phototherapy represents a safe and very eﬀective treatment modality for
the treatment of moderate to severe forms of psoriasis. Erythema from 
overexposure is by far the most common side-eﬀect. With repeated or
long-term application of UV-therapy, the consequences of high cumulative 
dosages (i.e. premature aging of the skin, carcinogenic risk) must be taken 
into account.
Goeckerman (UVB plus tar) or Ingram (UVB plus anthralin) therapies have 
been associated with remission times of at least 6 months and more than 
1 year for a considerable proportion of psoriatic patients. PUVA therapy is 
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associated with signiﬁcant and prolonged beneﬁts for psoriasis. Remissions
of more than 1 year have been reported in about 40% of patients treated 
with a single course of PUVA.280 However, one should bear in mind that 
the carcinogenic potential of PUVA is higher than of UVB. The most popu-
lar combination regimens include UVB (either narrowband or broadband) 
with vitamin D3 derivatives or systemic treatments.
Methotrexate
Methotrexate (MTX) is a folic acid antagonist interfering with the purine 
synthesis and thereby inhibits DNA synthesis and cell proliferation in the 
rapidly dividing psoriatic epidermis.281 It also has speciﬁc T-cell suppressive
capacities.282 Despite the emergence of novel biologic therapies, it is still an 
important eﬀective mainstay in the treatment of moderate to severe pso-
riasis (and psoriatic arthritis).
MTX can be given by the oral, intramuscular or intravenous routes, usually 
as a single weekly dose, accompanied with folic acid supplementation to 
minimize side-eﬀects. Following stable full blood counts and liver function
tests, patients can be maintained on a dose of 7,5-25 mg weekly. The most 
important potential side-eﬀect is bone marrow suppression. Patients need
to avoid alcohol intake due to the increased risk of liver ﬁbrosis.281 Prolonged 
treatment with MTX requires a liver biopsy to detect ﬁbrotic changes, al-
though this is now debatable as the measurement of type III procollagen in 
serum (P3NP) can be used to detect liver ﬁbrosis or cirrhosis.283;284 This has 
to be further validated in future studies however.
Retinoids
Acitretin is an oral retinoid (vitamin A derivative) approved for the treat-
ment of psoriasis. It is a synthetic hormone that binds to nuclear retinoid 
acid receptors (RAR), thereby altering gene transcription and returning ke-
ratinocytes proliferation and diﬀerentiation to normal.252 In general, mono-
therapy with acitretin is more eﬀective for pustular psoriasis than chronic
plaque, guttate or erythrodermic psoriasis which respond more slowly.281;285 
For a detailed account on acitretin therapy in psoriasis, the reader is referred 
to a review article by Yamauchi et al.281
Ciclosporin
Ciclosporin is an eﬀective short-term treatment for moderate-to-severe
psoriasis.286 It induces immunosuppression by inhibiting the ﬁrst phase of
T-cell activation; it may also exert a direct eﬀect on epidermal keratinocytes.
Ultimately, the production of cytokines that are important in cell-mediated 
immunity, such as IL-2 and IFN-γ, is inhibited.252;281 Unlike MTX, ciclosporin 
is not myelosuppressive, but requires careful monitoring for nephrotoxic-
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ity and hypertension. For a detailed account on ciclosporin the reader is 
referred to the review article of Griﬃths et al.287
Fumaric Acid Esters
Oral fumaric acid esters (fumarates) have initially been used to treat moder-
ate-to-severe psoriasis in Germany as a German chemist demonstrated the 
beneﬁts of fumarate therapy on his own psoriasis.288 Fumarates are natu-
rally occurring molecules that link the urea and citric acid cycles, with their 
beneﬁt in psoriasis now considered to be due to inhibition of T-cell activity
(induction of T-cell apoptosis), a shift to a Th2-type cytokine response and 
NFkβ inhibition.252;289;290 Nowadays they are eﬀectively used in the treat-
ment of psoriasis although approved in a very small number of Northern 
European countries, excluding the Netherlands.290-293
Others
Less commonly used systemic treatments for psoriasis include mycophenolic 
mofetil, hydroxyurea, 6-thioguanine, sulfasalazine, azathioprine and tacrolimus.281
1.5.3 Systemic therapy: biologics 
Extensive understanding of the immunopathogenesis has provided ration-
ale for the development of new strategies targeting the immune cells and 
molecules that induce and maintain the clinical changes seen in psoriatic 
plaques. These therapies are named ‘biologics’ or ‘biologicals’ and are used 
to treat patients with moderate-to-severe plaque type psoriasis in which 
the classic treatments have failed to a certain extent or are contra-indicated.
Biologicals are recombinant molecules that are designed on the basis
of genetic sequences from various organisms and that are often similar 
or identical to proteins produced by human beings. They include fusion 
proteins, recombinant proteins and monoclonal antibodies each blocking 
the induction or maintenance of T-cell activation in one or the other way 
through diverse sites and modes of action (ﬁgure 9).
Since their introduction, they have provided an eﬀective option to the array
of anti-psoriatic treatment modalities. Moreover, patients have experienced 
substantial improvements in their quality of life.
Biologics addressed in this thesis
Efalizumab
The humanized IgG1 monoclonal antibody efalizumab (Raptiva™) is direct-
ed against the CD11a subunit of LFA-1. LFA-1 is a T-cell surface molecule 
important in T-cell activation, T-cell migration to the skin and cytotoxic
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Interactions between APCs 
and T-cells are crucial in the 
pathogenesis of psoriasis. 
Several immunomodula-
tory biological therapies 
can target the molecules 
expressed on the surface of 
both cells. 
Alefacept blocks the interaction between LFA-3 on APCs and CD2 on T-lymphocytes. 
Moreover, alefacept functions as a bridging molecule between CD2 that is upregulated on 
CD45RO+ T-lymphocytes and the Fcγ III receptor (CD16) on NK cells which induces apoptosis 
of T-lymphocytes through the release of granzyme by NK cells. Efalizumab blocks the inter-
action between LFA-1 and ICAM-1 thereby inhibiting the T-cell activation and migration into 
the skin. Etanercept antagonizes the eﬀects of endogenous TNF by competitively inhibiting
its interactions with cell-surface receptors. Inﬂiximab binds to and inhibits the activity of
transmembrane-bound and soluble TNF-α with high speciﬁcity, aﬃnity and activity. Finally,
adalimumab is directed against TNF-α as well and blocks its interaction with the p55 and 
p75 cell-surface receptors thereby lysing the cells that express surface TNF-α. 
(Modiﬁed from Gottlieb AB. Nat Rev Drug Discov 2005; 4: 19-34. Kormeili T, Lowe NJ, Yamauchi PS. Br J
Dermatol 2004;151: 3-15.)
Figure 9 Sites and modes of action of major biologics 
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T-cell function. Binding of efalizumab to CD11a blocks LFA-1 from binding 
to ICAM-1, which is upregulated on psoriatic keratinocytes and its partner 
molecule for adhesion. Subsequently, this inhibits T-cell activation thus 
preventing cutaneous T-cell traﬃcking. The blockade is reversible and does
not deplete T-cells, suggesting that efalizumab can be used as a continous 
therapy.
Efalizumab is available as a subcutaneous preparation that patients self-
inject once weekly. Optimal eﬃcacy with efalizumab was seen with weekly
doses of 1 mg/kg (after a ﬁrst dose of 0.7 mg/kg) as 22-39% of the patients
achieved a 75% reduction in PASI within 12 weeks and 57% a PASI 50.129;130;294 
In addition, one third of patients with an outcome between 50% and 75% 
improvement in PASI reaches at least a 75% reduction after 12 more weeks 
of treatment (total of 47% reaching PASI75 after 24 weeks).129;295 Clinical 
improvement was seen as early as two weeks after initiation of treatment. 
The initial lower dose of efalizumab is lower in order to minimize the tran-
sient ﬂu-like symptoms that were observed in the clinical trials at the higher
doses.296 In these large clinical studies, efalizumab was well-tolerated, with 
the most frequent side eﬀects being transient, mild to moderate ﬂu-like
symptoms including mild headache, fever and chills. Trombocytopenia 
was observed occasionally thus monitoring should include platelet counts. 
Efalizumab has not been shown to be eﬀective in treating psoriatic arthri-
tis. To date, no evidence of cumulative end-organ toxicity has been found. 
The risk of malignancy, as with other immunomodulating drugs, has to be 
determined through additional patient experience. 
A major concern with efalizumab is the rebound of psoriasis, deﬁned as a
worsening of psoriasis by 125% relative to the pretreatment baseline, or the 
conversion of psoriasis morphology to a more serious subtype such as eryth-
rodermic or generalized pustular psoriasis that occurs within 12 weeks of 
discontinuing treatment. It has been observed in 3% of efalizumab patients 
during therapy and in 14% of patients following abrupt discontinuation of 
efalizumab, predominantly in the non-responder group.297 Formulating an 
appropriate transitional “rescue” therapy strategy before discontinuation of 
efalizumab may minimize the occurrence of rebound.298;299
Etanercept
As opposed to targeting T-cells, etanercept (Enbrel™) is a fusion protein 
comprising domains of the 75-kDa human tumor necrosis factor receptor 
and human IgG1, which inhibits the activity of soluble TNF-α and slows the 
inﬂammatory cycle in psoriasis driven by TNF-α. Etanercept also reduces the 
levels of several chemokines and cytokines, such as IL-8, CXCL10 and CCL20
in psoriatic lesions, leading to a decrease in T-cells, dendritic cells and keratino-
cyte hyperplasia.300;301 It is approved in the European Union (EU) and the 
United States for the treatment of rheumatoid arthritis, juvenile arthritis, 
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severe ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
In psoriasis trials, various dosage regimens have been used: self-injected 
subcutaneously administration of once a week 25 mg, twice 25 mg or 2 x 
50 mg  per week. The eﬃcacy of etanercept was found to be dose-depend-
ent, with a PASI75 response observed in 34% of patients in the 2 x 25 mg 
weekly group, and in 50% of patients in the 2 x 50 mg group after 12 weeks 
of treatment. An additional 12 weeks of treatment improved the eﬃcacy
up to 59% (PASI75) after 24 weeks at the 2 x 50 mg dose.139 Up to 96 weeks, 
improvements in PASI of at least 75% have been reported with administra-
tion of 50 mg etanercept biweekly.302 When treating patients for the ﬁrst 12
weeks with 50 mg twice weekly, then reducing the dose to 25 mg biweekly 
for 12 weeks, 77% of the patients maintained the PASI75 response rate after 
24 weeks.298 In addition, etanercept is highly eﬀective in psoriatic arthritis,
with a reduction in the signs and symptoms of joint disease in 73-87% of 
patients at 12 weeks of treatment.303 Also in children and adolescents with 
moderate to severe plaque psoriasis, etanercept signiﬁcantly reduces the
disease severity.304
Clinical data of both controlled trials and post-marketing surveillance sup-
port the safety and tolerability of the use of etanercept over longer peri-
ods of treatment (up to 96 weeks302). The main adverse events noted are 
transient, mild to moderate injection-site reactions (erythema and/or itch-
ing, pain, or swelling) which last 3-5 days.305 Infections, mainly of the upper 
respiratory tract, bronchitis or skin infections have less often been report-
ed. In contrast, fatigue and symptoms of depression might be relieved by 
treatment with etanercept.306;307 Etanercept therapy has rarely been linked 
to positive ANA and a lupus-like syndrome and increased risk of lympho-
ma, demyelinating disorders of the central nervous system and congestive 
heart failure. Anti-etanercept antibodies have been found up to 18,3 % of 
patients, but these were found to be non-neutralizing and had no appar-
ent eﬀect on the eﬃcacy or safety proﬁles of etanercept.302 In contrast to 
efalizumab, rebound of psoriasis is not likely when etanercept therapy is 
discontinued.295
Inﬂiximab
Inﬂiximab (Remicade™) is a chimeric monoclonal antibody that inhibits
both membrane-bound and soluble forms of TNF-α. It is approved in the EU 
and US for patients suﬀering from RA, Crohn’s disease, ankylosing spond-
ylitis and plaque psoriasis. Clinical trial results demonstrate that inﬂiximab
is a fast-acting agent, highly eﬃcacious for psoriasis. The rapid therapeutic
response may lie in the observation that inﬂiximab has not only anti-inﬂam-
matory activity but also apoptotic and anti-angiogenetic properties.308;309 
Inﬂiximab’s suppression of TNF-α activity not only aﬀects T-cells but also
keratinocytes and endothelial cells as the expression of K16 and the en-
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dothelial adhesion molecules ICAM-1, E-selectin and VCAM-1 all decreased 
signiﬁcantly compared to pretreatment levels.308;310
Inﬂiximab is administered at a dose of 5 mg/kg intravenously over 2 hours
at weeks 0, 2 and 6 and then every 8 weeks afterwards. Large clinical trials 
have shown that 80-88% of patients reached a 75% reduction in PASI after 
10 weeks of which 57% reached PASI90. At 1 year maintenance therapy, 
61% of these patients were at PASI75 whereas 45% reached PASI90.144;300;311 
Signiﬁcant improvement is often seen as early as the second infusion.
Loss of eﬃcacy however over time appears to correlate with lower serum
concentrations of inﬂiximab and development of antibodies to inﬂiximab
(23,3 % of all inﬂiximab-treated patients311) which occurs because 20% of 
the amino acid sequence is murine.252 Two suggested strategies to avoid 
the phenomenon of “loss of eﬃcacy over time” comprise on one hand, the
periodic administration of inﬂiximab on a regular basis of 8 weeks interval
(in stead of intermittent administration) and on the other hand, the con-
comitant use of a small dose of methotrexate. The latter has, so far, been 
shown helpful in patients with RA and Crohn’s disease298 but has not yet 
been investigated in patients with psoriasis. As with etanercept, inﬂiximab
is also proven to be eﬃcacious, although less, in patients with PsA as signs
and symptoms of active arthritis diminish.312;313
Inﬂiximab infusion has been associated with several adverse events. Most
common reported adverse event is upper respiratory infection. Other fre-
quent reactions include acute infusion reactions with fever, chills, chest 
pain, hypotension, nausea and dyspnoea. They can be managed by slowing 
or interrupting the infusion rate. Since anaphylactoid reactions may occur, 
one should monitor the patients close. Infection is another major concern 
and multiple reports have indicated reactivation of latent tuberculosis with 
inﬂiximab.314;315 Screening for tuberculosis is therefore indicated before 
starting therapy. Another point of focus with the use of inﬂiximab, is the
six-fold greater risk of potential development of lymphomas316 of which the 
majority represent non-Hodgkin’s lymphomas (81%). Recent data on liver 
toxicity of inﬂiximab show that 5% of patients have ﬁvefold increases of
their liver enzymes, indicating that monitoring of the hepatic enzymes is 
needful.142 Other rare adverse events include demyelinating diseases, wors-
ening of cardiac insuﬃciency, leucopenia, thrombopenia, pancytopenia
and reversible lupus-like syndrome.317
Adalimumab
Adalimumab (Humira™) is a fully human IgG1 monoclonal antibody that 
binds speciﬁcally to TNF-α, blocking its interactions at the p55 and p75 TNF
receptors thereby lysing the cells that express TNF. It is self-administered as 
40 mg subcutaneously once every other week after an initial dose of 80 mg. 
Initially, adalimumab was registered for the treatment of psoriatic arthritis.318 
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Large studies in psoriasis have shown that at week 12 of treatment, 53% 
of psoriatic patients reached PASI75. This response was sustained up to 60 
weeks of therapy.319 This proportion is intermediate between the results for 
inﬂiximab and etanercept.  Adalimumab was generally well tolerated and
as with the other TNF-α agents, primary concerns are infection, malignancy 
and development of anti-nuclear antibodies. The primary reported side ef-
fect was pain at the injection site. Additional long term safety data are not 
yet available for the indication of psoriasis, but is available from several tri-
als in RA. Adalimumab has recently been approved for the indication mod-
erate-to-severe psoriasis by EMEA and the FDA.
Others
Alefacept
Alefacept, originally known as LFA-3 T-cell inhibitor protein (LFA-3TIP), re-
duces the number of pathogenic T-cells. It is a fusion protein composed of 
LFA3 with the constant region of human IgG1. Alefacept (Amevive™) binds 
to CD2 on memory eﬀector T-cells to block costimulation by preventing
CD2 from binding LFA-3 on APCs, selectively interfering with the function 
of APCs and consequently the T-cell activation. Psoriatic lesions exhibit
a predominance of lymphocytes that are of the memory eﬀector type
(CD45RO+). An additional important mechanism of action of alefacept, is 
apoptosis of memory-eﬀector CD45RO+ T-cells in the skin as natural killer
cells and macrophages recognize the Fc portion of the alefacept molecule 
that has bound to CD2+ T-cells.252;320 After a 12-week period of weekly in-
tramuscular injections of  15 mg alefacept, 21% of patients achieved a 75% 
reduction in PASI and 46% a 50% reduction.321 A proportion of responding 
patients enjoyed long remissions from their psoriasis.322 Clinical improve-
ment develops slower than that observed with other biologicals. Alefacept 
therapy appears to be well-tolerated, albeit the primary concern is T-lym-
phocyte depletion. Therefore, patients are monitored with CD4 counts 
while on the drug. Although alefacept is approved by the FDA for treatment 
of psoriasis, it is not currently approved by the EMEA in Europe.
Anti-interleukin 12/23 agents160
A fully human IL-12/23 monoclonal antibody has recently been developed 
which binds with high aﬃnity to the p40 subunit of human IL-12 and -23.
This neutralizes the bioactivity of both cytokines, blocking interactions with 
their associated cell-surface receptors. Preclinical studies have implicated 
the IL-12 cytokine, a major driver of the Th1-response, in the pathogenesis 
of psoriasis in addition to its reported overexpression in psoriatic plaques. 
IL-23, which also shares the p40 subunit and is overexpressed in psoriatic 
plaques, activates a distinct T-cell lineage that expresses IL-17 which is sug-
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gested to be pathogenically important in the Th17 response. A phase II 
study demonstrated the great therapeutic eﬃcacy in psoriasis, conﬁrming
the role of the IL-12 / 23p40 cytokines in the pathophysiology of psoriasis. 
So far, long-term data of this novel promising biological are not available 
yet as large clinical trials are currently being conducted.
Although biological treatments have been of great advance in the manage-
ment of psoriasis, head-to-head trials and comparisons to traditional thera-
pies are essential to deﬁne their exact place in the hierarchy of systemic
therapies.
1.5.4  Lasers and their therapeutic application in psoriasis
The term laser is an acronym for Light Ampliﬁcation by the Stimulated 
Emission of Radiation. 
Although the use of lasers in dermatology began slowly through the six-
ties and seventies, the ﬁrst laser was developed by Maiman in 1959 using
a ruby crystal to produce red light with a 694-nm wavelength. The concept 
of stimulated light emission however was already introduced in 1917 by 
Einstein.323 Eventually in 1963, Dr Goldman was the ﬁrst to introduce the
use of lasers for cutaneous applications by promoting ruby laser treatment 
for a variety of cutaneous pathologies.324;325  The theory of selective pho-
tothermolysis, introduced by Anderson and Parrish in 1981326, opened the 
door for broad extensive use of lasers in dermatology. Technologic advances
brought new eﬀective and safe laser systems and a growing range of
applicable cutaneous lesions manifested itself. 
As psoriatic lesions encompass histopathological vascular abnormalities 
such as dilated, elongated and increased prominent superﬁcial capillaries
in the dermis (see paragraph 1.2), treatment with vascular lasers form a 
potential therapeutic option when facing psoriasis. This thesis includes 
the evaluation of two types of vascular lasers (pulsed dye laser (PDL) and
Neodymium-doped Yttrium Aluminium Garnet (Nd:YAG)) in the treatment 
of psoriasis.
Basic science of lasers327-329
A laser consists of several basic elements (ﬁgure 10):
• the lasing (gaining) medium,  e.g. a gas, liquid, solid or semiconductor
• an excitation power source, e.g a ﬂash lamp, a continuous light source
• an optical resonator and output coupler (reﬂective mirrors)
Lasers are named according to the nature of their lasing medium. The thera-
peutic action of laser energy is based on the unique properties of laser light 
itself and complex laser-tissue interactions. To know how the laser light is 
58
produced, ﬁrst the interactions that take place within a laser have to be ad-
dressed. 
Any atom or molecule has a natural tendency to exist in its natural or rest-
ing ground state. As the lasing medium is excited, molecules in the ground 
state are ‘pumped’ to a higher energy state. Once an electron is moved into 
a higher orbital level, its natural tendency will be to drop back to its resting 
state. By doing so, a given packet of energy will be released in a random 
direction as a single photon that will be characteristic for that atom or mol-
ecule. This is termed spontaneous emission. If the spontaneously emitted 
photon travels in an appropriate direction, it strikes one of the mirrors at 
each end of the resonating cavity and is reﬂected back into the lasing me-
dium. If this photon further strikes an already excited atom, the atom can 
be stimulated to decay back to the resting state, resulting in the release of 
a second photon identical to the initial photon. The net result is that two 
photons are of a single wavelength (monochromatic), are travelling in the 
same non-divergent direction (collimated) and proceeding in phase. This 
process which is termed stimulated emission, represents the key features 
of laser light and makes it the ﬁrst necessary element for laser light pro-
duction. When enough energy is pumped into the system, the majority of 
the molecules are raised into the excited state which is a prerequisite for 
the laser to function. Such a condition is called population inversion. Once 
population inversion occurs and as long as energy is still being pumped 
into the system, a suﬃcient cascade or positive feedback reaction produc-
ing more and more in-phase photons occurs, that leads to the ampliﬁcation
of laser light. 
Figure 10 Basic laser construction
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Properties of lasers330
Each type of laser produces light that is characteristic for that particular laser. 
Most lasers produce only one wavelength, although some lasers may pro-
duce several monochromatic bands. Lasers may diﬀer in the way in which
their light is emitted or delivered. Some lasers are capable of the continu-
ous discharge of light (continuous wave) whereas others seem to build up 
power before releasing their pulse of relatively high power allowing more 
selective tissue damage.327 The pulses delivered by such lasers are usually 
quite short and are followed by a lag phase before another pulse can be 
generated. Duration and power of the pulse can be varied. Laser pulses can 
be delivered by using ﬂash lamps as an excitation energy source, but can
also be produced by Q-switching in which a crystal is placed in front of the 
reﬂecting mirror in the resonating chamber. The pulse duration of any laser
will be determined by the thermal relaxation time (TRT) of the intended 
target (see under ‘Selective photothermolysis’).
The output of continuous wave lasers is measured as power in watts (W), 
for pulsed lasers output is measured as energy in joules (J) taking the pulse 
duration into account. Irradiance is a measure of power density and refers to 
laser power per unit area and takes the spot size into account (W cm-2). En-
ergy density or ﬂuence is deﬁned as the irradiance multiplied by exposure
time (J cm-2). The spot size of a laser is equivalent to the laser beam cross 
section. Fluence and irradiance  are inversely proportional to the square of 
the radius of the spot size. When halving the spot size the irradiance or ﬂu-
ence increases by a factor of 4.
Laser-tissue interaction330
Whenever light strikes tissues, it is scattered, transmitted, reﬂected or ab-
sorbed, depending on the nature of the tissue and the wavelength of the 
light. Transmission refers to the passage of light through a tissue without 
having an eﬀect on that tissue or on the properties of the light. Reﬂection 
refers to the repelling of light oﬀ the surface of the tissue without entry into
the tissue. Scattering of light occurs after light has entered the tissue and is 
due to heterogeneous structure of tissue. It spreads out the beam of light 
within the tissue resulting in radiation of a larger area than anticipated, be-
sides it limits the depth of penetration because it can occur both backward 
an forward. The absorption of the photons of laser light is responsible for 
its eﬀect on the tissue. The speciﬁc wavelengths of light match with cu-
taneous absorbing components (chromophores). The main chromophores 
in tissues are oxyhemoglobin, melanin and water (ﬁgure 11). Absorp-
tion of energy by a chromophore results in conversion of that energy into 
thermal energy. Infrared light is primarily absorbed by water, visible light 
by hemoglobin and melanin and ultraviolet light by melanin. The depth 
of penetration aﬀects the ability to treat certain chromophores at certain
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depths with certain wavelengths (ﬁgure 11). Oxyhemoglobin has three 
main absorption peaks (418, 542 and 577 nm). The dominant absorption 
peak for oxyhemoglobin is at 418 nm but this wavelength only penetrates 
to the dermal-epidermal junction (100 µm) which limits the use of a laser 
of this wavelength for cutaneous vascular lesions. As wavelength decreases 
towards the ultraviolet, the depth of penetration decreases synchronically. 
Consequently, near infrared light of the Nd:YAG laser has the greatest depth 
of penetration into biological tissues (ﬁgure 12). Beyond this infrared light 
lasers become ablative of nature. It has to be noted however, that some of 
the laser energy can be absorbed by epidermal melanin possibly resulting 
in hypopigmentation, hyperpigmentation or sometimes scarring. 
A method to limit potential damage is the use of simultaneous protective 
cooling systems which also have allowed to increase the energy ﬂuence
and improved treatment eﬃcacy.331 
Selective photothermolysis
The ultimate aim of use of lasers in dermatology is to direct energy precisely 
at a speciﬁc chromophore without causing a change in adjacent tissues.332 
The principle of selective photothermolysis refers to the process whereby 
appropriate selection of wavelength, exposure time (pulse duration) and 
energy density results in damage only to the desired target chromophore 
(and tissue), without signiﬁcant thermal damage to surrounding tissue
(thus minimizing collateral damage). Therefore, the wavelength must be 
absorbed by the chromophore in the lesion, the ﬂuence must be suﬃcient-
ly high to generate enough energy to thermally alter the target tissue and 
the pulse duration must be shorter than the TRT of the chromophore to 
prevent spread of thermal energy beyond the targeted chromophore.330 
The TRT is deﬁned as the time needed for the chromophore to cool to half
the temperature to which it has been heated by laser irradiation and is pro-
portional to the square of the size of the chromophore. In general, small 
objects cool faster than large ones; melanosomes of 0.5 to 1.0 µm have a 
shorter TRT than capillaries measuring 10 to 100 µm.332 If the pulse width 
equals or exceeds the thermal relaxation time, unnecessary thermal dam-
age occurs due to heat diﬀusion to surrounding tissues.
Lasers emitting visible light were designed on this basis of selective photo-
thermolysis. These lasers include the vascular targeted pulsed dye and Nd:
YAG lasers, currently addressed in this thesis.
Clinical laser systems
As new laser devices continue to emerge, an expanding range in versatile 
laser systems builds up and therefore a wide spectrum of skin lesions can 
be targeted which presently includes the psoriatic lesion. Table 4 reﬂects
an overview of lasers together with their corresponding cutaneous applica-
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Figure 11 Absorption spectra of tissue chromophores with wavelengths of medical lasers
Nd:YAG=neodymium:yttrium-aluminium-garnet; PDL= pulsed dye laser; Er:YAG= 
erbium;YAG (Modiﬁed from Acland KM and Barlow RJ. Br J Dermatol 2000; 143: 244-55.)
Figure 12 Depth of penetration by diﬀerent medical lasers
KTP=potassium titanyl phosphate; Nd= neodymium; PDL= pulsed dye laser; YAG= yttrium-
aluminium-garnet (Modiﬁed from Textbook ‘Dermatology’, 2nd ed., JL Bolognia et al., Vol. 2, p.2094)
62
tions. In general, cutaneous lasers can target vascular lesions or pigmented 
lesions, can generate skin resurfacing or can eﬀectuate hair removal.
When treating vascular lesions, the chromophore targeted is oxyhemo-
globin. Both congenital and acquired vascular lesions can be treated 
with vascular lasers, including port-wine stains, hemangiomas and facial 
telangiectasias. In addition, vascular lasers are often used successfully, 
but not evidence based, for other vascular-dependent but non-vascular 
indications328;333, such as in psoriasis.
Lasers in psoriasis
The superﬁcial dermal vasculature is a major contributor in the patho-
genesis of psoriasis. Yet, this expansion of the dermal microvasculature in 
psoriatic plaques has not been put a high value on when considering po-
tential targets for treatment, as traditional treatments mainly focus on the 
inhibition of epidermal proliferation, inﬂammation or both. Literature data
is accumulating however, pledging for marked eﬃcacy when the abnormal
supporting vasculature of psoriatic lesions is selectively removed by vas-
cular lasers. 
Studies using the PDL in psoriatic patients vary in design employing diﬀer-
ent ﬂuences, pulse durations and spot sizes. An overall clinical improve-
ment of 50-80% is reported in plaques after treatment with a proportion 
Table 4 Types of lasers and corresponding cutaneous application(s)329
CW=continuous wave; Nd=neodymium; QS=quality-switched;YAG=yttrium-aluminium-garnet
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Argon (CW)
Argon-pumped tunable dye laser (quasi CW)
Copper vapor / bromide (quasiCW)
Potassium-titanyl-phosphate
Nd:YAG, frequency doubled
Pulsed Dye
Ruby
• QS
• Normal mode
Alexandrite
• QS
• Normal mode
Diode
Nd:YAG
• QS
• Normal mode
Nd:YAG long-pulsed
Diode long pulsed
Erbium: glass
Erbium: YAG (pulsed)
Carbon dioxide (CW)
Carbon dioxide (pulsed)
Intense pulsed light source
Wavelength (nm)
418 / 514
577 / 585
510 / 578
532
532
510
585-595
694
755
800-810
1064
1320
1450
1540
2490
10,600
10,600
515-1200
Application
Vascular lesions
Vascular lesions
Pigmented lesions, vascular lesions
Pigmented lesions, vascular lesions
Pigmented lesions, red/orange/yellow tattoos
Pigmented lesions
Vascular lesions, hypertrophic scars, striae, verrucae, 
non-ablative dermal remodeling
Pigmented lesions, blue/black/green tattoos
Hair removal
Pigmented lesions, blue/black/green tattoos
Hair removal, leg veins
Hair removal, leg veins
Pigmented lesions, blue/black tattoos
Hair removal, leg veins, non-ablative dermal 
remodeling
Non-ablative dermal remodeling
Non-ablative dermal remodeling, acne
Non-ablative dermal remodeling
Ablative skin resurfacing, epidermal lesions
Actinic cheilitis, verrucae, rhinophyma
Ablative skin resurfacing, epidermal/dermal lesions
Superﬁcial pigmented lesions, vascular lesions, hair 
removal, non-ablative dermal remodeling
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of patients with complete clearance.334-340 Remission after PDL may extend 
to 15 months.337 As noted, some patients seemed to respond better than 
others. 
As PDL-treatment is relatively time-consuming, expensive and painful it 
is obviously not a leading ﬁrst choice treatment in psoriasis. The body of
evidence for the use of PDL in psoriasis is still limited as sample sizes were 
small, no randomization method was used and sporadically comparison 
with standard therapies for psoriasis was made.
There is a need for larger well-designed clinical trials to prove short- and 
long-term eﬀectiveness and safety proﬁle and to deﬁne appropriate pa-
tient selection criteria.333 However, for the localized recalcitrant variant of 
plaque psoriasis, it may be a fair treatment option.
In the immunohistochemical evaluation of Hern et al, the eﬀect of PDL was
limited to the superﬁcial capillary bed, with no changes in the micro vessels
of the upper reticular dermis.336 Therefore a vascular laser with a deeper 
penetration depth, such as the Nd:YAG (wavelength 1064 nm) laser might 
be able to destruct these deeper micro vessels possibly contributing to a 
clearance of psoriatic plaques and of potential beneﬁt to the treatment of
psoriasis. To date, no evaluative study has been done to put the Nd:YAG 
laser into place in the array of treatment modalities for psoriasis. 
For a more profound assessment on the use and application of non-vascu-
lar lasers in dermatology and speciﬁcally in psoriasis, the reader is referred
to the publications of Tanzi et al. and Tournas et al.329;341
1.6 Outline and objectives of this thesis
The main point of focus of this thesis encompasses the dynamics of on the 
one hand well-established psoriasis-associated markers of the T-cell and on 
the other hand of a novel potential pathogenesis-based marker in psoria-
sis (CD26 / DPPIV), in the context of clinical eﬃcacy of established and in-
novative treatments. The following aims and questions shed light on this 
outline.
AIM I Assessing clinical observations and interference with T-cell 
subsets of pathogenesis-based therapeutic interventions
The last decade innovative treatments have revolutionized the therapy of 
psoriasis. Pathogenesis-based treatments have become available which 
permit more precisely targeted therapeutic intervention including the bio-
logicals and vascular lasers. 
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A) To deﬁne the eﬀect of immune-targeted therapies on well-estab-
lished psoriasis relevant T-cell subsets in the cutaneous and peripheral 
blood compartment, and to address alleged compartmentalization 
between them in the context of clinical eﬃcacy.
A major question is whether innovative pathogenesis-based treatments act 
on the T-cell as a key player in the pathogenesis of psoriasis, either inﬂuenc-
ing the peripheral blood T-cells, the lesional T-cells or the shifting of T-cells 
between the systemic and cutaneous compartment.
Consequently, we deﬁned the following questions:
1a.
1b.
1c.
2.
B) To position vascular laser treatment compared to several estab-
lished treatments in the therapeutic array for psoriasis.
As clinical studies are sparse with respect to lasers and psoriasis, we ex-
panded our studies with some eﬃcacy, safety and immunohistochemical
issues in two explorative studies formulating the following questions: 
1.
2.
AIM II Deﬁning the expression of CD26 / DPPIV and characterizing it
as a potential novel marker in the immunopathogenesis of psoriasis
Based on current insights in the ﬁeld of auto-immune diseases, evidence
is provided that CD26 / DPPIV can interact with several key players in the 
pathogenesis of psoriasis. Therefore our objective was to deﬁne the expres-
sion of CD26 / DPPIV in the immunopathogenesis and treatment of psoriasis.
Are T-cell counts and –subsets aﬀected in the cutaneous and peripheral 
blood compartment in response to biological therapies such as efalizu-
mab and etanercept? 
Is recompartmentalization of T-cells between peripheral blood and le-
sional dermis and epidermis induced by biological treatments in pa-
tients with psoriasis and how does such relate to clinical eﬃcacy?
Can measurement of T-cell subset counts in blood or skin be used as a 
prognostic marker for clinical eﬃcacy?
What is the eﬀect of a conventional therapy (methotrexate) versus a
novel biologic therapy (adalimumab) on T-cell counts and –subsets in 
the cutaneous and peripheral blood compartment, in the context of 
clinical eﬃcacy?
Chapter 1
Is treatment with PDL a safe and eﬀective option for plaque type pso-
riasis compared to narrowband UVB and does the combination of PDL 
with narrowband UVB treatment generate a synergistic clinical eﬀect?
What is the clinical and immunohistochemical eﬀect of treatment with
a Nd:YAG (1064 nm) laser as opposed to the eﬀect of calcipotriol / beta-
methasonedipropionate ointment?
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In order to investigate the expression of CD26 / DPPIV in the cutaneous and 
systemic compartment, the following questions were addressed:
1.
2.
3.
4.
1.7  Investigational approach
1.7.1 Clinical eﬃcacy parameters
The Psoriasis Area and Severity Index (PASI) is the most frequently used 
scale to characterize the clinical severity of psoriasis. Equally, several manu-
scripts in this thesis employ the PASI as a clinical measuring parameter. The 
PASI scoring system assesses four body regions: the head (h), the upper ex-
tremities (u), the trunk (t) and the lower extremities (l), corresponding to 
10%, 20%, 30% and 40% of the total body surface area, respectively. 342 The 
area of psoriatic involvement for each of the four regions is assigned a nu-
merical value (A) of 0-6 corresponding to 0-100% involvement: 0 represents 
no involvement; 1, <10%; 2, 10<30%; 3, 30<50%; 4, 50<70%; 5, 70<90%; 6, 
90-100%. For each region, erythema (E), induration (I) and desquamation 
(D) are rated according to a ﬁve-point scale: 0, no involvement; 1, slight; 2,
moderate; 3, marked; 4, very marked. Subsequently, the PASI score is calcu-
lated from the following formula: PASI= 0.1Ah (Eh+Ih+Dh) + 0.2Au (Eu+Iu+Du) + 
0.3At (Et+It+Dt) + 0.4Al(El+Il+Dl). The PASI score can vary in increments of 0.1 
units from 0-72 with higher scores representing a greater severity of psoria-
sis. The PASI score is a quick and simple tool used primarily in clinical trials 
as a means to demonstrate improvement in a standardized manner. Clinical 
improvement is measured by the percentage change in PASI score which 
results in commonly used wording of PASI75 and PASI50, respectively re-
presenting 75% and 50% improvement in PASI score.
Despite its widespread application, use of the PASI score incorporates some 
drawbacks including its lack of sensitivity. For instance, erythema, desqua-
mation and induration are scored with equal weight within each of the four 
In what way is CD26 / DPPIV expressed in psoriatic skin? Can it function 
as a potential novel marker in lesional psoriatic skin compared to nor-
mal skin of healthy volunteers?
Does upregulation of CD26 / DPPIV in psoriatic skin cohere with kerati-
nocyte proliferation- and diﬀerentiation markers during development
of a psoriatic lesion?
What are the dynamics of peripheral blood CD26bright T-cells in psori-
atic patients compared to healthy conditions?
To what extent does treatment with inﬂiximab alter the expression of
CD26 / DPPIV in lesional skin and peripheral blood and how does such 
relate to clinical eﬃcacy?
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body regions. Consequently, a reduction in scaling with a concomitant in-
crease in skin erythema could be recorded as the same PASI score.343 In ad-
dition, although the PASI score ranges from 0-72, most patients have scores 
ranging between 0-15. PASIs of 40 or more are sporadically seen. Alterna-
tive psoriasis severity scores have been proposed but none of them is used 
as consistently as the PASI.344
After the PASI score, the most often employed score to measure psoriasis 
severity is the Physician’s Global Assessment (PGA) score (sometimes called 
Psoriasis or Investigator’s Global Assessment). The PGA has the investiga-
tor assign a single estimate of the patient’s overall severity of disease; typi-
cally a 6-point scale from clear to severe is used although many variations 
have been reported. Chieﬂy, the overall lesions are graded separately for
erythema, induration and scaling after which the sum of these three scales 
will be divided by three to obtain a ﬁnal PGA score.
The PASI and PGA stand for an overall severity index of psoriasis whereas 
the SUM score reﬂects the severity of only one designated psoriatic lesion.
Although its less widespread use compared to the PASI and PGA, it repre-
sents a good tool for a topical impression of lesional severity. Erythema, 
induration and scaling are scored on a ﬁve-point scale as in the PASI score
(range 0-4, see above). The total SUM score is deﬁned as the sum of the
individual scores of erythema, induration and scaling reﬂecting a ‘local PASI
score’. Ensued, this score ranges between 0-12 wherein 0 stands for ‘no pso-
riasis’ and 12 for ‘maximal signs of psoriasis’. 
The PASI, PGA and SUM score each are very practical to couple them with 
speciﬁc laboratory parameters, as was done in several investigations com-
posing this thesis.
1.7.2 Laboratory parameters 
Besides the clinical parameters, laboratory techniques were performed. In 
order to investigate the expression and enzyme activity of CD26 / DPPIV in 
human skin and to evaluate the eﬀect of several anti-psoriatic therapies on
T-cell-, epidermal proliferation- & diﬀerentiation and endothelial markers,
4 mm punch biopsies were taken from patients and healthy volunteers. Sub-
sequently, these were snap frozen and ultimately processed for immuno-
ﬂuorescent, immunohistochemical and enzymehistochemical stainings
and analyses. Also, epidermal sheets were isolated and used for RNA extrac-
tion in order to perform a qPCR to determine the epidermal CD26 / DPPIV 
expression on mRNA-level. The exact procedures of these techniques are 
described in the individual manuscripts. The used primary antibodies per 
technique have been summarized in table 5.
In order to assess the T-cell expression of CD26 / DPPIV in peripheral blood 
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of psoriatic patients and healthy volunteers, ﬂow cytometry was used. Flow
cytometry is a method that enables analysis and quantitative measurement 
of speciﬁc cell characteristics. In chapter 3.3 & 3.4, lymphocytes were single,
double and triple stained with ﬂuorescent dyes binding to designated sur-
face markers on T-cells. Table 5 incorporates the used antibodies.
1.7.3 Quantiﬁcation methods
A semi quantitative 4-point scoring method was used to evaluate the epi-
dermal keratinocyte expression of CD26 / DPPIV on protein level (immuno 
histochemistry) and enzyme activity level (enzyme histochemistry). For this 
purpose, sections were analyzed by microscopy at 200x magniﬁcation as-
sessing the full width of 4 mm. The semi quantitative score could range 
Table 5 Primary antibodies used for immunohistochemical staining techniques as 
well as for ﬂow cytometry.
(CD= cluster of diﬀerentiation, FITC= ﬂuorescein isothiocynate, PC7= phycoerythrin-Cy7,
PC5= phycoerythrin-Cy5, PE= phycoerythrin, BC= Beckman Coulter, BD= Becton Dickinson, 
IHC= immunohistochemistry, FCM= ﬂow cytometry)
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from no staining, to slight, to moderate or to pronounced staining. 
The quantity of CD26+ T-cells was assessed, choosing a region of interest 
(ROI) on the merged digital images of the sections treated with the immuno-
ﬂuorescence staining technique. In this ROI the number of lymphocytes
and speciﬁcally the CD26+ T-lymphocytes were counted. The digital images
were taken with an objective magniﬁcation of 400x.  
The proportion of CD26+ T-cell populations in peripheral blood was deter-
mined, using speciﬁc software for ﬂow cytometric analyses (WinList; Verity
Software House Inc,USA)
In order to quantify T-cell subsets in psoriatic skin sections, microscopy at 
200x magniﬁcation was used. The number of positive cells for CD3, CD4,
CD8, CD25, CD45RO, CD45RA, CD94 and CD161 were manually counted 
across the whole section in the epidermis from the basement membrane 
up to the stratum corneum; in the dermis these were counted from the 
basement membrane down to 100µm beneath. These quantiﬁcations were
expressed as “number of positive cells per mm skin length”. 
The endothelial (CD31) and proliferation- and diﬀerentiation markers (Ki-67
and K16) were evaluated on digital images using IP-lab software (Scana-
lytics, USA). The CD31, Ki-67 and K16 markers were expressed as “% positive 
surface area of the ROI”. 
For the exact methods of quantiﬁcation, the reader is referred to the cor-
responding manuscripts in this thesis.
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Summary
Background Therapies targeting the T cell-mediated pathology of psoriasis have
been found to achieve remarkable clinical improvement and have conﬁrmed the
crucial role of the immune system either in peripheral blood (PB) or in skin. No
analyses of T-cell counts in both compartments have been conducted in order to
conﬁrm or refute the hypothesized shifts between them.
Objectives To gain more insight in the dynamics of compartmentalization of T cells
between PB and lesional skin of patients with psoriasis, in response to immune-
targeted antipsoriatic therapies.
Methods Eighteen patients with psoriasis received either efalizumab (n = 9) or
etanercept (n = 9) for 12 weeks. Biopsies were taken for immunohistochemical
analysis of T-cell subsets and simultaneously T-cell subsets were isolated from PB
specimens by ﬂow cytometry.
Results The Psoriasis Area and Severity Index declined signiﬁcantly after 12 weeks
of etanercept, but not for efalizumab. After treatment with efalizumab, a signi-
ﬁcantly decreased number of all T-cell subsets was found in the dermis. In the
epidermis, CD4+, CD8+, CD25+, CD45RO+ and CD161+ T-cell subsets were
signiﬁcantly decreased. With respect to etanercept, few signiﬁcant changes in
T-cell subsets were found. The percentage of lymphocytes in PB was signiﬁcantly
elevated after efalizumab treatment regardless of responder status.
Conclusions Treatment with efalizumab establishes successful recompartmentaliza-
tion of T-cell subsets with modest clinical efﬁcacy after 12 weeks, whereas in
etanercept-treated patients, a signiﬁcant clinical response is no guarantee for
signiﬁcant changes in T-cell subsets in the different compartments. Reductions in
T-cell subsets cannot be used as predictive markers for the clinical response to
therapy. Interference with the studied T-cell populations in its own right seems
not to be responsible for the clinical efﬁcacy of efalizumab and etanercept.
Psoriasis is one of the most common human skin diseases. It
varies greatly in severity. For several decades it has been
suggested to be a T cell-mediated immune disease. Various
biological therapies that target various aspects of this T cell-
mediated pathology have given remarkable improvement in
patients with severe plaque-type psoriasis. These treatments
conﬁrm the crucial role of the immune system in psoriasis,1,2
either at the systemic level and ⁄or in the skin. Several biolo-
gics have been approved by the U.S. Food and Drug Adminis-
tration or the European Medicines Agency and have become a
valuable treatment option for severe psoriasis.
Studies addressing the T cell in psoriasis have been widely
conducted, focusing either on the dermal or the periph-
eral blood (PB) compartment. So far, the hypothesized
dynamic shifts of T cells between these two compart-
ments have remained underexplored as no studies have car-
ried out simultaneous analyses of T-cell counts in both
compartments.
The present study aims at mapping the dynamics of psoria-
sis-associated T-cell subsets in PB and lesional skin of patients
with severe psoriasis during the course of treatment with
immune-targeted therapies. By investigating both systemic and
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cutaneous T-cell subsets, it is possible to gain more insight in
the recompartmentalization of T cells in response to these
biologics.
Efalizumab is registered for severe psoriasis in the European
Union (EU). It is a humanized monoclonal antibody against
CD11a that blocks leucocyte function antigen-1 interactions
with cellular adhesion molecules 1 and 2, inhibiting T-lym-
phocyte activation and T-cell trafﬁcking. As a result, move-
ment of T cells into dermal and epidermal tissues and their
activation and reactivation are prevented. Accordingly,
efalizumab is a T cell-targeted treatment. The efﬁcacy of
efalizumab in psoriasis has been reported in large clinical
trials.3–5
Etanercept is the other biological agent which has been reg-
istered for several years for psoriasis in the EU. It is a fusion
protein which consists of the p75 portion of the tumour
necrosis factor (TNF)-a receptor linked to an IgG construct. It
binds speciﬁcally to TNF which is a proinﬂammatory cytokine
and thereby blocks its interaction with cell-surface TNF recep-
tors, rendering TNF biologically inactive. In psoriasis, the
inﬂammatory response is ampliﬁed as a result of increased
TNF-a expression in psoriatic plaques. Studies and reports of
daily clinical practice have indicated the efﬁcacy of this bio-
logical agent in psoriasis.6–11
In the current investigation, our objective was to investigate
the dynamics of psoriasis-associated T-cell subsets in PB and
lesional skin of patients with severe plaque-type psoriasis
through the course of treatment with immune-targeted thera-
pies, i.e. efalizumab and etanercept. In particular, we formu-
lated the following questions. (i) Are T-cell counts and
subsets affected in response to biological therapies? (ii) Is
recompartmentalization of T cells between PB and lesional
dermis and lesional epidermis induced by antipsoriatic treat-
ments and how does this relate to clinical efﬁcacy? (iii) Can
T-cell subset counts in blood or skin be used as a prognostic
marker for clinical efﬁcacy?
Therefore, we performed immunohistochemical stainings
for designated psoriasis-associated T-lymphocyte subsets on
psoriatic skin sections and at the same time we isolated
T-lymphocyte subsets from PB specimens by ﬂow cytometry
using ﬂuorochrome-conjugated monoclonal antibodies. In
particular, we quantiﬁed the number of T-cell subsets in PB
and the number of T cells in dermis and epidermis of the
psoriatic lesion and have correlated these counts with the
clinical severity of psoriasis.
Materials and methods
Patients
A total of 18 patients with severe plaque-type psoriasis [Psori-
asis Area and Severity Index (PASI) > 10] participated in this
12-week study. At random nine received efalizumab (ﬁve men
and four women; mean ± SEM age 51Æ3 ± 4Æ6 years and dis-
ease duration 19Æ8 ± 4Æ1 years) at a dosage regimen of
1 mg kg)1 weekly after an initial dose of 0Æ7 mg kg)1 weekly,
and nine received etanercept (six men and three women;
mean ± SEM age 53Æ7 ± 2Æ8 years and disease duration
22Æ4 ± 4Æ3 years) at a dosage regimen of 2 · 25 or 2 ·
50 mg weekly (respectively four and ﬁve patients due to
changes in the label of etanercept). Approval of the medical
ethics committee was obtained and all patients had given writ-
ten informed consent prior to any study procedures. Any topi-
cal and systemic antipsoriatic treatment had been suspended
for at least 2 weeks and 4 weeks, respectively, prior to partici-
pation. Furthermore, patients did not use any medication
interfering with disease activity of psoriasis (e.g. systemic cor-
ticosteroids, b-blockers, lithium carbonate, antimalarial medi-
cation and immunosuppressants) nor did they have any other
inﬂammatory dermatoses. Patients were allowed to use topical
antipsoriatic agents on a maximum of ﬁve lesions such as vita-
min D derivatives or low ⁄moderate strength topical steroids
(except on lesions designated for biopsy) in cases when the
effect of efalizumab or etanercept was unsatisfactory (non-
responders).
Biopsies and clinical assessment
One solitary plaque of at least 3 cm in diameter was chosen as
a target lesion. In all patients 4-mm punch biopsies were
taken over time, from representative sites in the target lesion
at least 1 cm from the margin of the psoriatic plaque, after
anaesthesia with 1% xylocaine ⁄adrenaline: one at baseline,
one after 4 weeks of treatment and one after 12 weeks of
treatment. Optionally skin defects were closed with one
suture.
At each visit severity scores (PASI) for overall severity of
psoriasis and SUM scores (for the severity of the target
lesion) were assessed by one single assessor. The SUM score
comprises the total score for erythema (0–4), induration
(0–4) and scaling (0–4); conversely, the PASI encompasses
the total body area involvement as well (range 0–72).
Venepuncture
PB for enumeration of lymphocytes was obtained from all
participating patients in 3-mL vacutainer tubes containing
ethylenediaminetetraacetate at baseline immediately before
administration of any medication, after 4 weeks of treatment
and ﬁnally after 12 weeks.
Immunohistochemical staining
Immunohistochemical staining was performed on all obtained
biopsies as previously described.12 In short, biopsies were
embedded in Tissue Tek OCT compound (Miles Scientiﬁc,
Napierville, IL, U.S.A.), snap frozen and stored at )80 �C until
use. After blocking endogenous peroxidase, sections were
washed in phosphate-buffered saline. Subsequently, sections
were incubated with the primary antibodies for 1 h. The
following primary antibodies (mouse antihuman) were
used: anti-CD3 (1 : 100; clone UCTH1), anti-CD4 (1 : 200;
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cutaneous T-cell subsets, it is possible to gain more insight in
the recompartmentalization of T cells in response to these
biologics.
Efalizumab is registered for severe psoriasis in the European
Union (EU). It is a humanized monoclonal antibody against
CD11a that blocks leucocyte function antigen-1 interactions
with cellular adhesion molecules 1 and 2, inhibiting T-lym-
phocyte activation and T-cell trafﬁcking. As a result, move-
ment of T cells into dermal and epidermal tissues and their
activation and reactivation are prevented. Accordingly,
efalizumab is a T cell-targeted treatment. The efﬁcacy of
efalizumab in psoriasis has been reported in large clinical
trials.3–5
Etanercept is the other biological agent which has been reg-
istered for several years for psoriasis in the EU. It is a fusion
protein which consists of the p75 portion of the tumour
necrosis factor (TNF)-a receptor linked to an IgG construct. It
binds speciﬁcally to TNF which is a proinﬂammatory cytokine
and thereby blocks its interaction with cell-surface TNF recep-
tors, rendering TNF biologically inactive. In psoriasis, the
inﬂammatory response is ampliﬁed as a result of increased
TNF-a expression in psoriatic plaques. Studies and reports of
daily clinical practice have indicated the efﬁcacy of this bio-
logical agent in psoriasis.6–11
In the current investigation, our objective was to investigate
the dynamics of psoriasis-associated T-cell subsets in PB and
lesional skin of patients with severe plaque-type psoriasis
through the course of treatment with immune-targeted thera-
pies, i.e. efalizumab and etanercept. In particular, we formu-
lated the following questions. (i) Are T-cell counts and
subsets affected in response to biological therapies? (ii) Is
recompartmentalization of T cells between PB and lesional
dermis and lesional epidermis induced by antipsoriatic treat-
ments and how does this relate to clinical efﬁcacy? (iii) Can
T-cell subset counts in blood or skin be used as a prognostic
marker for clinical efﬁcacy?
Therefore, we performed immunohistochemical stainings
for designated psoriasis-associated T-lymphocyte subsets on
psoriatic skin sections and at the same time we isolated
T-lymphocyte subsets from PB specimens by ﬂow cytometry
using ﬂuorochrome-conjugated monoclonal antibodies. In
particular, we quantiﬁed the number of T-cell subsets in PB
and the number of T cells in dermis and epidermis of the
psoriatic lesion and have correlated these counts with the
clinical severity of psoriasis.
Materials and methods
Patients
A total of 18 patients with severe plaque-type psoriasis [Psori-
asis Area and Severity Index (PASI) > 10] participated in this
12-week study. At random nine received efalizumab (ﬁve men
and four women; mean ± SEM age 51Æ3 ± 4Æ6 years and dis-
ease duration 19Æ8 ± 4Æ1 years) at a dosage regimen of
1 mg kg)1 weekly after an initial dose of 0Æ7 mg kg)1 weekly,
and nine received etanercept (six men and three women;
mean ± SEM age 53Æ7 ± 2Æ8 years and disease duration
22Æ4 ± 4Æ3 years) at a dosage regimen of 2 · 25 or 2 ·
50 mg weekly (respectively four and ﬁve patients due to
changes in the label of etanercept). Approval of the medical
ethics committee was obtained and all patients had given writ-
ten informed consent prior to any study procedures. Any topi-
cal and systemic antipsoriatic treatment had been suspended
for at least 2 weeks and 4 weeks, respectively, prior to partici-
pation. Furthermore, patients did not use any medication
interfering with disease activity of psoriasis (e.g. systemic cor-
ticosteroids, b-blockers, lithium carbonate, antimalarial medi-
cation and immunosuppressants) nor did they have any other
inﬂammatory dermatoses. Patients were allowed to use topical
antipsoriatic agents on a maximum of ﬁve lesions such as vita-
min D derivatives or low ⁄moderate strength topical steroids
(except on lesions designated for biopsy) in cases when the
effect of efalizumab or etanercept was unsatisfactory (non-
responders).
Biopsies and clinical assessment
One solitary plaque of at least 3 cm in diameter was chosen as
a target lesion. In all patients 4-mm punch biopsies were
taken over time, from representative sites in the target lesion
at least 1 cm from the margin of the psoriatic plaque, after
anaesthesia with 1% xylocaine ⁄adrenaline: one at baseline,
one after 4 weeks of treatment and one after 12 weeks of
treatment. Optionally skin defects were closed with one
suture.
At each visit severity scores (PASI) for overall severity of
psoriasis and SUM scores (for the severity of the target
lesion) were assessed by one single assessor. The SUM score
comprises the total score for erythema (0–4), induration
(0–4) and scaling (0–4); conversely, the PASI encompasses
the total body area involvement as well (range 0–72).
Venepuncture
PB for enumeration of lymphocytes was obtained from all
participating patients in 3-mL vacutainer tubes containing
ethylenediaminetetraacetate at baseline immediately before
administration of any medication, after 4 weeks of treatment
and ﬁnally after 12 weeks.
Immunohistochemical staining
Immunohistochemical staining was performed on all obtained
biopsies as previously described.12 In short, biopsies were
embedded in Tissue Tek OCT compound (Miles Scientiﬁc,
Napierville, IL, U.S.A.), snap frozen and stored at )80 �C until
use. After blocking endogenous peroxidase, sections were
washed in phosphate-buffered saline. Subsequently, sections
were incubated with the primary antibodies for 1 h. The
following primary antibodies (mouse antihuman) were
used: anti-CD3 (1 : 100; clone UCTH1), anti-CD4 (1 : 200;
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clone MT310), anti-CD8 (1 : 200; clone C8 ⁄144B), anti-CD25
(1 : 200; clone ACT-1), anti-CD45RO (1 : 100; clone UCHL1),
anti-CD45RA (1 : 200; clone 4KB5) and anti-CD94 (1 : 100;
clone HP-3D9) all from Dako (Copenhagen, Denmark) and
anti-CD161 (1 : 100; clone 191B8) from Immunotech
(Marseille, France). Secondary IgG-labelled polymer, horse-
radish peroxidase antimouse antibody EnVision+ (Dako), was
added for 30 min. To visualize the staining we applied amino-
ethylcarbazole+ high sensitivity substrate chromogen (Dako)
for 10 min at 37 �C. Counterstaining was performed with
Mayer’s haematoxylin (Sigma-Aldrich, St Louis, MO, U.S.A.).
Subsequently, the sections were mounted in glycerol gelatin
(Sigma-Aldrich).
Furthermore, from each patient we performed a haematoxylin
and eosin staining to verify that the biopsies under study
fulﬁlled the psoriasis-speciﬁc histological criteria.
Quantiﬁcation of T-cell subsets in psoriatic skin
Quantiﬁcation of the T-cell subsets in the sections was per-
formed as previously described, with light microscopy at
· 200 magniﬁcation.13 Quantitative cell counts of the various
T-cell subsets were expressed as positive cells mm)1 skin
length. The assessor was blinded to treatment and differed
from the one performing the clinical assessments.
Flow cytometry and data analysis
The following monoclonal antibodies were used for ﬂow
cytometry: CD3-FITC (Beckman Coulter, Hileah, FL, U.S.A.),
CD4-PE (Dako), CD8-PECy5 (Beckman Coulter), CD25-PECy5
(Becton Dickinson, Franklin Lakes, NJ, U.S.A.), CD45RO-
ECD (Beckman Coulter), CD45RA-FITC (Becton Dickinson),
CD94-PE (Beckman Coulter) and CD161-PE (Beckman
Coulter).
Before ﬂow cytometric analyses all erythrocytes were
lysed (10 min, in the dark) by means of ice-cold
155 mmol L)1 NH4Cl (pH 7Æ4) according to the lyse ⁄no
wash method. Staining of cells was determined in four-col-
our analysis by using an Epics XL ﬂow cytometer (Beckman
Coulter). All measurements were performed on minimally
50 000 cells. Data (collected in list mode) were analysed
blinded to treatment by the same assessor for the immuno-
histochemical quantiﬁcations, using the EXPO32 ADC soft-
ware (Beckman Coulter).
Statistical analysis
All analyses were performed using SPSS software, version
14.0 (SPSS, Chicago, IL, U.S.A.). Analysis of variance with
repeated measurement was used to analyse the effect of
treatment and time. Additional contrasts in the time-related
effects of the treatments (between baseline and 4 weeks of
treatment and between 4 and 12 weeks of treatment) were
analysed with paired t-tests. Statistical signiﬁcance was set
at 0Æ05.
Results
Patient population and clinical severity
Eighteen patients aged at least 18 years participated; their
demographics are presented in Table 1. The mean ± SEM PASI
and SUM score at onset of the various treatments together
with the interval scores (4 weeks) and the percentage change
after 12 weeks of treatment are also presented in Table 1. The
PASI declined signiﬁcantly after 12 weeks of treatment with
etanercept, but not with efalizumab (P = 0Æ669) which did
not reach a statistically signiﬁcant improvement. In addition,
the mean SUM score for efalizumab and etanercept decreased
signiﬁcantly. All biopsies fulﬁlled the disease-speciﬁc histo-
logical criteria for psoriasis.
Compartmentalization of T-cell subsets after 12 weeks
of treatment with efalizumab
Regarding the PB compartment in patients treated with
efalizumab, the CD8+ T lymphocytes were signiﬁcantly ele-
vated after 12 weeks whereas the CD94+ and CD161+ T-cell
amounts were signiﬁcantly decreased in this study (Table 2).
Remarkably, the percentage of lymphocytes and the leucocyte
count in PB were both signiﬁcantly elevated after 12 weeks.
With respect to the dermis we found a signiﬁcantly decreased
number of all T-cell subsets (CD3+, CD4+, CD8+, CD25+,
CD45RA+, CD45RO+, CD94+ and CD161+ T cells) and
regarding the epidermis, the CD4+, CD8+, CD25+, CD45RO+
and CD161+ T cells were signiﬁcantly decreased.
Clinically the psoriatic lesions had a signiﬁcantly lower
SUM score; however, the PASI had not decreased signiﬁcantly
after 12 weeks of efalizumab. The efalizumab patient group
was split into responders (PASI reduction > 50%) and non-
responders to therapy (PASI reduction £ 50%) in order to
investigate these ﬁndings further. Although we found four
Table 1 Demographics and clinical parameters of participating
patients with psoriasis
Efalizumab Etanercept
Number 9 9
Dosage regimen 1Æ0 mg kg)1 2 · 25 ⁄2 · 50 mg
weekly
Age (years) 51Æ3 ± 4Æ6 53Æ7 ± 2Æ8
M ⁄F 5 ⁄4 6 ⁄3
Baseline PASI 14Æ4 ± 2Æ3 18Æ9 ± 2Æ6
Interval PASI (4 weeks) 15Æ1 ± 3Æ4 12Æ9 ± 2Æ2
Reduction in PASI EOT (%) 11Æ1 ± 16Æ6 57Æ6 ± 12Æ1
(P-value) (0Æ67) (0Æ00)
Baseline SUM 6Æ8 ± 0Æ7 7Æ1 ± 0Æ5
Interval SUM (4 weeks) 5Æ3 ± 0Æ7 3Æ3 ± 0Æ6
Reduction in SUM EOT (%) 35Æ9 ± 10Æ4 69 ± 7Æ8
(P-value) (0Æ008) (0Æ00)
PASI, Psoriasis Area and Severity Index; EOT, end of treatment
(12 weeks). Results are shown as mean ± SEM.
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responders and ﬁve nonresponders, strikingly in both groups
a signiﬁcantly increased percentage of PB lymphocytes was
detected (P < 0Æ05).
Compartmentalization of T-cell subsets after 12 weeks
of treatment with etanercept
The PB compartment showed no signiﬁcant shifts in percent-
ages of T-cell subsets after etanercept therapy (Table 2). How-
ever, after 12 weeks we found a signiﬁcantly decreased
amount of CD8+, CD25+, CD45RA+ and CD161+ T cells in
the psoriatic dermis, whereas in the epidermis the CD45RO+
T-cell subset was signiﬁcantly increased.
The clinical response to etanercept showed a signiﬁcant
decrease on both lesional (SUM) and total body score (PASI)
(Tables 1, 2). As all patients responded well to etanercept, the
effect on T cells in responders and nonresponders could not
be compared.
Common effects of treatment with efalizumab and
etanercept on the dynamics of T-cell subsets in psoriasis
Both efalizumab and etanercept induced a decrease in the
amount of CD8+, CD25+, CD45RA+ and CD161+ T-cell sub-
sets in the psoriatic dermis, whereas no common effects on
T-cell subsets were found in the epidermis or PB.
Changes in T-cell subset counts in peripheral blood and
psoriatic skin related to clinical severity and extent
during 12 weeks of treatment
In order to determine whether shifts in psoriasis-associated
T-cell subset counts in the circulation and the psoriatic skin
are associated with the clinical severity of psoriasis (reﬂected
by the PASI), a comparison was made between the shifts in
the ﬁrst treatment period of 4 weeks and the second period
between 4 and 12 weeks of treatment. Results are shown in
Figure 1.
Efalizumab
Figure 1(a) represents the main signiﬁcant shifts in T-cell sub-
sets in all compartments and PB lymphocyte percentage during
a 12-week course of efalizumab treatment. The clinical effec-
tiveness of efalizumab, however, was not signiﬁcant (PASI)
after 12 weeks.
Notably, as depicted in Figure 1(b), the PASI tended to
increase during the ﬁrst 4 weeks of treatment with efalizumab
whereas the T-cell subsets in the psoriatic (epi)dermis tended
to be dropping in the ﬁrst 4 weeks of treatment. In the PB,
however, there was a marked lymphocytosis in this ﬁrst treat-
ment period, which seems mainly attributable to the CD8+
lymphocytes.
In the second treatment period, between 4 and 12 weeks,
the PASI tended to decrease compared with the ﬁrst 4 weeks
of treatment. In this phase, the percentage of lymphocytes and
speciﬁcally of the CD8+ lymphocytes tended to decrease in
contrast to the ﬁndings in the ﬁrst treatment period (Fig. 1c).
Etanercept
Figure 1(d) represents the main shifts in T-cell subsets and PB
lymphocyte percentage which occurred during a 12-week
course of etanercept treatment. In contrast to efalizumab, only
CD8 and CD25 in the dermis showed signiﬁcant changes due
to the treatment with etanercept. No striking changes in T-cell
Table 2 Dynamics in psoriasis-associated T-cell subset counts during a 12-week therapy with either efalizumab or etanercept in patients with
psoriasis. P-values are given
T-cell subset counts
PB Dermis Epidermis
EFA ETA EFA ETA EFA ETA
CD3 0Æ225 0Æ275 0Æ001 . 0Æ256 0Æ086 0Æ451
CD4 0Æ145 ND 0Æ001 . 0Æ078 0Æ005 . 0Æ518
CD8 0Æ044 ND 0Æ001 . 0Æ041 . 0Æ011 . 0Æ053
CD25 NS NS 0Æ00 . 0Æ034 . 0Æ00 . 0Æ07
CD45RO NS NS 0Æ01 . 0Æ34 0Æ004 . 0Æ011
CD45RA NS NS 0Æ003 . 0Æ026 . 0Æ136 0Æ275
CD94 0Æ042 . ND 0Æ048 . 0Æ085 0Æ094 0Æ139
CD161 0Æ042 . ND 0Æ00 . 0Æ024 . 0Æ009 . 0Æ086
PASI 0Æ669 0Æ00 .
SUM 0Æ008 . 0Æ00 .
Leucocyte count 0Æ001 0Æ631
Lymphocytes (%) 0Æ004 0Æ091
PB, peripheral blood; EFA, efalizumab; ETA, etanercept; PASI, Psoriasis Area and Severity Index; ., decrease during therapy; , increase
during therapy; NS, not shown; ND, not determinable.
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responders and ﬁve nonresponders, strikingly in both groups
a signiﬁcantly increased percentage of PB lymphocytes was
detected (P < 0Æ05).
Compartmentalization of T-cell subsets after 12 weeks
of treatment with etanercept
The PB compartment showed no signiﬁcant shifts in percent-
ages of T-cell subsets after etanercept therapy (Table 2). How-
ever, after 12 weeks we found a signiﬁcantly decreased
amount of CD8+, CD25+, CD45RA+ and CD161+ T cells in
the psoriatic dermis, whereas in the epidermis the CD45RO+
T-cell subset was signiﬁcantly increased.
The clinical response to etanercept showed a signiﬁcant
decrease on both lesional (SUM) and total body score (PASI)
(Tables 1, 2). As all patients responded well to etanercept, the
effect on T cells in responders and nonresponders could not
be compared.
Common effects of treatment with efalizumab and
etanercept on the dynamics of T-cell subsets in psoriasis
Both efalizumab and etanercept induced a decrease in the
amount of CD8+, CD25+, CD45RA+ and CD161+ T-cell sub-
sets in the psoriatic dermis, whereas no common effects on
T-cell subsets were found in the epidermis or PB.
Changes in T-cell subset counts in peripheral blood and
psoriatic skin related to clinical severity and extent
during 12 weeks of treatment
In order to determine whether shifts in psoriasis-associated
T-cell subset counts in the circulation and the psoriatic skin
are associated with the clinical severity of psoriasis (reﬂected
by the PASI), a comparison was made between the shifts in
the ﬁrst treatment period of 4 weeks and the second period
between 4 and 12 weeks of treatment. Results are shown in
Figure 1.
Efalizumab
Figure 1(a) represents the main signiﬁcant shifts in T-cell sub-
sets in all compartments and PB lymphocyte percentage during
a 12-week course of efalizumab treatment. The clinical effec-
tiveness of efalizumab, however, was not signiﬁcant (PASI)
after 12 weeks.
Notably, as depicted in Figure 1(b), the PASI tended to
increase during the ﬁrst 4 weeks of treatment with efalizumab
whereas the T-cell subsets in the psoriatic (epi)dermis tended
to be dropping in the ﬁrst 4 weeks of treatment. In the PB,
however, there was a marked lymphocytosis in this ﬁrst treat-
ment period, which seems mainly attributable to the CD8+
lymphocytes.
In the second treatment period, between 4 and 12 weeks,
the PASI tended to decrease compared with the ﬁrst 4 weeks
of treatment. In this phase, the percentage of lymphocytes and
speciﬁcally of the CD8+ lymphocytes tended to decrease in
contrast to the ﬁndings in the ﬁrst treatment period (Fig. 1c).
Etanercept
Figure 1(d) represents the main shifts in T-cell subsets and PB
lymphocyte percentage which occurred during a 12-week
course of etanercept treatment. In contrast to efalizumab, only
CD8 and CD25 in the dermis showed signiﬁcant changes due
to the treatment with etanercept. No striking changes in T-cell
Table 2 Dynamics in psoriasis-associated T-cell subset counts during a 12-week therapy with either efalizumab or etanercept in patients with
psoriasis. P-values are given
T-cell subset counts
PB Dermis Epidermis
EFA ETA EFA ETA EFA ETA
CD3 0Æ225 0Æ275 0Æ001 . 0Æ256 0Æ086 0Æ451
CD4 0Æ145 ND 0Æ001 . 0Æ078 0Æ005 . 0Æ518
CD8 0Æ044 ND 0Æ001 . 0Æ041 . 0Æ011 . 0Æ053
CD25 NS NS 0Æ00 . 0Æ034 . 0Æ00 . 0Æ07
CD45RO NS NS 0Æ01 . 0Æ34 0Æ004 . 0Æ011
CD45RA NS NS 0Æ003 . 0Æ026 . 0Æ136 0Æ275
CD94 0Æ042 . ND 0Æ048 . 0Æ085 0Æ094 0Æ139
CD161 0Æ042 . ND 0Æ00 . 0Æ024 . 0Æ009 . 0Æ086
PASI 0Æ669 0Æ00 .
SUM 0Æ008 . 0Æ00 .
Leucocyte count 0Æ001 0Æ631
Lymphocytes (%) 0Æ004 0Æ091
PB, peripheral blood; EFA, efalizumab; ETA, etanercept; PASI, Psoriasis Area and Severity Index; ., decrease during therapy; , increase
during therapy; NS, not shown; ND, not determinable.
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subset counts of the etanercept-treated patients were found in
the ﬁrst (between onset and 4 weeks of treatment) or second
treatment period (between 4 and 12 weeks of treatment)
which could be related to PASI increase or decrease (data not
shown). In contrast to the modest effects on T cells, etaner-
cept had a robust clinical effect, as shown by the reduction in
PASI, in this patient group.
Discussion
Psoriasis has been suggested to be a T cell-mediated auto-
immune disease. For several decades, studies have focused on
the central role of the T lymphocyte in psoriasis. Some investi-
gators have studied T cells in skin and others in the PB com-
partment. Frequently it is hypothesized that shifting of T cells
between the skin and systemic compartment is relevant to the
pathogenesis of psoriasis. However, the alleged dynamics of
T-cell shifts between the two compartments has never been
studied simultaneously in one investigation. In order to under-
stand the mode of action of antipsoriatic therapies targeting
the immune system, gaining more insight in the compartmen-
talization of psoriasis-associated T-cell subsets during and after
such therapies seems valuable. This study analyses compart-
mentalization of T cells in the cutaneous compartments
(dermis and epidermis) and systemic compartment (PB) in
patients with psoriasis using immune-targeted therapies
(efalizumab, etanercept). Furthermore, the study correlates
T-cell counts in these compartments with clinical efﬁcacy. The
aim was to gain more insight by asking the following ques-
tions. (i) Are T-cell counts and subsets affected in response to
biological therapies? (ii) Is recompartmentalization of T cells
between PB and lesional dermis and lesional epidermis
induced by antipsoriatic treatments and how does this relate
to clinical efﬁcacy? (iii) Can T-cell subset counts in blood or
skin be used as a prognostic marker for clinical efﬁcacy?
Both therapies have a different mode of action, primarily or
secondarily targeting the T cell and ultimately reﬂected in
some degree of clinical response. In this study the effect on
T-cell subsets of efalizumab and etanercept, the two biologicals
most frequently prescribed in daily practice, proved to be dis-
similar. Efalizumab has been shown to inhibit T-lymphocyte
activation and T-cell trafﬁcking.3–5 This knowledge has been
conﬁrmed and extended by our ﬁndings as efalizumab treat-
ment resulted in a signiﬁcant reduction of psoriasis-relevant
T-cell subsets in the epidermal and dermal compartment while
CD8+ T cells increased in the PB after 12 weeks of therapy.
The effect of efalizumab on T-lymphocyte trafﬁcking and in
particular the shift of T lymphocytes from the cutaneous to
the PB compartment was shown convincingly in the present
study. However, this apparent T-cell trafﬁcking alone does not
comprise the overall mode of action of efalizumab as the
mechanism of blocking T-cell (re)activation with efalizumab
should not be underestimated.14 However, this recompart-
mentalization of T cells was not indicative for the clinical
response to efalizumab therapy as the PASI did not show a
signiﬁcant decrease after 12 weeks. In order to determine
whether the recompartmentalization of psoriasis-associated
T-cell subset counts in the circulation and the psoriatic skin was
associated with the clinical severity of psoriasis, the dynamics
of changes during 12 weeks was studied by splitting the treat-
ment of 12 weeks into the ﬁrst 4 weeks and 4–12 weeks.
Between onset of efalizumab treatment and 4 weeks of treat-
ment, the clinical severity of psoriasis of efalizumab-treated
patients had a tendency to increase (Fig. 1b), in contrast to
(b) (c)
(a) (d)
Fig 1. Fluctuations in T-cell subset counts in response to treatment with efalizumab or etanercept. (a) Signiﬁcant changes in CD markers and
peripheral blood lymphocytes in response to a 12-week treatment with efalizumab and corresponding Psoriasis Area and Severity Index (PASI)
reduction (%). (b) Changes in CD markers and peripheral blood lymphocytes in response to efalizumab through the ﬁrst 4 weeks of treatment.
(c) Changes in CD markers and peripheral blood lymphocytes in response to efalizumab between 4 and 12 weeks of treatment. (d) Changes in
CD markers and peripheral blood lymphocytes in response to a 12-week treatment with etanercept and corresponding PASI reduction (%). Data
are shown in mean percentages ± SEM. ED, epidermis; D, dermis; BL, peripheral blood; *, signiﬁcantly changed (P < 0Æ05).
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the main psoriasis-associated T-cell subset counts in the skin
which tended to decrease and in sharp contrast to the increase
in PB T lymphocytes. Between 4 and 12 weeks T-cell counts
did not change substantially (Fig. 1c); however, the clinical
severity tended to show an initial improvement. We know
from other studies and from experience in daily clinical prac-
tice that prolonged treatment with efalizumab for 24 weeks or
more is needed for considerable clinical efﬁcacy.6,15 There-
fore, we may conclude from the present investigation that
recompartmentalization of subsets precedes clinical effective-
ness in patients treated with efalizumab.
When comparing responders (n = 4) and nonresponders
(n = 5) to efalizumab treatment, both groups showed a com-
parable increase of PB lymphocytes. Also in the psoriatic lesion
no consistent pattern of T-cell subsets exists which may iden-
tify the responder or nonresponder status. Efalizumab induces
a lymphocytosis regardless of clinical effectiveness and reduces
T-cell subsets in the lesion regardless of clinical efﬁcacy. As
responders and nonresponders could not be identiﬁed by the
degree of T-cell recompartmentalization, other principles
should be studied in order to understand the entire action of
efalizumab, such as the interaction between antigen-presenting
cells and T cells or the initiation of T-cell activation.
Focusing on the patient group treated with etanercept,
results were different from those of efalizumab as few signiﬁ-
cant reductions in T-cell counts in the various compartments
could be found (Table 2). However, etanercept showed high
clinical efﬁcacy after 12 weeks. Etanercept primarily blocks the
interaction with TNF receptors, making TNF a biologically
inactive cytokine. Secondarily, it affects the T cell by reducing
T-cell activation. The remarkable clinical efﬁcacy of etanercept
after 12 weeks of therapy was not preceded by a recompart-
mentalization of T cells. The discrepancy between the pro-
nounced clinical improvement and the modest reduction of
T-cell subsets suggests that reductions in T-cell subsets after
etanercept therapy are not the precondition for clinical efﬁcacy.
Both antipsoriatic agents in this study are part of the arsenal
of systemic therapies. It is reassuring that only modest changes
of the T-cell subsets in the PB (Table 2) could be detected.
Therefore we may assume that these agents mainly inﬂuence
the effector organ, the psoriatic skin.
In conclusion, comparing two major biological therapies in
this current investigation, data show that treatment with
efalizumab establishes successful recompartmentalization of
T-cell subsets with modest clinical efﬁcacy after 12 weeks,
whereas in etanercept-treated patients, a signiﬁcant clinical
response is no guarantee for signiﬁcant changes in T-cell sub-
sets in the different compartments of the skin and PB. There-
fore the present study, comparing tendencies of the clinical
efﬁcacy course with the changes in T-cell counts in the vari-
ous compartments, has provided insight in the dynamics of
compartmentalization of psoriasis-associated T-cell subsets.
Subsequently, it revealed that reductions in T-cell subsets in
the various compartments cannot be used as predictive mark-
ers for the clinical response to therapy. As a result, lack of
association between effects on T-cell subsets and clinical
effects suggests that interference with the studied T-cell popu-
lations in its own right is not responsible for the clinical efﬁ-
cacy of efalizumab and etanercept. This undoubtedly reﬂects
the complexity of psoriasis pathogenesis and the presence of a
multitude of immune pathways.
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Good clinical response to anti-psoriatic treatment with adalimumab
and methotrexate does not inflict a direct effect on
compartmentalization of T-cell subsets: A pilot study
ROSANNE G. VAN LINGEN, ELKE M. G. J. DE JONG, MAARTJE A. M. BERENDS,
MARIEKE M. B. SEYGER, PIET E. J. VAN ERP & PETER C. M. VAN DE KERKHOF
Department of Dermatology, University Medical Centre St Radboud, Nijmegen, The Netherlands
Abstract
Objectives: The most recently introduced therapeutics for psoriasis are biologicals which can target the T-cell-mediated
pathology of psoriasis in a direct or indirect manner. The present pilot study focuses on and compares the effect of a
conventional systemic agent (methotrexate; MTX) with the effect of a TNF-binding biological (adalimumab) on psoriasis-
associated T-cell subsets in peripheral blood (PB) and lesional skin. Insight is provided in the hypothesized
compartmentalization of these T-cell subsets between PB and the cutaneous compartment. Methods: Immuno-
histochemical stainings of designated T-cell subsets on psoriatic skin sections were performed and similar subsets were
isolated from PB specimens by flow cytometry. These counts were correlated with clinical severity. Results: Results showed
that adalimumab had a greater clinical effect than MTX treatment after 12 weeks. In the dermis, only the CD3+ T cells
were significantly reduced after 12 weeks of adalimumab therapy, whereas for MTX only CD3+ T cells in the epidermis and
CD45RO+ T cells in the dermis reduced significantly. However, PB T-lymphocyte populations did not show significant
shifts in quantification of T-cell subsets. Conclusion: Therefore, recompartmentalization of psoriasis-associated T-cell
subsets between PB and lesional skin was not induced in this study as a therapeutic principle. Consequently,
recompartmentalization of T-cell subsets does not seem an obligatory event in order to achieve good clinical response.
Key words: Adalimumab, methotrexate, psoriasis, (re)compartmentalization, T cell
Introduction
T cells belong to the key aspects of the psoriatic
pathogenesis. The most recent therapeutics intro-
duced in the treatment of moderate to severe plaque
psoriasis are the biologicals, of which each in its own
way affects the T cell to a certain extent. They have
become a valuable treatment option in the ther-
apeutic arsenal as large clinical trials and daily
practice have shown great clinical efficacy for the
majority of severely affected psoriatic patients. As
biologicals can target the T-cell-mediated pathology
of psoriasis in a direct or indirect manner, it seems
warranted to investigate this effect on the T cells in
psoriasis.
Convincingly, the most widely prescribed conven-
tional systemic agent for several decades for severe
psoriasis is methotrexate (MTX). MTX has potent
anti-inflammatory effects on T-cell-mediated
immune responses as it primarily blocks abnormal
rapid epidermal cell proliferation in psoriasis and
inhibits proliferation or induces apoptosis in acti-
vated T cells (1). Recently registered for the treat-
ment of severe plaque-type psoriasis in the EU is the
biological adalimumab, which is a fully human
immunoglobulin G1 monoclonal antibody binding
with high affinity and specificity to ;TNF (2). Upon
binding to TNF it can modulate biological responses
that are induced or regulated by TNF, subsequently
affecting the T cell, and is reported to be highly
effective and safe in the treatment of severe psoriasis
(3–5).
The current investigation comprised a satellite
study to the Phase III CHAMPION trial (6),
focusing on and comparing the effect of a conven-
tional systemic agent (MTX) with the effect of a
TNF-binding biological (adalimumab) on psoriasis-
associated T-cell subsets in peripheral blood and
lesional skin of patients with moderate to severe
plaque psoriasis. Further light was shed on the T-cell
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dynamics in the pathogenesis of psoriasis in order
to define whether generally hypothesized shifting
of T cells between the skin and the systemic
compartment is achieved in response to both
therapies. In the end, by comparing these two
treatments in a pilot study, preliminary insight is
provided in the effect of a conventional (MTX) and
a novel (adalimumab) therapy on the T cells in the
cutaneous and systemic compartment in psoriatic
patients and consequently in the hypothesized
compartmentalization of psoriasis-associated T-cell
subsets between peripheral blood and lesional
dermis and epidermis.
Therefore, we performed immunohistochemical
stainings for designated psoriasis-associated
T-lymphocyte subsets on psoriatic skin sections
and at the same time we isolated T-lymphocyte
subsets from peripheral blood specimens by flow
cytometry using fluorochrome-conjugated mono-
clonal antibodies. In particular, we have quantified
the number of T-cell subsets in peripheral blood and
the number of T cells in the dermis and epidermis of
the psoriatic lesion and have correlated these counts
with the clinical severity of psoriasis.
Patients and methods
Patients
A total of eight patients with moderate to severe
plaque-type psoriasis (Psoriasis Area and Severity
Index (PASI) w10) participated in this 12-week
study. Approval of the medical ethics committee was
obtained and each patient provided written informed
consent prior to any study-related procedures. Four
patients received 40 mg adalimumab subcuta-
neously every other week and four received MTX
per os in an increasing dosing regimen from 7.5 mg
up to 25 mg per week. Any topical or systemic
treatment had been suspended for at least 2 weeks
and 4 weeks respectively prior to participation.
Furthermore, patients did not use any medication
interfering with the disease activity of psoriasis
nor were any concomitant anti-psoriatic therapies
allowed during the study. The specific study proto-
col and study design are described elsewhere (6).
Biopsies and clinical assessment
One solitary plaque of at least 3 cm in diameter was
chosen as a target lesion. In all patients 4-mm punch
biopsies were taken over time from representative
sites in the target lesion at least 1 cm from the
margin of the psoriatic plaque after anaesthesia with
1% xylocaine/adrenaline: one at baseline (T50) and
one after 12 weeks of treatment (T512). Optionally,
skin defects were closed with one suture. At each
visit severity scores (PASI) for the overall severity of
psoriasis were assessed.
Venapuncture
Peripheral blood for enumeration of lymphocytes
was obtained from all participating patients in 3-ml
vacutainer tubes containing ethylenediaminetetra-
acetate at baseline immediately before any medica-
tion administration (T50) and finally after 12 weeks
of treatment (T512).
Immunohistochemical staining
Immunohistochemical staining was performed on all
obtained biopsies as previously described (7,8). The
following primary antibodies (mouse anti-human)
were used: anti-CD3 1:100 (pan T-cell marker)
(clone UCTH1), anti-CD4 1:200 (T-helper cells)
(clone MT310), anti-CD8 1:200 (cytotoxic T cells)
(clone C8/144B), anti-CD25 1:200 (activated T
cells) (clone ACT-1), anti-CD45RO 1:100 (memory
T cells) (clone UCHL1), anti-CD45RA 1:200
(naive T cells) (clone 4KB5) and anti-CD94 1:100
(NK-T cells) (clone HP-3D9) all from DAKO
(Copenhagen, Denmark) and anti-CD161 1:100
(NK-T cells) (clone 191B8) from Immunotech
(Marseille, France). Furthermore, we performed a
H&E staining to verify that the biopsies under study
from each patient fulfilled the psoriasis-specific
histological criteria.
Quantification of T-cell subsets in psoriatic skin
Quantification of the T-cell subsets in the sections
was enforced as previously done with light micro-
scopy at 2006 magnification (7,8). Quantitative cell
counts of the various T-cell subsets were expressed
as ‘positive cells per mm skin length’.
Flow cytometry and data analysis
The following monoclonal antibodies were used for
flow cytometry: CD3-FITC (Beckman <Coulter),
CD4-PE (DAKO), CD8-PECy5 (Beckman
Coulter), CD25-PECy5 (Becton Dickinson),
CD45RO-ECD (Beckman Coulter), CD45RA-
FITC (Becton Dickinson), CD94-PE (Beckman
Coulter) and CD161-PE (Beckman Coulter).
Flow cytometric analyses were performed by the
Hematology Laboratory of the Radboud University
Nijmegen Medical Centre which is certified for
analyzing peripheral blood specimens for diagnostic
use. Before flow cytometric analyses, all erythrocytes
were lysed (10 min, in the dark) by means of ice-
cold 155 mmol/l NH4Cl (pH 7.4) according to the
lyse/no-wash method. Staining of cells was deter-
mined in four-colour analysis by using a Beckman
Coulter Epics XL flow cytometer (Beckman
Coulter, Hileah, FL, USA). All measurements were
performed on a minimum of 50 000 cells. Data
(collected in list mode) were analyzed using the
EXPO32 ADC software (Beckman Coulter).
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Statistical analysis
All analyses were performed using SPSS software,
version 14.0. Analysis of variance with repeated
measurement (ANOVA) was used to analyze the
effect of treatment and time. Statistical significance
was set at 0.05.
Results
Patient population and clinical severity
In total, eight patients of at least 18 years old
participated; for whom the demographics are
expanded in Table I. The mean PASI¡SEM at
onset of the two treatments, together with the
percentage reduction after 12 weeks of treatment
are also given in Table I. Overall, baseline PASI
scores were comparable in range. Although the
patient groups were somewhat small, both therapies
showed to be clinically effective as the PASI scores
reduced significantly after 12 weeks of both thera-
pies, albeit to a different extent. Treatment with
adalimumab evoked a PASI reduction of 84.5%
(pv0.05) in contrast to 48.4% (pv0.05) in the
MTX group. Therefore, statistically significantly
more patients in the adalimumab group than in the
MTX group achieved a remarkable PASI reduction.
All biopsies fulfilled the disease-specific histologi-
cal criteria of psoriasis.
Compartmentalization of T-cell subsets after treatment
with adalimumab or MTX (Table II)
Table II reflects an overview of the changes in the
designated psoriasis-associated T-cell subsets after
12 weeks of therapy. After six injections of adalimu-
mab (every other week), only the CD3+ T cells in
the dermis reduced significantly, whereas for MTX
only the CD3+ T cells in the epidermis and the
CD45RO+ T cells in the dermis reduced signifi-
cantly. Although both adalimumab and MTX
possess a systemic mode of action, in the peripheral
blood neither adalimumab nor MTX induced a
significant change in T cells in general (CD3+) or in
specific T-cell subsets (data not shown).
Discussion
In line with earlier findings (6), the present pilot
study shows that adalimumab therapy results in
greater clinical efficacy than treatment with MTX
after 12 weeks. Namely, a mean PASI reduction of
84.5% was achieved in the patients treated with
adalimumab versus 48.4% in patients treated with
MTX. It should be noted, however, that daily
practice teaches that probably the greatest clinical
response to therapy with MTX is likely to be
achieved after a more lengthy treatment period.
Nevertheless, both PASI reductions showed to be
statistically significant after 12 weeks. However, this
good clinical response to treatment with adalimu-
mab and MTX did not obviously inflict a major
direct effect on compartmentalization of T cells in
the peripheral blood and lesional dermis and
epidermis of these patients. Immunohistochemical
analyses of psoriasis-associated T-lymphocyte sub-
sets on psoriatic skin sections before and after 12
weeks of therapy with either adalimumab or MTX
did reveal several significant reductions in T-cell
subset counts but did not lead to alleged compart-
mentalization. However, flow cytometric analyses in
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Table I. Demographics and clinical characteristics of participat-
ing psoriatic patients.
Adalimumab Methotrexate
Number of patients 4 4
Age, years 46.8¡3.5 34.8¡4.6
Female / male 1/3 1/3
Baseline PASI 26.5¡5.5 24.2¡6.4
EOT PASI 4.2¡1.3 13.1¡5
PASI-reduction %
(p-value)
284.5¡3.1 (0.016) 248.4¡9.6 (0.018)
Dosage regimen 40 mg/2 weeks 7.5–25 mg/week
Maximum doses 1 patient: 15 mg/week
1 patient: 20 mg/week
2 patients: 25 mg/week
EOT5end of treatment; PASI5psoriasis area and severity score.
Table II. Dynamics in designated T-cell subset counts in psoriatic patients during 12 weeks of therapy with adalimumab or methotrexate.
T-cell subset counts
Compartment Dermis Epidermis
Therapy ADA MTX ADA MTX
CD3 0.02. 0.328 0.154 0.018.
CD4 0.065 ?0.072 0.259 0.784
CD8 0.377 0.06 0.058 0.051
CD25 0.235 0.618 0.159 0.304
CD45RO 0.457 0.002. 0.066 0.062
CD45RA 0.149 0.397 0.161 0.22
CD94 0.283 0.239 0.182 0.464
CD161 0.064 0.531 0.154 0.499
Data presented as p-values. ADA5adalimumab; MTX5methotrexate; .5significant decrease during therapy.
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peripheral blood specimens before and after therapy
failed to reveal significant shifts in quantification of
T-cell subsets. Therefore, the present study does not
lend support for a recompartmentalization of T-cell
subsets between the peripheral blood and lesional
skin as a therapeutic principle in psoriasis. Yet, even
though the PASI score in the two patient groups was
shown to reduce significantly, it must be noted that
both patient groups were rather small.
Although the exact mode of action of conventional
therapy with MTX is not fully elucidated, it is well
known that it has potent anti-inflammatory effects
on T-cell-mediated immune responses as it primarily
blocks abnormal rapid epidermal cell proliferation in
psoriasis and inhibits proliferation or induces apop-
tosis in activated T cells (1). Further advances in the
knowledge about the effect of MTX on psoriatic key
players can enrich the understanding of the exact
mechanism of action. Jointly with the significant
clinical response, it may be suggested that MTX
ultimately influences lesional, but not peripheral
blood T cells, as our data show that treatment with
MTX had a significant reducing effect on CD3+ T
cells in the epidermis and memory-effector T cells
(CD45RO+) in the lesional dermis and no signifi-
cant effect on peripheral blood specimens.
In contrast with the findings of the T-cell subset
counts after MTX therapy, only the CD3+
T-lymphocyte population in the lesional dermis
was reduced by adalimumab therapy. The peripheral
blood specimens once again did not differ signifi-
cantly after 12 weeks of therapy. It is attractive to
speculate that primarily targeting TNF mainly seems
to influence the CD3+ T cell population in the
psoriatic dermis after 12 weeks of treatment with the
TNF-antagonist adalimumab. Surprisingly, in con-
trast with other effective biologic anti-psoriatic
therapies (9,10), in this study the CD45RO+ T-cell
subset was not significantly affected in both the
cutaneous and systemic compartments by treatment
with adalimumab.
Consequently, as no significant changes could be
found in the peripheral blood after both therapies,
no insight could be provided in the present study
concerning the hypothesized compartmentalization
of psoriasis-associated T-cell subsets between per-
ipheral blood and lesional dermis and epidermis.
To encapsulate, adalimumab and MTX have been
given a place in the treatment of moderate to severe
plaque psoriasis, although acting through a different
mechanism of action indirectly targeting one of the
major pathogenetic key players in psoriasis, the T
cell. Although a relatively small number of patients
could be evaluated, both therapies were shown to
influence several designated T-cell subsets modestly
in the cutaneous compartment. In the peripheral
blood specimens, T-lymphocyte populations were
not significantly altered after both therapies.
Therefore, in this pilot study, alleged recompart-
mentalization of T-cell subsets between the systemic
and cutaneous compartments in response to therapy
with adalimumab and MTX could not be brought to
light in contrast with the remarkable clinical effec-
tiveness. Consequently, compartmentalization of
T-cell subsets does not seem an obligatory event in
order to achieve good clinical response. However,
in the end, the mode of action of MTX and
adalimumab does not imply a direct effect on the
T cell, but the present data show that specific
lesional T-cell subsets can indeed be affected by
these therapies.
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A Comparative Study on the Efﬁcacy of Treatment with 585 nm
Pulsed Dye Laser and Ultraviolet B-TL01 in Plaque Type
Psoriasis
JAAP DE LEEUW, MD,*§ ROSANNE G. VAN LINGEN,¶ MD, HILDE  BOTH,* MD, BHUPENDRA TANK, PHD, 
*TAMAR NIJSTEN, MD, PHD,* AND H. A. MARTINO NEUMANN, MD, PHD *
BACKGROUND   Narrow-band ultraviolet-B and pulsed dye laser (PDL) affect psoriasis but via different 
pathways.
OBJECTIVE   To compare the results of PDL with ultraviolet-B light therapy (UVB) and to look for syner-
gism of both therapies in patients with plaque type psoriasis.
METHODS   In each eligible individual, four similar target plaques were selected, and halves of these plaques 
were treated using PDL, UVB, or a combination of PDL and UVB or were not treated. Results were recorded 
single-blind using the Physician’s Global Assessment score at study enrolment and week 13. Nonparametric, 
paired statistical tests were used to test for differences within and between therapies.The results were also 
analyzed after dichotomization of the changes in the Physician’s Global Assessment score into responsive and 
nonresponsive to treatment.
RESULTS   A signiﬁcant improvement of the psoriasis lesions was noted at Week 13 (P0.001) with each
therapy. No signiﬁcant differences were noted between the therapies. Synergism of PDL and UVB was not
observed.
CONCLUSIONS   PDL is safe for treating plaque type psoriasis, but its efﬁcacy is limited to a subgroup of
patients. Combining PDL with UVB has no additional beneﬁt.
The authors have indicated no signiﬁcant interest with commercial supporters.
an intra-dermal and intra-epidermal inﬂammatory
inﬁltrate composed mainly of T cells, accumulation
of neutrophil granulocytes, increased numbers of 
dendritic cells and mast cells, and expansion of the 
superﬁcial dermal vasculature histologically charac-
terize psoriasis.1 In normal skin, the superﬁcial mi-
crovasculature is composed of capillary loops that 
arise from terminal arterioles in the upper horizontal 
dermal vascular plexus, pass up into the dermal pa-
pillae, and arch back to connect with the postcapil-
lary venules in the horizontal plexus.2
Nonlesional skin has short lengths of microvessels 
in the superﬁcial, papillary dermis, whereas dilated
and elongated superﬁcial capillaries passing into the
dermal papillae, representing exaggerated tortuos-
ity and coiling of the apical segment of the capillary 
loop, characterize lesional psoriatic skin.3,4 The en-
dothelium of the superﬁcial microvasculature in le-
sional skin is four times thicker than in normal skin 
but not in the deeper vasculature, indicating that 
microvascular expansion is restricted to the upper 
plexus.5 Although present evidence indicates that 
psoriasis is primarily a T cell–dependent disease, the 
prominent increase in the dermal microvasculature
in lesional skin indicates that psoriasis is also angio-
genesis-dependent.6–8
pidermal hyperproliferation with epidermal 
thickening, parakeratosis and hyperkeratosis,E
* Department of Dermatology and Venereology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands;
§ ZBC MultiCare, outpatient clinic for Dermatology, Hilversum, the Netherlands; ¶ Department of Dermatology and
Venereology, University Medical Center St. Radboud, Nijmegen, the Netherlands
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Most traditional therapies for psoriasis have focused 
on the inhibition of epidermal proliferation and sup-
pression of inﬂammation. Limiting factors are that
none of these treatments is effective in all patients, 
each may have serious side effects, and the efﬁcacy
generally decreases over time.9,10 The alterations 
in the capillaries have been neglected as a possible 
therapeutic target, although it has been reported that, 
in a new psoriasis lesion, one of the earliest observ-
able changes is an increase in the dermal papillary 
vasculature.6–8,11,12 During treatment, microvascular 
improvement precedes clinical improvement.13 This 
indicates that the expanded superﬁcial microvascu-
lar bed in psoriasis skin is an essential component 
for maintaining clinical lesions.13 These observa-
tions have led to the hypothesis that, in psoriasis, se-
lective destruction of the dilated papillary vessels by 
selective photothermolysis may reduce the transmi-
gration of inﬂammatory cells, resulting in clearing
of psoriasis plaques.14 Selective photothermolysis, 
destroying only the dilated papillary vessels, sparing 
the normal sized vessels and without causing dam-
age to the epidermis, became an effective procedure 
once the pulsed dye laser (PDL) was introduced.15,16 
Partial and total clearance of psoriasis after PDL 
treatment was reported in several studies.14,17–22
Narrow-band ultraviolet-B light therapy (UVB), 
which is highly efﬁcacious against psoriasis,23–28 ap-
peared to be superior to broad-band UVB therapy28,29 
and nearly as effective as psoralen ultraviolet-A 
(PUVA) therapy, and because there are no photo-
sensitizerrelated adverse reactions and a possible 
lower long-term cancer risk, it can be considered 
to be the standard light therapy.30 UVB inhibits the 
proliferation of keratinocytes and induces immuno-
suppression. 31–34 UVB targets primarily structures 
in the epidermis, whereas PDL light passes through 
the epidermis and targets primarily the superﬁcial
vessels in the dermis, indicating that UVB and PDL 
clear psoriasis via different pathways.
The aim of this study was to evaluate the efﬁcacy
and the safety of PDL treatment in plaque type pso-
riasis, to compare the results of PDL treatment with 
the results of the UVB treatment and with those of 
the PDL+UVB treatment, and to look for a synergis-
tic effect of PDL+UVB treatment on psoriasis.
MATERIALS AND METHODS
Subjects
Patients were recruited from the outpatient dermatol-
ogy clinic of the Erasmus MC, University Medical 
Center, Rotterdam. Adult patients with stable plaque 
psoriasis with at least four psoriasis plaques were 
considered eligible. Patients who were intolerant to 
light (toxic or allergic), were using drugs with photo-
toxic or photoallergic potency, were younger than 18 
years, were pregnant, or had preexisting or manifest 
skin malignancy were excluded. A washout period 
of 2 weeks was indicated for topical drugs and of 
4 weeks for photo (chemo) -therapy and -systemic 
drugs, except for emollients. All included patients 
provided written informed consent to participate in 
the study. The Medical Ethical Committee of the
Erasmus MC, University Medical Center, Rotter-
dam approved this study. The study was started in 
October 2004 and ended in March 2006.
Materials
PDL treatment was performed using the V Star PDL 
(Cynosure Inc., Chelmsford, MA). The active me-
dium is a Rhodamine dye that emits yellow light at 
a wavelength of 585 nm. During treatment, the skin 
was cooled with cold air from the Smart Cool Cy-
nosure machine.35 PDL treatment parameters were 
wavelength 585 nm, pulse duration 0.450 ms, spot 
diameter 7 mm, spots overlapping 720%, and ﬂu-
ences between 5.5 and 6.5 J/cm2.
Ultraviolet 311-nm treatment was performed using 
the UVB-TL01 S (wavelength 311 nm) handheld 
device (Cosmedico Medizintechnik GmbH, Vil-
lingen- Schwenningen, Germany). Mean irradiance 
was 19.4mW/cm2. During treatment, the aperture of
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the appliance (5.0 x10.0 cm) was held against the 
skin, the implication being that the distance between 
the device and the skin was constant in every patient. 
Minimal erythema dose was determined by shoving 
a metal cover with 6 test squares (each 1 cm2) on the 
MultiCare device. The squares allowed the penetra-
tion of 100%, 83%, 65%, 49%, 34%, and 17% of 
UVB-TL01 irradiance of the device (19.4mW/cm2).
After 24 hours, the test squares were examined. The 
square showing just observable erythema was con-
sidered as MED.  Mean MED was 0.86 J/cm2 (range 
0.34–1.2 J/cm2).
Treatment Schedule
In each patient, four plaques were randomly allocat-
ed, divided into two halves (Figure 1A), and treated 
as shown in Figure 2. This paired approach enabled 
us to assess the effect of UVB, PDL, and UVB+PDL 
at Week 13 and to compare the effect of UVB and 
PDL with control sides in plaque b and in plaque c. 
The sides of plaques a and b that were not treated 
with UVB were protected with metal foil during ex-
posure. Plaque d was treated with the combination 
of UVB and PDL (PDL+UVB) on both sides, and 
the effect was compared with that of UVB (plaque 
b) and PDL (plaque c). Therefore, four plaques were 
available for blind observation: two plaques treated 
on both sides (plaque a, plaque d) and two plaques 
treated on one side (plaque b, plaque c). In some 
patients, the psoriatic lesions were too small to di-
vide into two halves. In these cases, two separate, 
comparable, nearby plaques were selected as sub-
stitutes (Figures 3–5). The four target plaques were 
selected, as much as possible, on symmetrical sites 
of the right arm, the left arm, the right leg, and the 
left leg. A clockwise rotation schedule of the various 
above-mentioned treatments, of plaque -a through 
plaque d, was used in which, in every new included 
patient, the schedule started on a different body site. 
The remaining plaques in patients who presented 
with more than the four study plaques were treated 
as follows: half of the body with  UVB-TL01 and 
the other half with PDL, following a rotation model 
according to the sequence of inclusion.
Figure 2. Treatment schedule of 4 plaques in each patient.
PDL = Pulsed Dye Laser, UVB = Ultraviolet-B TL01, PDL+UVB 
= combination therapy, NT = no treatment
Figure 1. One plaque divided into 
two halves on the left elbow.
A: Week 0 
PGA-score  III = 4, IV = 4 
Treatment : III = PDL, IV = NT 
B: Week 13 
PGA-score III = 0 after PDL 
PGA-score IV = 1 after NT 
PDL improvement 4 PGA levels 
NT improvement 3 PGA levels
Note : Considerable improvement of 
NT side adjacent to PDL side
� �
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Patients were treated with PDL every 3 weeks for 
10 weeks - in total four treatments (Table 1). During 
laser treatment, the patient’s skin was cooled with 
cool air to reduce the pain and to prevent damage to 
the melanocytes due to overheating.
UVB treatment parameters were wavelength 311 nm, 
start dose 70% of the MED, dose increments each 
treatment 20% of previous treatment until erythema 
threshold or clearing of the lesion was reached, three 
weekly treatments for 11 weeks (in total 30–33 treat-
ments) (Table 2).36,37 Mean initial dose was 0.62 J/
cm2 (range 0.24–0.86 J/cm2), cumulative dose 84 J/
cm2 (range 40–120 J/cm2).
Concomitant topical treatment with salicylic acid 
5% in petrolatum was permitted for all plaques to 
reduce scattering of the laser beam by scales but was 
discontinued 2 days before PDL treatment.
Clinical Assessment 
Apecialized dermatological nurses recorded clini-
cal results single-blind using the Physician’s Global 
Assessment (PGA) score38 (Table 1) at Week 13. 
This moment was chosen 2 weeks after cessation of 
the UVB treatment and 3 weeks after the last PDL 
treatment (ensuring that the postlaser purpura had 
totally disappeared) (Table 1). Although two PGA 
scores were recorded for the PDL+UVB–treated le-
sions (plaque d), to maintain blind assessment, we 
restricted the analysis to the right side of the treated 
plaques.
Deﬁnition of Response to Treatment
An improvement of 3 points or more from base-
line on the PGA score (maximum score 5) or total
� �
Figure 3. Two, almost conﬂuent plaques on the dorsum
of the left hand.
A: Week 0 : PGA-score VII = 3, VIII = 3
Treatment : VII = PDL, VIII = NT
B: Week 13: PGA-score VII = 1 after PDL
PGA-score VIII = 2 after NT
PDL improvement 2 PGA levels, NT improvement 1 PGA level
Note : Some improvement of NT side near PDL side.
Figure 4. Two conﬂuent plaques
right lower leg.
A:  Week 0 :
PGA-score VII = 4, VIII = 4
Treatment : VIII = PDL, VII = UVB
B: Week 13: 
PGA-score VIII = 0 after PDL
C: Week 13: 
PGA-score VII = 1 after UVB
PDL improvement 4 PGA levels
UVB improvement 3 PGA levels
Note: The UVB treated area shows 
more residual scaling than the PDL 
treated area. 
Side effect from both PDL and UVB: 
hyperpigmentation.
� �
�
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clearance (PGA score of 0) in plaque sides selected 
for this study was deﬁned as response to treatment.
Statistical Analyses
The Friedman test was used to test for statistically 
signiﬁcant differences in the change of PGA scores
of the UVB-, PDL-, and PDL+UVB–treated plaques 
at Week 13. We also assessed the difference in the 
degree of PGA score change  fter each of these thera-
pies in different plaques within the same patient. For 
UVB and PDL, change in PGA score was compared 
with the control side of the same plaque at Week 13. 
For each of these paired statistical tests, the Wilcox-
on signed rank test was used. Good clinical response 
(change of 3 levels of PGA score or clear at Week 
13) between the three therapy regimens was com-
pared using the McNemar test.
RESULTS
Study Population
In this single-center, single-blind, prospective, 
paired randomized controlled study 27 patients (17 
men and 10 women) aged 20 to 65 (mean 44.4) with 
skin types I to IV and stable plaque psoriasis with at 
least four psoriasis plaques were included (in total 
108 plaques). The mean duration of psoriasis was 
14 years (range 4–35 years). The distribution of the 
baseline PGA scores in each of the treatment groups 
was comparable (Figure 6).
Direct Paired Comparison Between Base-
line and Week 13
The PGA scores after treatment with UVB, PDL, 
and PDL+UVB were signiﬁcantly lower at Week 13
(P0.001) (Table 3 and Figure 6). For each therapy, 
in approximately 20% of plaques, no improvement 
was achieved, more than 60% showed improve-
ment of two levels in PGA score, and less than 20% 
showed improvement of three or more levels in 
PGAscore (Figure 7). No statistical differences were 
observed in treatment-induced PGA score changes 
between these three therapies (Table 3). A compar-
ison between PGA scores of the UVB- and PDL-
treated halves and the control halves of the psoriasis 
plaques showed no signiﬁcant differences (P = .47
and .42, respectively). In plaque a, a clearly visible 
difference between UVB treatment and PDL treat-
ment was seen in six patients in favor of UVB and in 
four patients in favor of PDL (Figure 4).
Analyses of PGA Scores in the Subgroup of 
Plaques That Responded to Treatment
Good clinical response (improvement of 3 points in 
PGA score from baseline or clearing of psoriasis)
Figure 5. Two small plaques sep-
arated from each other by non-
psoriatic skin right upper leg.
A: Week 0 : 
PGA-score V = 3,  VI = 3
Treatment : V = NT, VI = PDL
B: Week 13: 
PGA-score V = 3 after NT
C: Week 13:
PGA-score VI = 1 after PDL
PDL improvement 2 PGA levels
NT improvement 0 PGA levels
� ��
Note : No improvement of NT side separated from PDL side by non-psoriatic skin. Side-effect from PDL treatment: hyperpigmentation.
108
Chapter 2
was achieved in seven (25.9%) UVB-treated, nine 
(33.3%) PDL-treated, ﬁve (18.5%) PDL+UVB–
treated, and two (7.4%) nontreated halves of the 27 
psoriasis plaques. 
Total clearance (PGA score of 0) was achieved in 
the UVB-treated sides of ﬁve (18.5%) plaques, in
the PDL-treated sides of ﬁve (18.5%) plaques, in the
PDL+UVB–treated side of two (7.4%) plaques, and 
in a nontreated side of one (3.7%) plaque. In one pa-
tient, total clearance was obtained after PDL mono-
therapy and UVB monotherapy. Total clearance was 
achieved after PDL treatment in four plaques and 
after UVB treatment also in four plaques.
Side Effects of Treatment
Regarding side effects of the PDL therapy, all pa-
tients reported transient purpura (occasionally ac-
companied by crusts) for 1 to 2 weeks, 20 (74%) re-
ported moderate discomfort (which is considerably 
reduced by cooling the skin during treatment), and 20 
(74%) reported evident but transient hyperpigmen-
tation after therapy. Although hypopigmentation and 
atrophic scarring were reported in some studies,16,18 
these side effects were neither reported in a recent 
study22 nor observed in our study. Regarding side 
effects of the UVB treatment, nine (33%) patients 
reported pain, 15 (55%) reported photo-dermatitis, 
and 20 (74%) reported some hyperpigmentation. 
Regarding side effects of PDL+UVB therapy, all 
patients reported purpura, 17 (63%) reported pain, 
13 (48%) reported photo-dermatitis, and 19 (70%) 
reported hyperpigmentation.
DISCUSSION
Recent breakthroughs in the treatment of psoriasis 
have led to better understanding of the pathogen-
esis of this disease.34,39,40 Although major advances 
in the development and use of targeted biologicals 
for controlling psoriasis have been made, the need to 
develop safer and more cost-effective cures remains. 
Potential targets for future drugs are cytokines in-
volved in T-cell activation and T-cell trafﬁcking.40 
Inhibition of immunocyte trafﬁcking by selective
photothermolysis of the elongated and dilated papil-
lary blood vessels by PDL was demonstrated to be 
efﬁcacious in plaque type psoriasis.13,16–22 The PDL 
was developed on the concept of selective absorp-
tion of a brief radiation pulse that generates and 
conﬁnes heat to oxyhemoglobin, resulting in the
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haemoglobin to met-haemoglobin, which reduces 
the 585 nm light absorption and increases that of 595 
nm compared with native oxy-haemoglobin, both 
caused by heating of the blood during irradiation. 
The remaining small disparity between 585 nm and 
595 nm can easily be corrected by augmenting the 
ﬂuence. Therefore, similar results may be obtained
with the wavelengths of 585 nm and 595 nm. The 
purpura level for both wavelengths is a good indica-
tor of the proper vascular damage that
has been achieved.43 
According to the principles of photothermolysis 
the optimal pulse-duration to treat dilated capillary 
vessels in a psoriasis plaque is considered to be in 
the range of 0.450- to 1.5-msec (less or equal to the 
Thermal Relaxation Time of the vessels),18 which is 
short enough to damage the dilated psoriasis vessels 
and long enough to spare the normal-sized capillary 
blood vessels. 
The optimal spot-diameters for destroying psoriasis 
vessels are 5- and 7-mm. The 7-mm spot diameter 
has the advantage that the number of pulses required 
to treat the clinical area is 35% lower than when 
treating with the 5-mm spot diameter, reducing the 
time of treatment, and that the penetration of the la-
ser light is slightly deeper.44
The beam proﬁle of the PDL machine has a Gaus-
sian-like distribution of energy, resulting in consid-
erable more light energy in the centre of the beam 
compared with the border.45 In order to obtain a 
uniform pattern of applied energy, overlapping of 
the spots by about 20% is imperative. From this 
point of view it is likely that without overlapping, 
the inhibition of the immunocyte trafﬁcking in pso-
riasis is sub-optimal resulting in decreased clinical 
responses.
In order to have a correct simultaneous compari-
son between the results of UVB and PDL, the end-
point of the study was chosen to be just after +/- 30 
treatments with UVB, which is a standard number 
of treatments, and 3 weeks after 4 treatments with 
PDL. A universal evidence-based standardized pro-
tocol concerning time-intervals for PDL therapy is 
not yet available.
The PGA-scoring system was chosen instead of the 
PASI-scoring system, because in the observation of 
individual plaques the percentage of the total surface 
area involvement is not an issue, the PGA-scoring is 
far less time-consuming than the PASI-scoring, and 
also because the blinded observers (research nurses) 
were better trained in scoring the PGA than the PASI. 
In addition it has been shown, that PGA and PASI
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are highly correlated and share a high overall 
reliability.38
In the statistical data analyses of all included patients 
PDL and UVB, as well as the combination therapy 
PDL+UVB resulted in a signiﬁcant improvement
(P0.0001 for all 3 treatment modalities) in the PGA 
scores at T13 compared with T0 (Figure 6, Table 
3). However, there were no statistically signiﬁcant
differences between the three treatment modalities 
mutually (Table 3). After dichotomising the changes 
in PGA scores into responsive and non-responsive 
to treatment, PDL scored better than UVB and UVB 
better than PDL+UVB, but according to the McNe-
mar’s test these differences were not statistically 
signiﬁcant. This indicates that in terms of response,
PDL was statistically as effective as UVB treatment, 
but there was no synergistic effect of combining 
PDL treatment with UVB treatment in the sub-group 
of patients who responded to treatment. A specula-
tive explanation for this lack of synergism may be 
that the inhibition of vessel-active cytokines pro-
duced by keratinocytes and immunocytes by UVB-
treatment normalises the diameters of the papillary 
blood vessels whereby these vessels no longer form 
a target for PDL. A total clearance of psoriasis af-
ter both UVB and PDL was seen in only 1 patient. 
Complete clearance after UVB, but not after PDL 
was achieved in 4 patients and after PDL, but not 
after UVB also in 4 patients, indicating that patients 
who do not respond to UVB may respond to PDL 
and vice versa.
The non-treated sides of the study plaques also 
showed an unexpectedly good response. The differ-
ences between the UVB-treated and the nontreated 
sides, and between the PDL-treated and the non-
treated sides were not signiﬁcant (P = .47 and P = .42,
respectively). A putative explanation for this phe-
nomenon is that the non-treated sides could have 
beneﬁted from the UVB- and the PDL treatment of
the neighbouring sides, although in a previous study 
it was suggested that there was no carry-over effect 
between the side treated with PDL and the non-
treated side.18 In contrast, the differences between 
the improvements reﬂected in the PGA scores of
the NT sides seen in the Figures 1, 3 and 5 indi-
cate an inverse relationship between improvement 
and the distance between PDL treated sides and NT 
sides, indicating an effect of PDL in a limited area 
around the irradiated site. This observation is sup-
ported by Babilas et al., who demonstrated tissue 
damage and thrombus formation in- and also out-
side the irradiated area of hamster skin 24 hours af-
ter PDL treatment.46 Although the carry-over effect 
in PDL warrants further study, our ﬁndings indicate
that overlapping spot-sizes may not be necessary in 
the PDL treatment of psoriasis. This implies mul-
tiple beneﬁts such as a reduction in the duration of
treatment, less discomfort to the patients and lower 
costs. Currently, we are investigating this possibility 
in a separate immunohistochemical study using skin 
biopsies obtained from the participating patients in 
this investigation. Other possible mechanisms by 
which the non-treated sides could have beneﬁted
are via a systemic effect of the treatment of the re-
maining plaques with UVB and PDL, and/or a non-
expended good effect of the permitted concomitant 
treatment with salicylic acid ointment. A spontane-
ous remission was not likely, because the majority 
of the patients (19) were treated during the winter.
Taibjee et al.47 conducted a trial on the treatment 
oﬂocalised plaque psoriasis in which the efﬁcacy
of the excimer laser was compared with the ef-
ﬁcacy of the PDL laser (wavelength 595 nm, spot
diameter 7-mm, pulse width 1.5msec and ﬂuence
10 J/cm2). They reported a complete clearance in 
41% of the patients in the excimer group after 17 
treatments and in 27% of the patients in the PDL 
group, requiring 3.2 treatments. Many patients in 
that study found PDL to be a very convenient treat-
ment modality because of monthly hospital visits. 
Side effects caused by the excimer were blistering 
in 68% and hyperpigmentation in 41% of the pa-
tients versus 0% blistering and 9% hyperpigmenta-
tion caused by the PDL47 Those results are in good 
agreement with the results presented here. Dur-
ing the laser treatment cooling of the skin is im-
perative in order to reduce the pain, to protect the
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melanocytes in the epidermis from damage and to 
prevent activation of epidermal effector T cells via 
pericapillary heat diffusion after treatment, which 
will tend to promote the persistence of clinical 
lesions.20
Better results of PDL treatments may be obtained by 
increasing the number of sessions, reducing the time 
intervals between treatments, increasing the ﬂuence
and the pulse width to respectively 10 J/cm2 and 1.5 
msec (Taibjee et al.47), applying mineral oil imme-
diately prior to PDL treatment and by concomitant 
treatment with calcipotriol ointment.48
CONCLUSIONS AND LIMITATIONS
All tested treatment modalities appeared to be efﬁca-
cious in the treatment of plaque type psoriasis. There 
were no statistically signiﬁcant differences between
the efﬁcacy of PDL treatment and UVB treatment.
A combination of PDL and UVB treatment had 
no additional value because of lack of synergism. 
Surprisingly no statistically signiﬁcant differences
were seen between UVB treatment and PDL treat-
ment on the one hand and the non-treated sides on 
the other hand. There is no clear explanation for 
this, but an unexpected carry-over effect (although 
a previous study suggested otherwise18) from the 
neighbouring PDL- and UVB-treated sides is sup-
ported by the observation of an inverse relationship 
between improvement of NT sides on the one hand 
and the distance between the PDL treated sides and 
the NT sides on the other hand. Another possibil-
ity is a systemic effect of the treatment of remaining 
the plaques. After all, it seems likely that dividing of 
plaques is not the best approach to study the efﬁcacy
of topical therapies, but if pursued, then the treat-
ment has to be strictly restricted to study plaques, 
without treatment of other remaining plaques. In the 
present study patients with a complete clearance of 
the target lesion appeared to be divided into either 
PDL responders or UVB responders, indicating that 
patients who do not respond to UVB may respond 
to PDL and vice versa. Treatment with PDL resulted 
only in mild and transient side effects and therefore 
appeared to be safe. PDL treatment is certainly not 
the panacea for every psoriasis patient and should 
not be used in widespread psoriasis or in patients 
who respond adequately to simple topically ap-
plied treatments. PDL treatment should be reserved 
for patients with persistent plaque type psoriasis, 
not responding to usual treatments (particularly on 
‘‘non-covered body’’ sites), plaque type psoriasis 
complicated by side effects of medication, psoriasis 
palmoplantaris, psoriasis inversa, patients not willing 
to use topical corticosteroids or systemic treatment 
and patients at risk for skin cancer caused by actinic 
damage or immunosuppression. Most patients in our 
study preferred PDL therapy above UVB (20 vs 7 
patients) because of the less frequent treatment ses-
sions, the subjective improvement in the quality of 
life and the lack of reports on carcinogenesis due 
to PDL treatment, whereas longterm side effects in-
cluding carcinogenesis caused by excimer UVB and 
narrow-band UVB remain uncertain. With regard to 
the patient’s preference and the efﬁcacy, the PDL
treatment should be considered as a serious option 
in the treatment of plaque type psoriasis.
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Nd:YAG laser (1064 nm) fails to improve localized plaque type psoriasis: a 
clinical and immunohistochemical pilot study
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Chronic and localized plaque-type-psoriasis is often therapy resistant as 
a result of which dermatologists are often troubled in ﬁnding a suitable
treatment option. Traditional therapies for psoriasis merely focus on the 
inhibition of epidermal proliferation, inﬂammation, or both. The earliest
changes however in a novel psoriatic lesion concern abnormal micro-
vasculature. The position of lasers in the treatment of psoriatic lesions 
is debatable as different views exist with respect to efﬁcacy and toler-
ability. The current investigation evaluates the clinical and immunohis-
tochemical effect of the Nd:YAG(1064 nm)laser in chronic localized 
psoriasis, as this laser can penetrate up to the deeper abnormal psoriatic 
vasculature. The effects are compared to treatment with the well-estab-
lished calcipotriol/betamethasone dipropionate ointment. The use of the 
Nd:YAG laser with treatment-intervals of four weeks was found not to 
be of additional value in the array of treatment modalities for chronic 
localized plaque-psoriasis. Targeting the more superﬁcial located mi-
crovasculature in psoriasis seems of stronger signiﬁcance in achieving
clinical effect than the deeper vasculature targeted by the Nd:YAG laser. 
Therefore, the present data are of importance in preserving dermatolo-
gists from treating psoriatic lesions with a Nd:YAG laser. However, fur-
ther studies incorporating changes in methodology, in particular short-
ened time-intervals between treatments, are needed in order to refute or 
conﬁrm this position.
Key words: Nd: YAG laser – psoriasis -  therapy- 1064nm
modalities, seems available for these patients to clear also 
these recalcitrant plaques. In general, these plaques are re-
stricted to a small body surface area, which makes the choice 
for a systemic therapy unattractive. Therefore, an unmet 
need exists for an effective treatment of such chronic therapy 
resistant psoriatic lesions. 
Psoriasis is a chronic inﬂammatory skin disease in which
epidermal proliferation,  angioneogenesis and T-cell expan-
sion within the papillary dermis are the most impressive 
features.[1;2] Traditional therapies for psoriasis realise the 
inhibition of epidermal proliferation, inﬂammation, or  both.
The earliest changes noted in an early psoriatic lesion, how-
ever, are elongated, widened and tortuous microvessels.[3-5] 
The  position of lasers in dermatology has increased dur-
ing the past two decades. As new laser devices continue to 
emerge, an expanding range in versatile laser systems devel-
ops but also an extremely broad spectrum of potential can-
didate disorders has developed which presently includes the 
psoriatic lesion. As compared to other treatment options for 
psoriasis, the use of lasers aims at a selective removal of the 
diseased endothelial target structures whilst the epidermis is 
particularly protected from heat injury rendering it an excel-
lent potential treatment option for localized plaque psoria-
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sis. Studies have led to the idea that the selective destruction 
of the dilated papillary vessels by the principle of selective 
photothermolysis eliminates the extravasation of inﬂamma-
tory mediators into the interstitium inducing improvement 
of psoriatic plaques[6-10]. This selectivity can be achieved 
by choosing the appropriate laser light wavelength and pulse 
duration responsible for the amount of heat diffusion. As put 
forward, psoriasis has previously been shown to respond to 
several types of lasers[7;11-14]. In particular with respect to 
vascular lasers, psoriatic lesions have shown to improve with 
pulsed dye laser treatment (PDL, 595 nm) although some 
debate between different groups exists with respect to the 
efﬁcacy and tolerability.[15-19] However, the remission is
usually transient as studies have shown that the persistent 
secretion of cytokines in treated psoriatic lesions were re-
sponsible for a relapse of endothelial proliferation causing a 
rebound in vasculature and return of the psoriatic plaque.[1] 
Infrared light with a wavelength of 1064 nm, like that of the 
neodymium-doped yttrium aluminium garnet (Nd:YAG)  la-
ser can penetrate the skin up to a depth of 7 mm.[20] So 
far, no study has been carried out to put the Nd:YAG laser 
in to place in the array of treatment modalities for localized 
psoriasis. The deep penetration could well represent a great 
advantage of the Nd:YAG laser over the PDL since the tar-
get endothelial structures in psoriasis are located up to a few 
millimeters deep in the psoriatic skin. As the psoriatic blood 
O ften some chronic and localized plaque pso-riasis appears to be therapy resistant and no ad-equate solution, in terms of effective treatment
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vessels play an important role in immunocyte-trafﬁcking in
psoriasis, it is credible that selective removing of the deeper 
abnormal psoriatic vasculature in the dermis by means of the 
Nd:YAG 1064 nm laser may be of beneﬁt for treatment. In
the long run, this could possibly result in a more long-lasting 
therapeutic effect. 
The current pilot study evaluates the clinical efﬁcacy and
tolerability of a Nd:YAG 1064 nm against an active well-es-
tablished comparator: calcipotriol/betamethasone dipropion-
ate ointment (CBD). An intrapatient, left-right comparative 
study was conducted wherein patients with localized psoria-
sis were treated with both the Nd:YAG laser (1064 nm) and 
topical therapy with CBD for a period of three months. CBD-
treatment was given once daily whereas the number of Nd:
YAG treatments was three, with a 4-week interval between 
treatments. In addition, in order to elucidate the mode of ac-
tion, immunohistochemical assessments were performed on 
lesional skin biopsies. Our goal herein was to provide insight 
in the effect of  the 1064-nm wavelength and CBD-oint-
ment on key-phenomena in the psoriatic dermis and epider-
mis, e.g. keratinocyte differentiation (K10), T-lymphocytes 
(CD3+ cells) and capillary expansion (Von Willebrandfactor 
and CD31).
Patients & Methods
Patients
Six patients aged at least 18 years with stable, localized 
plaque psoriasis were included in the study after giving writ-
ten informed consent. All patients had a washout of systemic 
treatments or phototherapy for at least four weeks and had 
not used topical treatment for the last two weeks prior to par-
ticipation. Other exclusion criteria were pregnancy, lactation 
and a history of photosensitivity. The study was approved by 
the local medical ethics committee. 
Study design 
Two weeks before the start of treatment, 10% salicylic acid 
in petrolatum album was prescribed in order to reduce desq-
uamation of the plaque and enhance light penetration and 
penetration of the CBD-ointment through the stratum cor-
neum, ultimately standardizing and optimizing the pretreat-
ment situation for both topical and laser treatment. Since 
treatment with the Nd:YAG 1064 nm (“Gentle YAG VR”, 
wavelength 1064 nm, with dynamic cryogen cooling device 
for minimizing patient discomfort, Candela Corporation) 
has not been described before, questions remain as to the 
1064nm laser’s optimal operating parameters for positively 
effecting dermal endothelial structures. Therefore, we ﬁrst
tested for optimal settings in three patients with psoriasis for 
ﬁnal use in the main pilot study. At the initial visit,  two simi-
lar plaques of at least 10 cm2 were selected. These plaques 
were similar in terms of body localization and clinical sever-
ity score (SUM-score). Consequently, one psoriatic plaque 
was treated varying in spotsizes and ﬂuences all within the
spectrum of optimal depth for effective endothelial destruc-
tion (table 1). Primary outcome measures which were used 
after 4 weeks and further throughout the study, comprised 
the SUM-score (for evaluating the clinical effect) and the oc-
currence of adverse events (for evaluating safety). No major 
signiﬁcant differences in clinical effect between the settings
could be observed, nor did any interfering adverse events 
occur. All ﬂuences were tolerated equally. As no speciﬁc
preferable setting in terms of clinical efﬁcacy or safety was
deducible from the testing, the maximal applied ﬂuence per
spotsize (1,5 mm spot, 375 J cm-2; 3 mm spot, 310 J cm-2) 
from the testing was chosen for application in the main pilot 
study. Comparing PDL-studies with different time-intervals, 
the intervals vary from weekly to once every 2 to 3 weeks. 
Even, sometimes residual crusting resulted in postponement 
of the laser-treatment. Therefore, we opted for a time-inter-
val of four weeks between Nd:YAG treatments.
In the main study, at random, one of the two selected SUM-
comparable plaques was treated with calcipotriol 50 μg g-1 
and betamethasone dipropionate 0.5 mg g-1 ointment (CBD) 
(Daivobet/Dovobet; Leo Pharma, Ballerup, Denmark) once 
daily for the duration of three months. The other plaque was 
symmetrically divided in halves to treat one halve with the 
1,5 mm spot (ﬂuence 375 J cm-2) and the other with the 3 mm 
spot (ﬂuence 310 J cm-2) each by a single pass, once every 4 
weeks. In total, the plaque was treated three times. Prior to 
Nd:YAG treatment, watery oil was applied on the designat-
ed psoriatic plaque in order to further reduce the amount of 
scattering and enhance light penetration through the stratum 
corneum. After three months of treatment, patients entered a 
follow-up period of eight weeks in which they did not apply 
the CBD ointment nor received Nd:YAG laser treatment. 
Clinical assessments
Clinical severity of the designated plaques was assessed us-
ing the SUM-score at baseline and after 4 and 8 weeks and 
during the follow-up period. The SUM score is a cumula-
tive measure which includes scores for eythema, indura-
tion (plaque thickness) and scaling on the following scale: 
0, absent; 1, minimal (very light pink, hardly any elevation, 
rare scale); 2, mild (light red/ pink, slight elevation, poorly 
deﬁned scale); 3, moderate (red, moderate elevation, deﬁned
scales); 4, severe (very red, marked ridge, heavy scaling). 
Ultimately, a global SUM score (range 0-12) was determined 
as the sum of all three scores together, reﬂecting the overall
plaque severity. 
Furthermore, the Visual Analogue Scale (VAS) for pain 
(range 0-10) was used for patients to report the level of ex-
perienced pain during Nd:YAG treatment with the two spot-
sizes. A score of 0 represented a total absence of pain and 10 
represented maximum pain. 
Nd:YAG 1064 nm 
settings 
 
Fluence J cm-2 
Spotsize 1,5 mm -
Pulse duration
10 ms
300
325
350
375
Spotsize 3 mm -
 Pulse duration
20 ms
250
270
290
310
Table 1. Nd:YAG 1064 nm test settings varying in spotsize 
and ﬂuence.
nm= nanometer, mm= millimeter, cm=centimeter, ms= milliseconds, J= Joule.
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Biopsies 
Biopsies (4 mm) were taken at a central representative site in 
the target lesions after 3 months of treatment (week 12): one 
from the Nd:YAG treated, one from the CBD treated lesion 
and one from an untreated psoriatic plaque which served as 
a control. Before the biopsy procedure, local anesthesia was 
given (xylocaine/adrenaline 1:100.000). Skin defects were 
optionally closed using one suture. 
Immunohistochemical staining
Immunohistochemical staining on parafﬁn and cryostat sec-
tions was performed as previously described.[21;22] The 
following primary antibodies (mouse anti-human) were 
used: anti-CD3 (1:100) (cryostat, clone UCTH1), anti-K10 
(parafﬁn, 1:100, clone RKSE60) (Monosan Laboratories
Uden Netherlands), anti-von Willebrand Factor (parafﬁn,
vWF, 1:200, clone F8/86) and anti-CD31 (parafﬁn, 1:200,
clone JC70A) both from DAKO (Copenhagen, Denmark). 
Furthermore, from each patient we performed a H&E stain-
ing to verify that the biopsies under study fulﬁlled the pso-
riasis-speciﬁc histological criteria.
Blinded quantiﬁcation of markers
Quantiﬁcation of K10 and CD3 and determination of the
thickness of the epidermis was enforced as previously 
done[23] using the image processing program ImageJ 1.37 
(National Institutes of Health, USA) and IP-lab (Scanalytics, 
USA). Quantitative cell counts of the T-lymphocytes (CD3) 
were expressed as ‘Positive cells per mm skin length’. K10 
was quantiﬁed using the % of a representative region of in-
terest (ROI)  in the epidermal surface as unit. As the stain-
ings of both CD31 and vWF showed a similar pattern, CD31 
was chosen as the endothelial marker used for quantiﬁcation.
Quantiﬁcation of CD31 was enabled creating a division in
several distinct ROI’s as depicted in ﬁgure 1, ultimately ex-
pressing CD31 as positive area in  % of the ROI. In order to 
observe and evaluate the potential depth of penetration of 
the Nd:YAG laser in the dermis, two separate parts of the 
dermis were selected on the one hand comprising the inter 
rete ridges dermis and on the other hand the more lower pap-
illary dermis. The choice for this separation was based on the 
background information that the PDL showed to primarily 
target the more superﬁcial capillaries in the rete ridges and
the Nd:YAG was theorized to penetrate deeper up to the low-
er papillary dermis. All sections were analyzed in a blinded 
manner as the sections were coded by an independent co-
worker before assessment.
Statistical analyses
To compare SUM-scores between different moments in time 
during treatments, we performed the Kruskal-Wallis test. In 
addition, we performed matched pair analysis using the Wil-
coxon signed Ranks test to compare the SUM-scores over 
time with the non-treated plaques. 
To compare the epidermal thickness and immunohistochem-
ical expression of K10, CD3 and CD31 between the two 
treatments (Nd:YAG 3 mm spot and CBD) and the untreated 
psoriatic biopsy, the Student’s t-test was used. A statistically 
signiﬁcant difference was set at p< 0.05. All analyses were
carried out using SPSS software version 14.0.
Results
In total, 6 patients participated in this study (4 males, 2 fe-
males) with a mean age of 47.7 ± 5.2 years. Two patients 
had to be excluded one because of refusal of the biopsy pro-
cedure, the other because the applied ﬂuences had to be re-
duced since the patient reported intolerable pain at the initial 
ﬂuences.
Figure 1. Quantiﬁcation method for CD31 positive endothelium.  The papillary dermis was divided in the “inter rete ridges 
dermis”, wherein a region of interest (ROI) was drawn encompassing the dermal area’s between the rete ridges, and in the low 
papillary dermis wherein the area up to 200 μm below the tips of the rete ridges was incorporated in the ROI. * = 200 μm
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Clinical efﬁcacy
The results for the mean SUM-scores per treatment modality 
during the study are shown in ﬁgure 2A . A quick glance at 
the ﬁgure shows that at baseline all plaques had a compa-
rable SUM-score, that the treatment with CBD caused the 
largest reduction of SUM-score and thus clinical effect and 
that the two spotsizes used for the Nd:YAG laser did not dif-
fer greatly in clinical effect. The mean reductions in SUM-
score between baseline and week 12 for Nd:YAG 1,5 mm, 
Nd:YAG 3mm and the CBD-ointment were 17%, 27%, 62% 
respectively. With respect to the control plaque, there was 
a 9% increase in SUM-score after 12 weeks. The reduction 
in SUM-score induced by CBD-ointment reached statistical 
signiﬁcance at week 4, week 8 and week 12 (all p<0.05) as 
compared to baseline. There was a signiﬁcant reduction in
SUM-score caused by treatment with the Nd:YAG (both 1.5 
and 3 mm spotsize) at week 4, respectively 29% and 24 % 
compared to baseline. However, this effect was not main-
tained further throughout the study. Between week 12 and 16 
(follow-up period), only the mean SUM-score for the CBD 
treated plaques augmented signiﬁcantly to a moderate extent
(+33%, p<0.05).
Visual Analogue Scale (VAS)
With respect to the level of experienced pain during Nd:YAG 
treatment, the mean VAS-score per spotsize at the different 
time-points is depicted in ﬁgure 2B. It can be derived that all 
patients reported a higher VAS-score when treated with the 
3mm spot and corresponding ﬂuence than with the 1,5 mm
spot. In addition, the VAS-score was comparable in range 
during the ﬁrst, second and third treatment and did not differ
greatly except for one patient whom experienced intolerable 
pain at the initial ﬂuences. Therefore, the ﬂuences for this
particular patient were reduced by ± 40% and this patient 
was excluded form further clinical and immunohistochemi-
cal analyses.
Morphological and immunohistochemical analyses
Figure 3 illustrates the results of the quantities of the epider-
mal thickness, the endothelial marker (CD31), keratinocyte 
differentiation (K10) and CD3-counts after treatment with 
CBD and the Nd:YAG laser compared to the non-treated 
control biopsies (NoTx). The number of CD3+-lymphocytes 
decreased signiﬁcantly (p<0.05) in the epidermis of the
CBD treated group and only a tendency of a decrease af-
ter therapy(p<0.1) was observed in the epidermis of the Nd:
YAG treated group compared to the amount of CD3+ T-cells 
in the control biopsies of non-treated psoriatic plaques. With 
respect to the dermis, in the Nd:YAG treated group the CD3+ 
T-cells were signiﬁcantly decreased after therapy (p<0.05)as
compared to the control group of biopsies whereas the CBD 
group showed no signiﬁcant reduction in CD3+ T-cells.
The epidermal thickness decreased signiﬁcantly in the CBD
group of biopsies (-43.2%, p<0,05), whilst for the Nd:YAG 
group no signiﬁcant decrease could be observed (-24.9%,
p>0,05) compared to the untreated biopsies. The area posi-
tive for CD31 in the ROI in both the inter-reteridges dermis 
and the low papillary dermis, was not signiﬁcantly different
between each of the two treatment groups versus the control 
group. As for the K10 positive epidermal area, no signiﬁcant
increased amount of normal differentiating keratinocytes af-
ter treatment with CBD or the Nd:YAG laser could be ob-
served. 
Side-effects Nd:YAG laser 
Two patients experienced a burning sensation on the Nd:
YAG treated lesions 2-6 hrs after therapy. Two patients re-
ported transient purpuric discoloration of small areas of the 
lasers lesions. One patient had several white spots on the Nd:
YAG treated psoriatic lesion directly after lasering. Four pa-
tients reported development of mild crusts in the week after 
receiving laser treatment. One patient reported slight ﬂuid
leakage from the Nd:YAG treated lesion. Another patient 
experienced increased itch on the Nd:YAG treated lesion 
compared to the CBD-treated plaque. Scarring was not seen 
in any of the patients. With respect to the treatment with the 
CBD-ointment, no side-effects were observed, in particular 
no atrophy of the skin.
Discussion
As psoriasis persists to be a chronic skin disease of which 
the pathogenesis is not completely understood, the search for 
new treatments and insights continues. Psoriasis is probably 
Figure 2: A) Results for the clinical efﬁcacy of treatment with
CBD-ointment and the Nd:YAG laser compared to no treat-
ment (No Tx) reﬂected in mean SUM-scores.
B) Results for experienced pain during Nd:YAG treatment 
with different spotsizes reﬂected in mean VAS-scores. The
VAS-scores at the different points in time are taken together.
Error bars indicate the Standard Error of the Mean. 
* = signiﬁcantly decreased compared to baseline (p<0.05).
** = signiﬁcantly increased compared to week 12 (p<0.05).
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not one single disease entity, as multiple expression pat-
terns are observed ranging in severity, extent, aspect of le-
sions. Furthermore, individual needs vary among patients. 
The need and search for adequate and effective special-
ized therapies for recalcitrant localized psoriatic lesions 
persists, as no optimal treatment solution is yet available. 
In the ﬁeld of lasers, many have investigated the effect
of (laser)light to target diseased psoriatic skin structures. 
The PDL was shown by some groups to be a good thera-
py for recalcitrant localized psoriasis, although the effect 
was momentary and results can be at variance.[6;19] The 
present pilot study is the ﬁrst to evaluate whether the Nd:
YAG laser is a potential treatment modality for this kind 
of psoriatic lesions. It is plausible that when targeting the 
deeper vasculature more effectively, damage can be caused 
possibly resulting in longer lasting effect of clearance of 
psoriatic plaques. Subsequently, when focussing on the 
histologic changes that ensue after irradiation with the 
1064 nm-wavelength, clariﬁcation of the relevant micro-
scopic events can be obtained. In contrast to this outlined 
hypothesis however, in this study clinical and well-deﬁned
histological evidence supporting this Nd:YAG-theory was 
not acquired. In order to enlighten this discrepancy, sev-
eral interpretations are thinkable bearing in mind that the 
present pilot study comprised a minimal sample size. 
It is necessary for pulse duration to be matched to vessel 
size; the larger the vessel diameter, the longer pulse dura-
tion is required to effectively damage the vessel thermally. 
Absorption by hemoglobin in the long vivible to near in-
frared range appears to become more important for vessels 
over 0.5 mm and at least 0.5mm below the skin surface. 
However, high energies must be used for adequate penetra-
tion. The key eventually is to ﬁnd the optimal parameters
for this laser for positively effecting dermal endothelial 
structures without excess heat that may cause collateral 
damage. It can be theorized that if the energy level was 
below the chromophores threshold and the pulse width 
was extended beyond the thermal relaxation time, the heat 
could be absorbed by the chromophore but then dissi-
pated to surrounding tissues before reaching a destructive 
threshold level[24] and an ensued clinical effect. Alterna-
tively, it could well be, based on the results of this study, 
that the overlying diseased psoriatic skin is irresponsive in 
terms of clearance when deeper lying vasculature is being 
targeted by a 1064 nm Nd:YAG laser. In addition, as the 
inﬂammation in psoriatic plaques is highly vivid, it could
well be reasonable to treat these plaques more frequently 
than once a month in order to achieve a clinical effect of 
the Nd:YAG laser.
Although lacking clinical efﬁcacy, Nd:YAG treatment in-
stigated a substantially reduced number of CD3+ T cells in 
the dermis in the present pilot study. The present study is 
at variance with ﬁndings of Bovenschen et al.[6]  however, 
who showed a  reduction in CD3+ T-cells in the psoriatic 
skin after PDL therapy but also a marked clinical effect of 
the PDL in psoriasis. One could question therefore whether 
changes in the amount of  CD3+ T-lymphocytes after laser 
therapy alone can lead to clinically improved psoriatic le-
sions. Some have found that peak epidermal temperature 
can have an important inﬂuence on the histologic changes
after nonablative laser therapy.[25] Therefore, a possible 
diffuse thermal effect on the T-cell after Nd:YAG therapy 
Figure 3: Overview of the results of the mean changes in CD3-counts (A), epidermal thickness (B), the endothelial 
marker (CD31) (C) and keratinocyte differentiation (K10) (D) in response to the treatment with CBD-ointment and the 
Nd:YAG laser compared to no treatment (No Tx).
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could lie at the basis of changes in amount of CD3+ T-cells 
as previously touched upon by Ruiz-Esparza et al.[12] Three 
anecdotal reports on psoriatic plaques responding to low-en-
ergy Nd:YAG (1320 nm) irradiance were described, corre-
sponding with a diffuse thermal effect even though the exact 
mechanism of this therapy remained unknown. 
In order to minimize patient discomfort and epidermal spar-
ing, cooling through direct contact was used throughout the 
present study, optimally practising minimal pressure against 
the skin not to compress the target vessel with excessive 
hand pressure. Trained staff is requisite to garantee proper 
and consistent use of the laser. It is important to notice that 
scatter and reﬂection are two key aspects inﬂuencing the
penetration of the laser light to the targeted depth. Although 
patients were pretreated with 10% salicylic acid in petrola-
tum album and watery oil was applied in order to enhance 
an optimal penetration, in the end psoriatic plaques have a 
different texture compared to non-psoriatic skin presumably 
inﬂuencing the ultimate depth of penetration.
With respect to the active comparator (CBD-ointment), con-
sistent with earlier ﬁndings [6] the clinical severity of the
treated plaques reduced signiﬁcantly likewise the epidermal
thickness. Although effectively reducing the thickness of the 
epidermis and corresponding reduction in SUM-score, the 
CBD-ointment does not tend to have an effect on the amount 
of abnormal differentiating keratinocytes and on the exces-
sive microvascular expansion in psoriasis.
To summarize, in the present pilot investigation the Nd:YAG 
1064 nm laser was found not to be of additional value in the 
array of treatment modalities for chronic localized plaque 
psoriasis since no clinical and histological evidence came 
across to support this. It is evident that the superﬁcial dermal
vasculature remains a major contributor to the pathogenesis 
of this disease and targeting this vascular expansion is a good 
manner to try to tackle the inﬂux of immunocytes to the site
of inﬂammation. However, this study brings to light that the
amount of CD31 positive endothelium in the papillary der-
mis of psoriatic plaques was not signiﬁcantly altered by the
effect of the Nd:YAG 1064 nm laser. Dermatologists in the 
ﬁeld of lasers should take the present ﬁndings to heart and be
vigilant when considering the Nd:YAG laser as a potential 
treatment option for chronic therapy resistant psoriatic le-
sions. Targeting more superﬁcial located vascular expansion
in psoriasis is likely to be of stronger importance in achieving 
clinical effect than the deeper vasculature. However, further 
studies incorporating changes in methodology, in particular 
shortened time-intervals between treatments, are needed in 
order to refute or conﬁrm this position.
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Summary
Background Psoriasis is known to affect 2–3% of the population and can be con-
sidered an organ-speciﬁc autoimmune disease. CD26/dipeptidyl-peptidase IV
(DPP-IV) is a membrane-bound protease with diverse properties. In theory, the
expression of CD26/DPP-IV has common grounds with three principal key play-
ers of the psoriatic pathogenesis: keratinocytes, T cells and cytokines.
Objectives To assess CD26/DPP-IV expression in psoriasis in order to expand on
the search for complementary biomarkers related to inﬂammation and prolifera-
tion in psoriasis.
Methods The pattern of expression of CD26/DPP-IV was investigated on the
mRNA-, protein- and enzyme-functionality level using immunohistochemical,
immunoﬂuorescent and enzyme activity labelling techniques.
Results An 11-fold signiﬁcant increase of CD26/DPP-IV on the mRNA level was
demonstrated in psoriatic epidermal sheets compared with normal skin. Immuno-
histochemistry on psoriatic sections showed a distinct patchy honeycomb-like
CD26/DPP-IV staining in the suprapapillary layers. Moreover, a clearly distin-
guishable column-like staining pattern throughout the suprabasal compartment
along the rete ridges was seen, whereas in normal skin these patterns were
absent. Strikingly, CD26/DPP-IV enzyme activity correlated with this immuno-
histochemical reactivity pattern for the CD26/DPP-IV protein. The T-cell bound
expression of CD26/DPP-IV in psoriatic skin was explicitly present, albeit in
small quantities.
Conclusions Our data provide clear evidence for a versatile upregulation of CD26/
DPP-IV expression in psoriatic (epi)dermis. Although the exact functional contri-
bution remains speculative, the topographical distribution of this complex multi-
functional protein suggests a suitable role as a complementary biomarker in
psoriasis.
Over recent years, an increasing number of publications have
focused on CD26 or dipeptidyl-peptidase IV (CD26/DPP-IV),
and its various properties have been described. CD26/DPP-IV
is a glycoprotein which belongs to a group of membrane-
bound proteases, which hydrolyse dipeptide sequences that
have proline or, to a lesser extent, alanine at the penultimate
position. Besides its protease activity, CD26/DPP-IV has a
multifunctional role as it can act as a costimulatory protein for
CD45RO, a receptor for adenosine deaminase and an adhesion
molecule for collagen and ﬁbronectin, and it can be involved
in apoptosis.1–6 It is attractive to speculate that CD26/DPP-IV
via these mechanisms may be relevant to pathophysiological
conditions.7 The expression level of CD26/DPP-IV differs
greatly between tissues including T lymphocytes, and endo-
thelial and epithelial cells.8,9 CD26/DPP-IV is known to be
involved in the pathology of a variety of autoimmune diseases
such as multiple sclerosis and rheumatoid arthritis.10–12
Remarkably, data in the literature are sparse with respect to
the expression of CD26/DPP-IV in psoriatic skin.13–15
The pathogenesis of psoriasis comprises three principal key
players. Both keratinocytes and T cells participate actively and
interact (in)directly with each other in psoriatic tissue, orches-
trated by the production of proinﬂammatory cytokines and
chemokines.16–18 Keratinocyte products inﬂuence immune
activation and, vice versa, products of activated immunocytes
alter keratinocyte responses.17 In vivo, CD26/DPP-IV is known
to be expressed on human keratinocytes in variable amounts
in various inﬂammatory dermatoses.7,14 It was shown that
� 2008 The Authors
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DPP-IV inhibitors can suppress keratinocyte proliferation in vitro
and the keratinocyte differentiation can partially be restored
in vivo.7
The expression of CD26/DPP-IV on the surface of the sec-
ond key player, the T cell, has brieﬂy been described in psori-
atic and healthy subjects, mainly in peripheral blood T
cells.19–21 So far, the T-cell bound expression in the skin of
healthy and psoriatic patients has, to our knowledge, remained
untouched.
Cytokines and chemokines represent the third key player in
the psoriatic chronic immune response. They are considered
mediators responsible for activation and recruitment of inﬁl-
trating leucocytes and therefore play a crucial role in the
development and persistence of psoriatic skin lesions. CD26/
DPP-IV is likely to play a pivotal role in processing these mol-
ecules. The extracellular protease domain of CD26/DPP-IV
(both on keratinocytes and T cells) can cleave dipeptides from
the amino terminus of proteins, such as cyto- and chemokines,
which are abundantly present in a chronic immune response
in psoriasis, resulting in alterations in receptor speciﬁcity and
subsequently reduced biological activity.22 Taken together, it
is conceivable that in psoriasis, a disease wherein the interplay
between activated T cells, keratinocytes and cytokines is
determinative, CD26/DPP-IV can act on all these three key
players.
The multifunctional characteristics of CD26/DPP-IV
prompted us to investigate its pattern of expression on the
earlier mentioned cell types implicated in the pathogenesis of
psoriasis. The mRNA produced is a good indicator for the
de novo synthesis of protein in the tissue of interest. Therefore
quantitative real-time polymerase chain reaction (qPCR) analy-
sis was performed on epidermal sheets to study CD26/DPP-IV
expression at the mRNA level. Subsequently, frozen sections
of normal and psoriatic skin were collected and examined
using immunohistochemical and immunoﬂuorescent label-
ling techniques, in order to characterize both epidermal and
dermal CD26/DPP-IV expression. In addition, cytochemical
enzyme activity assays were performed in order to see
whether the demonstrated protein is actually enzymatically
active in psoriasis or not. To summarize, our objective was to
assess the expression of CD26/DPP-IV in psoriatic skin and to
expand on the search for complementary (discriminating)
biomarkers related to inﬂammation and proliferation in
psoriasis.
Materials and methods
Patients
For qPCR analysis seven healthy subjects (age range 21–
35 years) and nine patients with psoriasis (age range 49–
70 years) were included. Affected lesional psoriatic skin was
used for the isolation of epidermal sheets.
For the immunohistochemical, enzyme cytochemical and
immunoﬂuorescent staining methods, 11 patients with psoria-
sis (age range 32–59 years) and four healthy volunteers
(age range 18–21 years) were included in the study. Any
topical or systemic treatment was suspended for at least
2 weeks and 4 weeks, respectively, prior to participation.
Written informed consent was obtained before enrolment. All
psoriatic patients had a moderate to severe plaque-type psoria-
sis. The diagnosis of psoriasis was based on clinical and histo-
logical (haematoxylin and eosin staining) criteria.
Clinical scores and biopsies
SUM-scores were performed to assess the clinical status of the
biopsied psoriatic plaques. The SUM-score comprises the sum
of separate scores for erythema (0–4), induration (0–4) and
scaling (0–4). Four-millimetre punch biopsies were taken
from the centre of the psoriatic plaque after anaesthesia with
1% xylocaine/adrenaline.
Real time quantitative polymerase chain reaction
technique for CD26/DPP-IV expression in vivo
Isolation of epidermal sheets
Isolation of epidermal sheets was performed as previously
described.23 Brieﬂy, a 4-mm punch biopsy was incubated for
4 h at 4 �C in PBS (with Ca2+/Mg2+) containing 12 mg mL)1
dispase (Roche Diagnostics, Basel, Switzerland) and 5 lg mL)1
actinomycin-D (Sigma-Aldrich, St Louis, MO, U.S.A.). After
incubation, the dermis was removed with tweezers and the
remaining epidermal sheet was stored in Trizol (for RNA
extraction).
RNA extraction and real-time quantitative polymerase
chain reaction
Epidermal sheets or cultured keratinocytes were used for RNA
extraction, and reverse transcriptase reactions were performed
with 1 lg RNA as described previously.24 The reverse trans-
criptase reaction products were used for real-time qPCR ampli-
ﬁcation, which was performed with the MyiQ� Single-Color
Real-Time Detection System for quantiﬁcation with SYBR�
Green Supermix and melting curve analysis (Bio-Rad, Rich-
mond, CA, U.S.A.), as described previously.25 DNA was PCR-
ampliﬁed under the following conditions: 4Æ5 min at 95 �C
followed by 40 cycles of 15 s at 95 �C and 1 min at 60 �C,
with data collection in the last 30 s. For all PCRs, iQ� SYBR
Green Supermix (Bio-Rad) was used in the reaction. All pri-
mer concentrations were 300 nmol L)1 in a total reaction vol-
ume of 25 lL. The amount of mRNA for the CD26/DPP-IV
gene in each sample was normalized to the amount of mRNA
of the human acidic ribosomal protein (hARP; RPLP0, ribo-
somal phosphoprotein P0) reference gene in the same sample.
We used hARP as we have previously found it to be very use-
ful for normalization procedures when using RNA from
biopsy material. The hARP gene is, at least for skin biopsies,
more suitable than commonly used genes such as actin or
glyceraldehyde-3-phosphate dehydrogenase, as hARP correlates
� 2008 The Authors
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far better with 28S ribosomal RNA (not shown). Primers for
qPCR were only accepted if their efﬁciency was 100 ± 10%.
Thus the PCR product concentration was doubled at each cycle
and the threshold cycle (Ct) will be linear with the log of the
initial concentration. For graphic representation of relative
mRNA expression levels we used the DDCt method.26 Primer
sequences were: CD26/DPP-IV forward 5¢-TCATTCAGTAAAG-
AGGCGAAGTATTATC-3¢; CD26/DPP-IV reverse 5¢-CAGTTTTT-
TGGAGGGCATCTG-3¢; hARP forward 5¢-CACCATTGAAAT-
CCTGAGTGATGT-3¢; and hARP reverse 5¢-TGACCAGCCC-
AAAGGAGAAG-3¢. All primers were obtained from Biolegio
(Nijmegen, the Netherlands).
Immunohistochemical staining
Immunohistochemical staining was performed as previously
described.27,28 The following primary antibodies (mouse anti-
human) were used: anti-CD3 (1 : 100; clone UCTH1; Dako,
Copenhagen, Denmark) and anti-CD26/DPP-IV (1 : 50; clone
BA-5; Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.).
Furthermore, from each patient we performed a haematoxylin
and eosin staining to verify that the biopsies under study
fulﬁlled the psoriasis-speciﬁc histological criteria.
Image analysis
With an objective magniﬁcation · 20 a representative section
of the slide was chosen and analysed by two evaluators.
Immunohistochemical staining resulted in a honeycomb-like
and a column-like staining pattern in the psoriatic epidermis.
For characterization of this epidermal CD26/DPP-IV expres-
sion, the following semiquantitative four-point scale was used
to assess both the honeycomb-like and the column-like stain-
ing pattern on the full width of the section (4 mm): ), no
staining; ±, slight staining; +, moderate staining; ++, pro-
nounced staining.
Zenon immunoﬂuorescence labelling technique
The Zenon labelling technique, as described before by Boven-
schen et al.,29 was used to combine the aforementioned
antibodies. Brieﬂy, for double staining, the following ﬂuoro-
chromes were used: Alexa Fluor 488-conjugated IgG1 Fab
fragments (Molecular Probes, Eugene, OR, U.S.A.), a green
ﬂuorochrome, for anti-CD3 and Alexa Fluor 594-conjugated
IgG1 Fab fragments (Molecular Probes), a red ﬂuorochrome,
was used for the anti-CD26/DPP-IV monoclonal antibody.
After incubation of the speciﬁc monoclonal antibodies with
the concomitant Alexa Fluor isotype-speciﬁc IgG Fab fragment,
the excessive ﬂuorochrome was blocked with IgG-blocking
agent.
Staining procedure
For ﬂuorescent immunohistochemical staining 7-lm sections
were cut on AAS-coated slides. Sections were air-dried, ﬁxed
with acetone, and stored in PBS. After coupling and diluting
the antibodies, sections were incubated at room temperature
for 1 h with 100 lL antibody solution. After washing the
slides with PBS, the sections were ﬁxed in 3Æ8% buffered
formalin (J.T. Baker, Deventer, the Netherlands). Then they
were incubated for 5 min with diamidino-2-phenylindole
(DAPI; 1 000 000 dilution of 1 mg mL)1 stock solution;
Molecular Probes) which is ﬂuorescent upon binding to DNA
and was used to counterstain the cell nuclei. The slides were
mounted in Prolong Gold antifade reagent (Molecular Probes).
During the whole process, the slides were kept in the dark as
much as possible.
Microscopy
The sections and antibodies were examined according to the
method of Bovenschen et al.29 using a 100 W mercury lamp
for immunoﬂuorescence microscopy (Axioskop 2 MOT; Zeiss,
Jena, Germany) with an objective magniﬁcation · 40.
Image analysis
In order to analyse the colocalization pattern of the CD26/
DPP-IV on T lymphocytes (CD3+), the photographs of
those single staining patterns representing the same part of
the skin were merged. A representative region of interest
was chosen in each photograph and analysed using Axio-
Vision software (Zeiss), in which the number of lympho-
cytes and speciﬁcally the CD26+ T lymphocytes were
counted.29
CD26/DPP-IV enzyme histocytometry
The demonstration of CD26/DPP-IV activity was performed
using the method described by Khalaf et al.,30 with minor
modiﬁcations. The obtained 4-mm biopsy specimens were
frozen in Tissue-Tek and sections (10 lm) were cut using a
cryostat and put on 3-aminopropyl-triethoxy-silane-coated
slides. The sections were air-dried for at least 20 min after
which they were ﬁxed in cold acetone for 10 min.
For the incubation mixture 3 mg of substrate (gly-
pro-MNA; Bachem, Bubendorf, Switzerland) was dissolved in
0Æ2 mL dimethylformamide (DMF) and added to 4Æ6 mL of
PBS (pH 7Æ2). Subsequently 5 mg of fast blue B salt (Sigma-
Aldrich) dissolved in 0Æ2 mL DMF was added and ﬁltered. Sec-
tions incubated with the DPP-IV inhibitor diprotin A (Bachem,
Bubendorf, Switzerland)31,32 were used as a negative control.
As positive control tissue for CD26/DPP-IV-speciﬁc activity,
murine kidney was used.33 This tissue was treated in the same
way as the human samples.
Sections were incubated with the substrate reaction mixture
in a humid chamber (200 lL per slide) at room temperature
for 45 min followed by a short wash with distilled water and
counterstained with Mayer’s haematoxylin. Then the sections
were washed in alkaline tap water and rinsed with distilled
water. Finally they were embedded with glycerol gelatin.
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Sections were analysed immediately using transmission light
microscopy.
Statistical analysis
All analyses were performed using SPSS 12.0.1 software.
Regarding the mRNA expression of CD26/DPP-IV in psoriasis
and in healthy subjects, the Student’s unpaired two-tailed t-test
was performed. Results are presented as means ± SEM. Statisti-
cal signiﬁcance was set at P < 0Æ05.
Results
Histopathological and clinical severity data
All healthy biopsied volunteers had microscopically and histo-
logically normal skin. The haematoxylin and eosin staining of
the psoriatic biopsies showed psoriasis-speciﬁc histological
hallmarks such as hyperplasia of the rete ridges, suprapapillary
thinning or absence of the stratum granulosum.
All participating psoriatic patients had a stable plaque psori-
asis without pinpoint papules surrounding the plaques. The
clinical severity of the psoriatic lesion was assessed using the
SUM-score. Their mean SUM-score at the time of biopsy was
7Æ09 ± 0Æ46 (SEM).
Expression of CD26/DPP-IV in normal and psoriatic skin
in vivo
An 11-fold increase of CD26/DPP-IV on the mRNA level
was found in the examined psoriatic epidermal sheets com-
pared with normal skin (Fig. 1). This strong upregulation
was statistically signiﬁcant (P = 0Æ002). In normal skin, the
CD26/DPP-IV protein expression on keratinocytes was
primarily shown to be absent (Fig. 2a) except for some focal
positivity of the suprapapillary layers of the epidermis (not
shown). When immunohistochemical staining procedures
were performed on frozen sections of psoriatic lesions,
notable changes in expression were found. A clearly distin-
guishable column-like staining pattern from the basal layers
throughout the suprabasal compartment in rete ridges was
seen in nine of 11 psoriatic sections, whereas in normal skin
this pattern was absent (Table 1, Fig. 2a, b). In addition, a
distinct patchy focal honeycomb-like structure was observed
in the basal layers of the epidermis, in particular just above
the top of the dermal papillae, extending with one to two
keratinocyte layers into the stratum spinosum (Fig. 2c, d).
The semiquantitative analysis of this honeycomb-like staining
in psoriatic sections showed a moderate to pronounced
CD26/DPP-IV staining, compared with a less pronounced
staining in normal skin (Table 1).
The dermal reactivity for CD26/DPP-IV showed a
complex staining pattern not suitable for a clear-cut analysis of
T-cell bound CD26/DPP-IV expression in the dermis (Fig. 2e).
CD26/DPP-IV enzyme histocytochemical activity in the
psoriatic (epi)dermis (Fig. 2f–i) and normal skin (Fig. 2h)
revealed an equal topographical distribution compared with
the immunohistochemical positivity for the CD26/DPP-IV
protein (Fig. 2a–e); the column-like staining and patchy
suprapapillary staining of the basal layers in the psoriatic
epidermis, which were observed by immunohistochemistry,
were also seen using the enzyme histocytometric technique.
Diprotin A, a DPP-IV inhibitor, proved to be a good negative
control in all investigated tissues (Fig. 2j, m). The murine
kidney tissue, which functioned as a positive control tissue,
showed distinct and extensive areas of enzyme activity as
anticipated (Fig. 2k, l).
In order to immunophenotype T lymphocytes, the Zenon
immunoﬂuorescence double-labelling technique in combin-
ation with image analysis was used to identify colocalization
of CD26/DPP-IV on T lymphocytes. Overall, in normal skin
immunoﬂuorescence labelling showed that T lymphocytes
were only sporadically present in both the dermis and epider-
mis. The presence of CD26+ T cells was restricted to a spor-
adic cell in the dermis in only one healthy subject. After
staining the psoriatic sections with the Zenon immunoﬂuores-
cence technique, pronounced differences in T-lymphocyte
expression of CD26/DPP-IV were noted compared with nor-
mal skin (Table 1). In the dermal as well as in the epidermal
compartment, T lymphocytes expressing CD26 on their sur-
face were detected (Fig. 3a–f). The percentage of CD3+ lym-
phocytes which stained positive for CD26, was quantiﬁed per
region of interest and ranged between 0% and 17% in the
psoriatic dermis (mean 7Æ9 ± 1Æ72 SEM). In the psoriatic
epidermis, between 0% and 31% of the T lymphocytes
coexpressed CD26/DPP-IV (mean 13Æ9 ± 3Æ38 SEM) (Table 1).
The T lymphocytes were mainly situated in groups within the
dermal papillae, surrounding small vessels. Fewer T cells were
localized in the epidermis. To summarize, colocalization of
CD26/DPP-IV on T lymphocytes is explicitly present in psori-
atic plaques, albeit in small quantities in both the dermis and
epidermis.
Fig 1. CD26/dipeptidyl-peptidase IV (DPP-IV) is upregulated in
lesional skin of psoriatic patients. CD26/DPP-IV mRNA levels in
epidermal sheets were signiﬁcantly higher (P = 0Æ002) in lesional skin
from psoriatic patients (PS; n = 9) than in normal skin (NS; n = 5).
CD26/DPP-IV mRNA levels were determined by quantitative
polymerase chain reaction. Error bars indicate standard deviation.
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Discussion
T-helper (Th) 1 lymphocytes, keratinocytes and cytokines are
believed to play critical roles in the pathogenesis of psoriasis.
Evidence has been provided that CD26/DPP-IV may interact
with all these three key players. We have characterized the
pattern of expression of DPP-IV at the mRNA and protein level
in psoriasis compared with normal skin in order to determine
whether or not its expression can function as a (discriminat-
ing) biomarker in psoriasis. Some restricted, divergent studies
have addressed the expression of the CD26/DPP-IV molecule
in the psoriatic inﬂammatory condition. Their major ﬁndings
comprised a typical focal immunostaining in the epidermis
and an increased overall immunostaining of epidermis in
lesional skin,14 which disappeared after treatment with topical
calcipotriol.15 However, the potential of CD26/DPP-IV to
function as a (discriminating) biomarker related to prolifera-
tion and inﬂammation in psoriasis was not investigated. These
studies did not comprise homogeneous groups of psoriatic
patients and expression was not validated on the mRNA level
or investigated on T cells.
In the present study we found an evident signiﬁcant upreg-
ulation (11-fold) of CD26/DPP-IV on the mRNA level in pso-
riatic epidermis compared with normal epidermis. These
ﬁndings gave rise to further investigations on the distribution
of CD26/DPP-IV in lesional psoriatic skin and allowed us to
ﬁnd out in what way this expression is topographically
distributed in the epidermis. We conﬁrmed the observed dif-
ferences at mRNA level after immunohistochemical staining
for CD26/DPP-IV at the protein level. We enriched earlier
ﬁndings14 by noting a distinct column-like staining pattern in
the rete ridges of psoriatic epidermis. This is a novel feature
and may indicate that the CD26+ basal keratinocytes are capa-
ble of keeping their CD26-positivity when proliferating and
differentiating upward in the stratum spinosum. Table 1
shows that nine out of 11 psoriatic patients expressed this
column-like staining pattern of keratinocytes. On the one
hand, the robust expression of CD26/DPP-IV in the basal and
Table 1 Keratinocyte expression of CD26/
dipeptidyl-peptidase IV (DPP-IV) in normal
and psoriatic skin, and T-cell bound CD26/
DPP-IV expression in psoriatic skin
Keratinocyte expression T-cell bound CD26/DPP-IV expression
Honeycomb-
like
Column-like
pattern
Dermis
(% CD3+CD26+ mm)2)
Epidermis
(% CD3+CD26+ mm)2)
Patient
1 + + 6 19
2 + + 7 9
3 ++ ++ 17 31
4 + ) 3 0
5 + + 10 11
6 + + ND ND
7 ± + 16 29
8 + ++ 5 7
9 ± ) 0 4
10 + + 5 22
11 ++ ++ 10 7
Healthy subjects
1 ) ) 0 0
2 + ) 0 0
3 + ) 1 0
4 ± ) 0 0
), no CD26/DPP-IV staining; ±, slight CD26/DPP-IV staining; +, moderate CD26/DPP-IV
staining; ++, pronounced CD26/DPP-IV staining; ND, not done.
Fig 2. Equal topographical immunohistochemical and enzyme histocytometric staining of psoriatic skin vs. normal skin with CD26/dipeptidyl-
peptidase IV (DPP-IV). (a) Immunohistochemical staining of normal skin with CD26/DPP-IV; (b) in psoriatic skin a clearly distinguishable
column-like staining pattern in the suprabasal compartment in the rete ridges was observed; and (c) a patchy suprapapillary staining of the
psoriatic epidermis extending from the stratum basale up to several keratinocyte layers of the stratum spinosum was observed. (d) In addition, a
distinct focal honeycomb-like structure in the suprabasal layers of the psoriatic epidermis was noted. (e) The dermal reactivity for CD26/DPP-IV
shows a complex staining pattern not suitable for a clear-cut analysis of T-cell bound CD26/DPP-IV expression in the dermis. (f,g,i) Enzyme
histocytometric staining of psoriatic skin vs. normal skin (h) with CD26/DPP-IV (clone BA-5) revealed an equal topographical staining pattern
compared with the immunohistochemical staining pattern of CD26/DPP-IV (a–e). (j) Enzyme histocytometric reactivity was absent in serial
sections using the DPP-IV inhibitor diprotin A. (k, l) Frozen sections of murine kidney were stained with CD26/DPP-IV as a positive control (m)
and with diprotin A.
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suprabasal layers of the rete ridges of the epidermis in psoria-
sis suggests that CD26-related processes are relevant in the
maintenance of epidermal hyperproliferation. On the other
hand, the chronic over-reaction of the immune system present
in the psoriatic epidermis causes damage and therefore is
undesirable. Therefore, it is attractive to speculate that the
proteolytic activity of CD26/DPP-IV among other things could
possibly intervene in the unbalanced epidermal immune
activation status and tone down this disequilibrium.
In a previous study, increased CD26/DPP-IV expression was
also shown in spongiotic dermatitis,14 which could exclude
speciﬁcity for psoriasis. However, the large difference between
epidermal expression of CD26/DPP-IV in psoriatic and normal
skin suggests that assessment of this marker during treatments
may be useful. In this respect, dose-dependency studies with
individual cytokines with either Th1 or Th2 speciﬁcity in both
psoriasis and spongiotic dermatitis could be the subject of
future investigations.
It must be noted that the positive immunohistochemical
staining on sections of psoriatic skin represents a positivity
for that protein and does not necessarily mean that CD26/
DPP-IV enzyme activity is present at that site. For that pur-
pose visualization of enzyme activity in tissue sections was
performed by means of enzyme cytochemical methods. We
found a remarkable correspondence between the CD26/DPP-
IV-positive-stained epidermal areas after immunohistochemi-
cal techniques compared with the enzyme cytochemical
staining procedures, which shows that the expression of
CD26/DPP-IV at protein level is not merely present but also
enzymatically active.
Further speciﬁcation of the topographical distribution of
CD26/DPP-IV on T cells was possible in our study, devel-
oping a double-staining technique with CD3. To the best of
our knowledge, the colocalization of CD26 on T cells in
the (epi)dermal compartment has never been described
before. We found that dermal T cells and epidermal T cells
both express CD26 on their surface, possibly indicating that
CD26+ T cells are able to migrate to the dermis and epi-
dermis. On the other hand, T cells may possibly be able to
acquire CD26 expression in situ after having migrated to the
skin. Previous investigations showed a decreased number of
CD8 CD26 bright T cells in peripheral blood of patients
with severe psoriasis.21 Our current results show that
between 0% and 31% of the epidermal T lymphocytes
express CD26/DPP-IV on their surface compared with 0–
17% in the dermis. Given the fact that epidermal T cells in
the epidermis are predominantly CD8+,27,28 it would be
interesting to investigate whether these (epi)dermal CD26/
DPP-IV+ T cells are CD8+, to ﬁnd out whether these cells
express CD26 in a dim or bright way and to deﬁne further
the T-cell subsets expressing CD26/DPP-IV. It is attractive to
speculate that epidermal CD8+CD26+ T cells are increased
in the psoriatic skin at the expense of extravasation of these
cells from peripheral blood.
This study reveals and conﬁrms that CD26/DPP-IV can
exert a crucial function and can act on the major patho-
genic key players, as it is expressed both on keratinocytes
and T cells in the psoriatic lesion and has been shown to
have a functional enzyme activity as well. Herewith, poten-
tially important cytokines and chemokines involved in the
psoriatic pathogenesis can be affected or degraded in
(a)
(d)(c)(b)
(e) (f)
Fig 3. Phenotyping of CD26+ T cells in lesional psoriatic
(epi)dermis using the Zenon immunoﬂuorescence labelling technique.
Sections of lesional psoriatic skin were double stained using direct
immunoﬂuorescence labelling for CD3 and CD26/dipeptidyl-peptidase
IV (DPP-IV). (a) Costaining of CD3 (green) and CD26 (red) in
lesional psoriatic skin revealed colocalization of these two proteins
(merge; yellow) in the dermis (inset). (b) Monoclonal anti-
CD26 antibody. (c) Monoclonal anti-CD3 antibody. (d) DAPI
counterstaining of nuclei. (e, f) Colocalization of CD3 (green) and
CD26 (red) was also evident in lesional psoriatic epidermis (merge;
yellow).
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biological activity. In vitro studies have been reported and
demonstrated an altered receptor speciﬁcity, binding or acti-
vation for the chemokines RANTES, IP-10, Mig, SDF-1a and
-b, ITAC, eotaxin and MDC;8 in vivo studies with these indi-
vidual cytokines are of future interest.
Currently, DPP-IV inhibitors are of major interest, due to
their potent immunosuppressive and anti-inﬂammatory effects
in various disease models. Because of the diverse expression of
CD26/DPP-IV in psoriasis outlined in this study, the skin may
be an important organ for evaluating the effect of these
DPP-IV inhibitors and the potential therapeutic applications in
the future.
To summarize, we have shown that CD26/DPP-IV is
strongly upregulated in psoriatic epidermis and that keratino-
cytes and T cells in psoriatic lesions express CD26/DPP-IV
although in a variable way. Moreover, the CD26/DPP-IV
expression on a protein level in psoriatic skin was demon-
strated to be enzymatically active. This points to a versatile,
complex yet possibly important role of this protein as a com-
plementary biomarker in psoriasis. Focusing on the immuno-
logical and functional expression of CD26/DPP-IV in
keratinocytes in vitro could provide a better insight in CD26/
DPP-IV regulation and seems warranted. Furthermore, the
effects on CD26/DPP-IV expression of known and experimen-
tal antipsoriatic agents are an interesting point of focus as
well. Although the exact functional contribution of these
properties of CD26/DPP-IV needs to be further elucidated, the
topographical distribution of this complex multifunctional
protein suggests a relevant contribution in epidermopoiesis
and T-cell signalling in psoriasis.
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Abstract The inXammation process in psoriatic skin is
characterized by inXux of leukocytes, hyperproliferation
and aberrant diVerentiation of keratinocytes regulated via
cytokines. Dipeptidyl-peptidase IV (DPPIV) is known to be
upregulated on keratinocytes in the psoriatic lesion. The
objective was to gain insight into dynamics of DPPIV
expression and enzyme activity together with keratinocyte
proliferation and diVerentiation markers during develop-
ment of a psoriatic lesion, in order to investigate coherence
in mechanisms behind the upregulation of DPPIV in psori-
atic skin. The expression of DPPIV, Ki-67 antigen and ker-
atin-16 (K16) was studied in the dynamic margin zone of
the psoriatic lesion, examining skin sections of the clini-
cally uninvolved skin, the early lesion and the chronic
lesion of psoriatic patients compared to healthy volunteers
using immunohistochemical and enzymehistochemical
staining methods. DPPIV-expression and enzyme activity,
Ki-67 antigen and K16 are signiWcantly upregulated in the
centre and inner margin of the lesion compared to clinically
uninvolved skin and the healthy volunteers skin. Mutually
between the centre and inner margin, this upregulation did
not diVer signiWcantly. The clinical symptomless skin
proved to have signiWcantly elevated DPPIV enzyme activ-
ity compared to the skin of healthy volunteers. We demon-
strate that DPPIV is expressed and enzymatically active
well before the development of an overt psoriatic lesion.
The abnormal DPPIV distribution in psoriatic skin does not
coincide with known markers of aberrant growth and diVer-
entiation of keratinocytes, which makes DPPIV (expression
and enzyme activity) a marker standing on its own.
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Introduction
Psoriasis is considered to be an organ-speciWc autoimmune
disease, caused by a combination of genetic and environ-
mental factors and is triggered and maintained by an acti-
vated cellular immune system. Its pathology is mainly
characterized by cutaneous inXammatory inXux of leuko-
cytes and hyperproliferation and aberrant diVerentiation of
keratinocytes. Within the psoriatic lesion, there is a mutual
interaction between these keratinocytes and mononuclear
leukocytes by means of a third involved party, the cyto-
kines [5, 11]. The chemical modiWcation of cytokines and
hence the modiWcation of their physiological function is of
major importance to understand their actual role in the
pathophysiology of the psoriatic process.
Dipeptidyl peptidase IV (CD26) is a 110-kDa mem-
brane-anchored glycoprotein with a variety of functions [1,
4]. In general, it is widely distributed throughout the human
body and varies in density and form between various
organs and cell types. Its proteolytic properties enable it to
directly modify substrates such as cytokines in their natural
in vivo form, (e.g., CXCL12, CCL5, CXCL11, CXCL10,
GLP-1/2) [1, 4, 7, 14].
In human skin, DPPIV is known to be expressed on
keratinocytes and known to be upregulated in psoriasis [4,
13, 19, 22]. However, little data are available concerning
the potential functional implications of such an upregula-
tion. Selective blockers of DPPIV activity are currently
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being developed as modulators of immunological responses
[15]. Recently, it was shown that such an inhibition could
suppress keratinocyte proliferation in vitro and partially
restore keratinocyte diVerentiation in vivo [19]. Mapping
the DPPIV glycoprotein in psoriasis may therefore add to
our current knowledge. Considering the common grounds
of the three main pathological components of psoriasis (T
cells, keratinocytes and cytokines) and the various proper-
ties of DPPIV, it is attractive to speculate that DPPIV might
be involved in the modulation of the inXammatory process
and the keratinocyte abnormalities in psoriasis.
Ensued from this, our goal was to map the epidermal
expression and enzyme activity of DPPIV in relation to
known markers of proliferation (Ki-67) and abnormal mat-
uration (Keratin 16) of psoriatic keratinocytes in the epider-
mis [10]. Coherence in dynamics of expression of these
three markers could result in expanding knowledge on the
existing epidermal disbalance in psoriasis. We studied the
expression and enzyme activity of DPPIV in the dynamic
margin zone of the psoriatic lesion in order to investigate
whether DPPIV distribution diVers with the distribution of
K16 and Ki-67 in clinically uninvolved psoriatic skin, in
the early lesion and subsequently in the chronic psoriatic
lesion. Accordingly, coherence in dynamics of DPPIV
(expression and enzyme activity) with keratinocyte prolif-
eration and diVerentiation markers during the development
of a psoriatic plaque could reveal more insight into the
mechanisms behind the known upregulation of DPPIV in
psoriatic skin.
Patients and methods
Patients
A total of seven psoriatic patients (mean age § SEM,
63 § 3 years) with mild-to-moderate plaque psoriasis [Pso-
riasis Area and Severity Index (PASI) ¸2 and ·12] and a
control group, composed of three healthy volunteers (mean
age 52 § 6 years), participated in this study. Patients had
stable plaque-type psoriasis. None of the participants had
used any systemic anti-psoriatic or immune-modulating
therapy for at least 4 weeks and no topical therapy for at
least 2 weeks prior to the biopsy. The healthy volunteers
had no history of dermatological or immunological disease.
All participants had given written informed consent before
enrollment.
Biopsies
From the psoriatic patients three 4-mm punch biopsies were
obtained, respectively, from the centre of the plaque, the
inner margin of the plaque comprising the outmost clini-
cally involved area and the clinically uninvolved skin (at
least 2 cm from the lesion). From the healthy volunteers
one 4-mm punch biopsy was obtained. All participants
received local anesthesia (1% xylocaine/adrenaline) before
the biopsies were taken. Skin defects were optionally
closed with one suture. The obtained specimens were
embedded in Tissue-Tek OCT compound (Sakura, Zoeter-
woude, Netherlands), snap-frozen in liquid nitrogen and
stored at ¡80°C until use.
Histochemical methods
Immunohistochemical procedure
The immunohistochemical staining was performed as
described previously [2, 23]. BrieXy, cryostat sections of
7 �m were sliced onto (3-amino propyl)triethoxysilane
(AAS)-coated slides, air-dried for 10 min and Wxed in cold
acetone for 10 min. After blocking for endogenous peroxi-
dase for 20 min, sections were incubated with either CD26
monoclonal antibody (1:50) (clone BA-5, Santa Cruz Bio-
technology, Santa Cruz, FL), Ki-67 (1:25) (clone MIB-1,
DAKO, Copenhagen, Denmark) or anti-Keratin-16 (1:20)
(clone LL025, Monosan, Uden, Netherlands), diluted in
1%BSA/PBS for 1 h. Subsequently, sections underwent
secondary incubation with IgG-labelled polymer, horserad-
ish peroxidase antimouse-antibody EnVision+ (DAKO,
Copenhagen, Denmark) for 30 min. As a coloring agent
aminoethylcarbazole + high-sensitivity substrate chromo-
gen (DAKO, Copenhagen, Denmark) was used for 10 min
at 37°C. Before and after each incubation, sections were
washed with PBS for 15 min. All incubations were per-
formed in a dark, humid environment. Counterstaining was
performed with Mayer’s hematoxylin. Subsequently, the
sections were mounted in glycerol gelatin.
Enzymehistochemical procedure
The demonstration of DPPIV activity was achieved using
the method, described by Khalaf et al. [9] with some minor
modiWcations [22]. The frozen biopsies were sliced into 10-
�m sections on AAS-coated slides. These were air-dried for
20 min and Wxed in cold acetone for 10 min. For the incu-
bation mixture, 3 mg of glycyl-propyl-4-methoxy-2-naph-
thylamide (GPMN) (Bachem, Bubendorf, Switzerland) was
dissolved in 0.2 ml dimethylformamide. This substrate was
added to 4.6 ml of PBS and subsequently mixed with 5 mg
of fast blue B salt (FBB) (Sigma–Alderich, St. Louis, MO)
dissolved in 0.2 ml dimethylformamide and Wltered. The
samples were incubated in a humid, dark chamber at room
temperature for 45 min with 200 �l of the incubation mix-
ture added to each section. After incubation the slides were
washed with distilled water, brieXy counterstained with
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Mayer’s hematoxylin and immersed for 30 s in alkaline tap
water. After rinsing with distilled water, they were mounted
in glycerol gelatin.
Negative and positive controls
In the immunohistochemical procedure, as a negative con-
trol the primary antibody was omitted. As a negative con-
trol in the enzymehistochemical procedure, inhibition of
DPPIV activity was accomplished by pretreating the slides
with 200 �l of 5 mM Diprotin A (Peptides International,
Louisville, KY) for 15 min at 37°C [3]. As positive control,
murine kidney tissue was used in the enzymehistochemical
procedure [18, 21].
Image analysis
QuantiWcation
The immunohistochemical and enzymehistochemical
DPPIV-stained sections were analyzed using transmission
light microscopy with an objective magniWcation of 200£.
Per patient, three of the diVerent biopsy sections (center,
inner margin, clinically uninvolved psoriatic skin) were
analyzed for the full width of the section. For quantiWcation
of the epidermal DPPIV expression and enzyme activity,
the following semi-quantitative Wve-point scale was used:
0 = no staining, 1 = slight staining, 2 = moderate staining,
3 = moderately pronounced staining, 4 = pronounced stain-
ing.
In order to analyze K16 and Ki-67 positive cells, digital
photographs were made at 100£ magniWcation. Each pho-
tograph was analyzed using IP-lab software (Scanalytics,
USA). For quantiWcation of the number of cells positive for
Ki-67 and the percentage epidermal area positive for K16, a
deWned window was set in the epidermis as the region of
interest (ROI) which was representative for the whole sec-
tion. The total ROI and the K16-positive area within the
ROI were measured. The K16 value was expressed as per-
centage K16-positive area of the ROI (%). The number of
Ki-67 positive cells was determined by counting the Ki-67
positive nuclei in a representative epidermal ROI. A line,
following the stratum basale of the ROI, was set out and
measured. The number of Ki-67 positive nuclei was
expressed as positive cells per mm length of basement
membrane.
Statistical analysis
Results are presented as means §SD of the mean. All anal-
yses were carried out using Statistica® statistical software,
version 7.0. Comparison of the non-parametric immunohis-
tochemical and enzymehistochemical DPPIV values for the
plaque centre, inner margin and clinically uninvolved skin
was performed using the Kruskal–Wallis analysis of vari-
ance. For analysis of the markers K16 and Ki-67 concern-
ing the plaque centre, inner margin and clinically
uninvolved skin we performed analysis of variance
(ANOVA) and if signiWcant, Duncan’s post hoc compari-
son was performed. The Student’s t test was carried out to
study the diVerence in expression of markers between the
uninvolved psoriatic skin and the healthy volunteers skin.
Correlation was tested with the Spearman’s correlation test.
Statistical signiWcance was set at P < 0.05.
Results
Patients
Histologically, the skin of the healthy volunteers was nor-
mal (hematoxylin–eosin staining). Seven patients (5 males,
2 females) diagnosed with psoriasis participated. In order to
assess the severity of the psoriatic lesion used for biopsy,
SUM scores (0–12) were determined. SUM score is a psori-
atic lesion severity score, comprising erythema (0–4), indu-
ration (0–4) and desquamation (0–4) wherein a score of 0
represents no psoriasis and 12 the highest possible severity
of the plaque. The mean SUM score in this study was
5.57 § 0.34.
Epidermal distribution of dipeptidyl-peptidase IV, Ki-67 
and Keratin-16 (Fig. 1)
In correspondence with earlier Wndings [22], upregulation
of DPPIV on keratinocytes was seen in all of the patients,
although to a diVerent extent. In line with these earlier Wnd-
ings, the immunohistochemical and the enzymehistochemi-
cal staining of DPPIV followed a similar epidermal pattern;
focally pronounced patches of staining, mainly displaying a
honeycomb like structure, in psoriatic sections. In those of
the healthy volunteers this pattern was practically absent. In
brief, the psoriatic pattern was generally more extensive
and predominantly located para-papillary with an optimum
in the epidermal area around the top of the papillae. Usually
the staining was conWned to the lower two third of the total
epidermis, or more speciWcally to the lower three quarters
of the stratum spinosum (Fig. 1). In both healthy and psori-
atic skin, no staining in the stratum lucidum was observed.
In the psoriatic coupes, additional column-like structures
could regularly be observed.
The DPPIV immunohistochemical expression and
enzyme activity in the centre of the plaque, the inner mar-
gin and the clinically uninvolved skin showed a comparable
pattern with correlations, respectively, of 0.79, 0.85 and
0.87 (P<0.02). Considering this comparable pattern, the
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enzyme activity of DPPIV was chosen in this study as a ref-
erence for drawing comparisons with the Ki-67 and K16
markers as it encompasses more potential to study dynam-
ics than the protein expression does. Namely, protein
expression only conWrms the presence of DPPIV whereas
enzyme activity denotes presence and activity of DPPIV.
As far as the proliferation marker Ki-67 is concerned, it
predominantly appeared in the stratum basale in both psori-
atic and healthy skin although to a diVerent extent (Fig. 1).
Solitary Ki-67 positive cells could be observed sporadically
in the stratum spinosum of the clinically uninvolved skin of
psoriatics and the skin of healthy volunteers. Obviously, in
the centre and inner margin of the psoriatic lesion, gener-
ally a greater number of Ki-67-positive cells was observed
in all patients.
Keratin-16, a diVerentiation marker, only stained posi-
tive in the epidermis of the plaque centre and inner margin
conWrming the aberrant diVerentiation in these parts as
opposed to the clinically uninvolved psoriatic and healthy
skin (Fig. 1). The staining was seen throughout the whole
stratum spinosum, with an optimum towards the stratum
basale.
Dynamics in epidermal distribution of dipeptidyl-peptidase 
IV, Ki-67 and Keratin-16 (Fig. 2)
Throughout the dynamics of the margin zone of the psoriatic
lesion, a stronger signiWcant DPPIV enzymatic activity could
be noticed in both the inner margin and centre of the lesion
compared to the clinically uninvolved psoriatic skin
(1.38§ 0.24 and 1.57§ 0.27 vs. 0.62§ 0.15; P < 0.01 and
P < 0.05) (Fig. 2). Clinically uninvolved psoriatic skin also
showed a signiWcant increase in enzymatic activity compared
to skin of healthy volunteers (P < 0.05). However, when
observing the expression in the centre and the inner margin
mutually, no signiWcant diVerence in expression was detected.
Equal to the DPPIV enzyme activity, Ki-67 antigen was
signiWcantly strongly expressed in both the plaque centre
Fig. 1 Expression of DPPIV 
protein expression, enzyme 
activity, Keratin 16 and Ki-67 
throughout the margin zone of a 
psoriatic lesion compared to nor-
mal skin. Plaque centre, inner 
margin, clinically uninvolved 
skin (UIS): £200 magniWcation. 
Healthy volunteers skin (HV): 
£100 magniWcation. Notice-
ably, in the skin of healthy vol-
unteers the DPPIV enzyme-
activity staining creates a 
brownish background staining
Fig. 2 Mean scores of DPPIV 
enzyme activity, Ki67 and K16 
expression throughout the mar-
gin zone. * = signiWcant. 
(Mean § SEM)
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and the inner margin compared to the clinically uninvolved
psoriatic skin (172.65 § 16.06 and 167.60 § 13.84 vs.
70.44 § 7.97; both P < 0.01) (Fig. 2). The clinically unin-
volved psoriatic skin showed a stronger proliferation ten-
dency of keratinocytes than the healthy volunteers skin,
albeit borderline signiWcant (P = 0.057). However, when
observing the Ki-67 expression in the centre and the inner
margin mutually again, no signiWcant diVerence in expres-
sion was detected.
With respect to the expression of K16 in the various
parts of the margin zone, the plaque centre and the inner
margin showed signiWcantly more expression of K16 in
comparison to the clinically uninvolved psoriatic skin
(67.0 § 3.13 and 65.43 § 2.1 vs. 0 § 0) (Fig. 2). This was
in line with the expected expression pattern because in
uninvolved psoriatic skin and healthy volunteers skin there
exists a natural absence of K16 expression. Mutually how-
ever, the centre and margin did, once more, not diVer sig-
niWcantly in K16 expression.
Correlation of epidermal distribution of dipeptidyl-peptidase 
IV, Ki-67antigen and K16
In general, there were no signiWcant correlations observed
between enzymatic cytochemical activity of DPPIV and
expression of aberrant proliferation or diVerentiation of
keratinocytes throughout the dynamics of the margin zone.
Remarkably, the Ki-67 positive cell count and percent-
age of K16 positively stained epidermis showed a strong
overall correlation in the psoriatic patients, taking together
both the plaque centre and the inner margin (� = 0.88;
P < 0.05). Though, when investigating the correlation of
these markers per locus separately, no signiWcant correla-
tion could be observed (plaque centre � = 0.54; inner mar-
gin � = 0.3).
Discussion
Dipeptidyl peptidase IV has diverse properties as an ecto-
peptidase, enabling it to play a key role in the chronic pso-
riatic immune response which is mainly orchestrated by T
cells, cytokines and keratinocytes in psoriasis. Direct evi-
dence that DPPIV inhibitors are relevant to keratinocyte
biology has been provided by the observation that such
inhibitors can suppress keratinocyte proliferation in vitro
and can partially restore keratinocyte diVerentiation in
vivo [19]. This would imply that DPPIV may aVect and
interact with the aberrant keratinocyte abnormalities in
psoriasis. In line with previous Wndings [22], the present
study conWrms a strong upregulation of DPPIV on kerati-
nocytes in psoriatic epidermis but additionally reveals it
to be continuously present throughout the dynamics of the
margin zone. Moreover, it aimed to shed light on the func-
tional implication of this upregulation combining it with
the expression of markers characteristic for proliferation
(Ki-67) and diVerentiation (K16) in psoriatic keratino-
cytes as coherence in dynamics of expression of these
markers could result in creating an epidermal biomarker
in psoriasis.
Topographically, the distribution of the enzyme activity
of DPPIV did not coincide entirely with the areas of hyper-
proliferation and aberrant diVerentiation of keratinocytes in
a psoriatic section which ultimately makes DPPIV expres-
sion (enzyme activity and protein expression) an entity in
itself in psoriasis. The margin zone was previously proven
to be a suitable model for studying the dynamics of a psori-
atic lesion by representing the chronic and the early process
and the uninvolved skin [6, 20, 23]. The inner margin was
presumed to represent an early active lesion and therefore
reXecting a diVerent level of expression. DPPIV enzyme
activity, Ki-67 and K16, all three show, throughout the
margin zone, signiWcant upregulation in the centre and
inner margin of the plaque compared to the clinically unin-
volved skin and the healthy volunteers skin. However,
mutually the upregulation in expression in the centre and
inner margin did not diVer signiWcantly for both the Ki-67,
K16 marker as well as for DPPIV enzyme activity. One
could suggest that in this study within a psoriatic lesion
there exists a homogeneous level of keratinocyte prolifera-
tion, diVerentiation and DPPIV enzyme activity as parts
representing an early (inner margin) or more chronic (cen-
ter) lesion do not seem to make a diVerence in expression
for the markers under study. Moreover, correlation tests
applied to the margin zone in this investigation showed no
coherence in dynamics of epidermal DPPIV enzyme activ-
ity, hyperproliferation and aberrant diVerentiation of kerati-
nocytes.
The symptomless skin at 2-cm distance from a psoriatic
lesion proved to have signiWcantly elevated DPPIV enzyme
activity as compared to skin of healthy volunteers, whereas
Ki-67 and K16 were essentially slightly present or absent in
the symptomless skin. Although the symptomless skin may
harbor some “preclinical lesions” or can be subclinically
involved, we can conclude that in an early phase of the pso-
riatic process well before an overt lesion has developed, an
increased DPPIV enzyme activity is present clearly show-
ing that DPPIV is involved in an early phase of the psoriatic
cascade [8, 12].
A number of other molecules exhibiting DPPIV-like
enzyme activity have been introduced recently, and termed
“DPP-IV activity and/or structure-homologues” (DASH)
[17]. This group comprises several proteases including attr-
actin, DPP 8 and 9 [16, 17]. DASH have potential abilities
to complement and/or functionally substitute DPPIV on the
level of its enzymatic activity. In this light, a marginal note
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has to be made as the DASH might be involved in DPPIV-
like processes (as could be the case in the current investiga-
tion). Due to the ubiquitous expression pattern and multi-
functional nature of DPPIV speciWcally and the majority of
the DASH in general, it may be diYcult to deduce the
selectivity of DPPIV from the DASH group. However, our
results did not show discrepancies between the immunohis-
tochemical and enzymehistochemical staining, which
implies that the possible presence of DPPIV homologues
does not interfere with the interpretation of the data in the
current study.
Our goal was to determine whether the distribution of
DPPIV in the epidermis throughout the dynamics of the
margin zone, coheres with markers for proliferation and
diVerentiation of keratinocytes in psoriasis in order to
expand knowledge on the existing epidermal dysbalance in
psoriasis. Considering the localization of DPPIV expres-
sion and enzyme activity in the epidermis, being primarily
concentrated towards the (supra) basal layers, it is possible
to presume an active role for DPPIV in the proliferation of
keratinocytes in the pathogenesis of psoriasis. On the other
hand, considering the functional enzymatic characteristics
of DPPIV, it may well be feasible that the peptidase activity
actually restrains the inXammatory disbalance in the psori-
atic skin through down-regulation of cytokines secondarily
aVecting the keratinocyte malfunctioning. Therefore, the
psoriatic skin represents an interesting eVector organ for
DPPIV inhibitors which could tackle not only keratinocytes
and cytokines but also (DPPIV+) T cells, key players in the
psoriatic pathogenesis all sharing common grounds with
DPPIV. Future studies should address the eVect of such
inhibitors in psoriasis.
In conclusion, we have demonstrated diVerential expres-
sion and activity of DPPIV in normal and diseased skin
throughout the dynamics of the margin zone. In addition,
we have shown that DPPIV (protein expression and
enzyme activity) is expressed well before the development
of the overt psoriatic lesion before the accumulation of T
cells and other inXammatory cells. Moreover, the DPPIV
enzyme activity does not increase signiWcantly in the more
chronic phase of the psoriatic process. Therefore, DPPIV is
a consistent feature of the psoriatic lesion. The abnormal
enzyme activity in psoriatic diseased skin does not seem to
correlate with known markers of aberrant growth and
diVerentiation of keratinocytes, which makes DPPIV a
marker standing on its own. Future studies should focus on
whether DPPIV can be regarded a useful biomarker for
therapy evaluation.
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has to be made as the DASH might be involved in DPPIV-
like processes (as could be the case in the current investiga-
tion). Due to the ubiquitous expression pattern and multi-
functional nature of DPPIV speciWcally and the majority of
the DASH in general, it may be diYcult to deduce the
selectivity of DPPIV from the DASH group. However, our
results did not show discrepancies between the immunohis-
tochemical and enzymehistochemical staining, which
implies that the possible presence of DPPIV homologues
does not interfere with the interpretation of the data in the
current study.
Our goal was to determine whether the distribution of
DPPIV in the epidermis throughout the dynamics of the
margin zone, coheres with markers for proliferation and
diVerentiation of keratinocytes in psoriasis in order to
expand knowledge on the existing epidermal dysbalance in
psoriasis. Considering the localization of DPPIV expres-
sion and enzyme activity in the epidermis, being primarily
concentrated towards the (supra) basal layers, it is possible
to presume an active role for DPPIV in the proliferation of
keratinocytes in the pathogenesis of psoriasis. On the other
hand, considering the functional enzymatic characteristics
of DPPIV, it may well be feasible that the peptidase activity
actually restrains the inXammatory disbalance in the psori-
atic skin through down-regulation of cytokines secondarily
aVecting the keratinocyte malfunctioning. Therefore, the
psoriatic skin represents an interesting eVector organ for
DPPIV inhibitors which could tackle not only keratinocytes
and cytokines but also (DPPIV+) T cells, key players in the
psoriatic pathogenesis all sharing common grounds with
DPPIV. Future studies should address the eVect of such
inhibitors in psoriasis.
In conclusion, we have demonstrated diVerential expres-
sion and activity of DPPIV in normal and diseased skin
throughout the dynamics of the margin zone. In addition,
we have shown that DPPIV (protein expression and
enzyme activity) is expressed well before the development
of the overt psoriatic lesion before the accumulation of T
cells and other inXammatory cells. Moreover, the DPPIV
enzyme activity does not increase signiWcantly in the more
chronic phase of the psoriatic process. Therefore, DPPIV is
a consistent feature of the psoriatic lesion. The abnormal
enzyme activity in psoriatic diseased skin does not seem to
correlate with known markers of aberrant growth and
diVerentiation of keratinocytes, which makes DPPIV a
marker standing on its own. Future studies should focus on
whether DPPIV can be regarded a useful biomarker for
therapy evaluation.
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Abstract
Background: T cells have been shown to be highly relevant in
psoriasis. CD26 is a novel T-cell activation marker involved in
various T-cell functions, e.g. (i) co-stimulation, (ii) migration and
(iii) T-cell memory response. In particular, CD26bright peripheral
blood T cells have been shown to be altered in several
autoimmune diseases.
Objective: To characterize CD26-expression of T-cell subsets in
psoriatic patients compared to healthy subjects.
Methods: Peripheral blood was obtained from 15 untreated
patients with severe psoriasis and from nine healthy subjects. The
presence of speciﬁc CD26-related T-cell subsets was assessed by
ﬂow cytometry.
Results: The CD26bright expression of CD8+ lymphocytes
revealed a statistically signiﬁcant (P<0.05) decrease in psoriatic
patients. The majority of CD4+CD26bright cells are CD45RO+,
whereas the minority of CD8+CD26bright cells are CD45RO+ in
both groups.
Conclusions: The present study demonstrates that the
CD8CD26bright T-cell population is markedly decreased in
peripheral blood of psoriatic patients. Moreover, CD26 expression
did not show a restriction to memory T cells. As CD26 is of
relevance for T-cell functions, future investigations should focus
on elucidating these functions in psoriasis. It is attractive to
speculate that the reduction in the CD8CD26bright subpopulation
may represent a biomarker for recompartimentalization of
activated T cells and a reduced CD8CD26bright count may
correlate with increased responsiveness to T-cell targeted
treatments.
Key words: CD26 – peripheral blood – psoriasis – T-cells
Please cite this paper as: Reduced CD26bright expression of peripheral blood CD8+ T-cell subsets in psoriatic patients. Experimental Dermatology 2008; 17:
343–348.
Introduction
Psoriasis vulgaris can be considered one of the most com-
mon disﬁguring skin diseases, in which a multifactorial
basis is the input for divergent therapeutic modalities since
decades. The aetiology regarding the initial trigger for
developing this skin disease and its matching characteristic
features, remains speculative. Unravelling the psoriatic
pathogenesis, one of the adhered hypothesis states that pso-
riasis is thought to be a T-cell-mediated skin disease in
which activated T cells have been shown of major signiﬁ-
cance. These cells are known to be present in skin lesions
and in peripheral blood of psoriatic patients (1,2). A spec-
trum of cytokines and chemokines are produced by these T
cells which ultimately results in hyperproliferation of kerat-
inocytes (3). In particular, Th1 cytokines, such as tumor
necrosis factor-a (TNF-a), Interleukin (IL) 2 and -12 and
interferon-c have been shown to dominate over Th2
cytokines, such as IL- 4 and IL-10 (4). Activation of Th1-
producing T cells by antigen presenting cells (APCs), with
IL-12 ⁄ Il-23 as important mediators, have been suggested to
be of great importance in the pathogenesis of psoriasis (5).
More recently, biologic therapies, targeted speciﬁcally on
T-cell epitopes have been shown to be effective in psoriasis,
including alefacept (CD2-LFA3 co-stimulatory pathway)
(6), efalizumab (LFA1-ICAM1 co-stimulatory pathway)
(7,8) and anti-IL-12 ⁄ -23 (9). Psoriasis can therefore be seen
as a disease in which the interplay between activated T
cells, keratinocytes and cytokines is determinative.
CD26 is a surface glycoprotein of T cells, belonging to
the class of membrane-associated peptidases and is identical
to dipeptidylpeptidase IV (DPPIV). Evidence is accumulat-
ing that CD26 is a key player in three different T-cell func-
tions: (i) co-stimulation, (ii) migration, and (iii) memory
DOI:10.1111/j.1600-0625.2007.00650.x
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response (10–15). To induce T-cell proliferation and lym-
phokine secretion T cells require a second co-stimulatory
signal, provided by a number of so-called accessory mole-
cules expressed on the T-cell surface interacting with mole-
cules on APCs (16). It has been suggested that CD26, as
such an accessory molecule, in concerted action with
CD45RO (memory T-cell marker) on the T-cell surface,
can interact with an undeﬁned counter-receptor on APCs
resulting in T-cell activation (17). In addition, the enzyme
activity of CD26 ⁄DPPIV is capable of cleaving dipeptides
at the N-terminus of polypeptides with proline, or alanine
in a lesser extent, at the penultimate position. Inﬂamma-
tory cyto- and chemokines can be processed by CD26, such
as CCL5(RANTES) and IL-2 (18). Interestingly, CD26 is
described to be expressed on keratinocytes as well (19). To
summarize, ensued from the above-mentioned all three
major participants in the psoriatic interplay (T cells, cyto-
kines, and keratinocytes) could be targeted performing an
expression-analysis of CD26.
The aim of the present study was to focus on the T-cell-
related expression of CD26 in peripheral blood of psoriatic
patients. In vitro studies have shown that CD26 is constitu-
tively expressed by 56% of CD4+ T cells and by 35% of
CD8+ T cells (20). In resting peripheral blood mononu-
clear cells a small subpopulation expresses CD26 at high
density, which subpopulation is designated as ‘CD26bright
T cells’. Several authors have claimed that the CD26bright
T cells belong to a CD45RO+ subpopulation (21,22).
Further studies are required to ﬁnd out whether this
co-expression is the reality of the in vivo situation. Remark-
ably, in vivo, peripheral blood CD26bright T cells have
been shown to be increased in patients during active phases
of other autoimmune diseases, such as rheumatoid arthri-
tis, Graves disease and multiple sclerosis and decreased in
immunocompromised patients (HIV) (23–28). In psoriasis,
this CD26bright population has not been studied yet. The
identiﬁcation of these T cells in normal and psoriatic con-
ditions may contribute to a better understanding of the
underlying pathogenesis of psoriasis. Therefore, we have
characterized peripheral blood lymphocytes of patients with
untreated severe widespread psoriasis and healthy volun-
teers by multiparameter ﬂow cytometric analysis.
Methods
Study population
Fifteen patients (six females, nine males between 31 and
59 years of age) with severe psoriasis, deﬁned as with a
Psoriasis and Severity Index (PASI) of 12 or greater, and
nine healthy subjects (three females and six males between
19 and 50 years of age) without any history or signs of skin
diseases participated in this study after giving informed
consent. All patients had a washout of systemic treatments
or phototherapy for at least 4 weeks and had not used top-
ical treatment for the last 2 weeks at time of venapuncture.
Furthermore, they did not have comorbidities and did not
use interfering medication.
Isolation of peripheral blood lymphocytes
Peripheral blood specimens were collected in 3 ml vacu-
tainer tubes (BD Vacutainer Systems, Plymouth, UK) con-
taining ethylenediaminetetraacetate (EDTA). Aliquots of
100 ll were placed directly into staining tubes containing
the appropiate volumes of ﬂuorochrome-conjugated mono-
clonal antibodies. The tubes were mixed by gentle vor-
texing and were incubated at room temperature (20�C) for
30 min. in the dark. Two millilitres of commercially avail-
able lysing solution (FACS Lysing Solution; BD Biosciences
Pharmingen, San Diego, CA, USA) diluted 1 in 10 into
water, was added to each tube. The tubes were vortexed
and incubated for exactly 10 min at room temperature in
the dark, after which they were centrifuged for 10 min at
200·g. Subsequently, the supernatant was discarded and
the pellet was washed and centrifuged in phosphate buffer
saline (Braun, Melsungen AG, Germany) for 10 min at
200·g. After the supernatant was discarded again, the
resulting cell pellets were resuspended and ﬁxed in 1%
paraformaldehyde (Cytoﬁx 1:4 diluted, BD Fixation Buffer,
BD Biosciences Pharmingen, San Diego, CA, USA).
Monoclonal antibodies
Fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-,
PE-Cy5 and PE-Cy7-conjugated monoclonal antibodies
were used in various designated combinations. The follow-
ing combinations of FITC-PE-Pc5 and Pc7-conjugated
reagents were arranged to assess the CD26 expression in
peripheral blood: anti-CD3+ (T cells) and anti-CD4+
(T-helper cells), CD8+ (cytotoxic T cells) and CD26
(quadruple staining). Anti-CD45RO+ (memory T cells),
anti-CD25+ (early-activated T cells), and anti-CD26+ were
coupled with either anti-CD4+ or anti-CD8+ (quadruple
staining). Table 1 lists the antibodies used.
Flow cytometry
All assays were run on a FC500 ﬂow cytometer (Beckman
Coulter, Cytomics FC500, Miami, FL, USA) equipped with
an argon ion laser emitting at 488 nm. The ﬂow cytometer
was calibrated routinely, as recommended by the manufac-
turer. List mode data were acquired (CXP Software Version
2.1, 2005, Miami, FL, USA). All samples were processed in
duplo within 24 h of venapuncture.
List mode data analysis
List mode ﬁles were analysed using WinList (Verity Soft-
ware House Inc, Winlist Version 5.0, Topsham, ME, USA)
software. A regional gate was set on CD3+ (FITC) versus
van Lingen et al.
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forward scatter to gate for T lymphocytes in the sample
being studied. At least 20 000 gated events were acquired
for each antibody combination.
Statistical analysis
The statistical signiﬁcance between the two groups involved
the Student’s unpaired two-tailed t-test. P-values below
0.05 were considered statistically signiﬁcant. Data analysis
was performed using SPSS 12.0.1 software.
Results
Participating patients had longstanding psoriasis with a
mean PASI of 16.6 at time of venapuncture. Overall, there
was no signiﬁcant increase with respect to the extent of
lesions during the washout period (mean delta PASI
1.3 ± 1.1 (SEM)).
Distribution of CD26-subsets in T cells in healthy
controls and untreated psoriatic patients
Lymphocyte subsets were measured as a percentage of
total gated T cells (CD3+). The CD26 expression in the
CD3+population showed a negative-, a dim- and a
bright positive fraction. These three fractions were
quantitatively similar in psoriatic patients versus healthy
controls (Fig. 1a,b), without statistically signiﬁcant
differences.
The CD3+ population in the psoriatic patients consisted
of similar proportions of CD4+ and CD8+ T cells com-
pared to healthy controls (Fig. 2). With respect to the
CD4+ population, the intensity of the CD26 expression
(negative ⁄dim ⁄bright) showed no signiﬁcant differences
between psoriatic patients and the healthy controls. How-
ever, the CD26bright expression on CD8+ lymphocytes
revealed a marked and statistically signiﬁcant (P = 0.014)
decrease in psoriatic patients compared to the healthy
volunteers (Fig. 1c,d).
Association of CD45RO+ and CD26bright
expression on T cells in healthy controls
and untreated psoriatic patients
Table 2A summarizes quantitatively the co-expression of
CD45RO and CD26 on either the CD4+ or CD8+ subsets
in psoriatics and healthy controls. These data show that
CD26bright cells are not speciﬁcally restricted to the
CD45RO+ population. In the CD4+ T cells, 72.1% of the
CD26 bright subset are CD45RO+ in psoriatics, corre-
sponding to 67.6% in healthy volunteers.
Of the CD8+ cells, however, only 24.4% of the CD26po-
sitive subset is CD45RO+ in psoriatics, compared to 10.1%
in healthy subjects. Thus, whereas the majority of
Table 1. Monoclonal antibodies (MAb) used
CD MAb ⁄ clone Label Source
CD3 UCTH1 FITC Beckman Coulter
CD4 SFCI12T4D11(T4) PC7 Beckman Coulter
CD8 SFCI12Thy2D3(T8) PC7 Beckman Coulter
CD8 RPA-T8 PC5 Becton Dickinson
CD25 M-A251 FITC Becton Dickinson
CD26 L272 PE Becton Dickinson
CD45RO UCHL1 PC5 Becton Dickinson
FITC, ﬂuorescein isothiocyanate; PC7, phycoerythrin-Cy7; PC5,
phycoerythrin-Cy5; PE, phycoerythrin.
(a) (c)
(d)(b)
Healthy subject
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Figure 1. Expression of CD26 in peripheral
blood of psoriatic patients and healthy
subjects. (a): Lymphocytes were gated based
on morphology by side- and forward scatter
properties as discriminators. Example of
statistically equal CD26-, CD26dim and
CD26bright expression on T cells (CD3+) in
both groups. (b): Representation of
(statistically equal) mean percentages of CD26
fractions on T cells. (c): Representative
example of CD8+CD26 expression in
peripheral blood of psoriatic patients and
healthy subjects. (d) Dispersal of individual
CD8CD26bright expression in both groups.
The CD8+CD26bright population is markedly
reduced in the psoriatic patient group.
CD26 T-cell expression in psoriatic patients
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response (10–15). To induce T-cell proliferation and lym-
phokine secretion T cells require a second co-stimulatory
signal, provided by a number of so-called accessory mole-
cules expressed on the T-cell surface interacting with mole-
cules on APCs (16). It has been suggested that CD26, as
such an accessory molecule, in concerted action with
CD45RO (memory T-cell marker) on the T-cell surface,
can interact with an undeﬁned counter-receptor on APCs
resulting in T-cell activation (17). In addition, the enzyme
activity of CD26 ⁄DPPIV is capable of cleaving dipeptides
at the N-terminus of polypeptides with proline, or alanine
in a lesser extent, at the penultimate position. Inﬂamma-
tory cyto- and chemokines can be processed by CD26, such
as CCL5(RANTES) and IL-2 (18). Interestingly, CD26 is
described to be expressed on keratinocytes as well (19). To
summarize, ensued from the above-mentioned all three
major participants in the psoriatic interplay (T cells, cyto-
kines, and keratinocytes) could be targeted performing an
expression-analysis of CD26.
The aim of the present study was to focus on the T-cell-
related expression of CD26 in peripheral blood of psoriatic
patients. In vitro studies have shown that CD26 is constitu-
tively expressed by 56% of CD4+ T cells and by 35% of
CD8+ T cells (20). In resting peripheral blood mononu-
clear cells a small subpopulation expresses CD26 at high
density, which subpopulation is designated as ‘CD26bright
T cells’. Several authors have claimed that the CD26bright
T cells belong to a CD45RO+ subpopulation (21,22).
Further studies are required to ﬁnd out whether this
co-expression is the reality of the in vivo situation. Remark-
ably, in vivo, peripheral blood CD26bright T cells have
been shown to be increased in patients during active phases
of other autoimmune diseases, such as rheumatoid arthri-
tis, Graves disease and multiple sclerosis and decreased in
immunocompromised patients (HIV) (23–28). In psoriasis,
this CD26bright population has not been studied yet. The
identiﬁcation of these T cells in normal and psoriatic con-
ditions may contribute to a better understanding of the
underlying pathogenesis of psoriasis. Therefore, we have
characterized peripheral blood lymphocytes of patients with
untreated severe widespread psoriasis and healthy volun-
teers by multiparameter ﬂow cytometric analysis.
Methods
Study population
Fifteen patients (six females, nine males between 31 and
59 years of age) with severe psoriasis, deﬁned as with a
Psoriasis and Severity Index (PASI) of 12 or greater, and
nine healthy subjects (three females and six males between
19 and 50 years of age) without any history or signs of skin
diseases participated in this study after giving informed
consent. All patients had a washout of systemic treatments
or phototherapy for at least 4 weeks and had not used top-
ical treatment for the last 2 weeks at time of venapuncture.
Furthermore, they did not have comorbidities and did not
use interfering medication.
Isolation of peripheral blood lymphocytes
Peripheral blood specimens were collected in 3 ml vacu-
tainer tubes (BD Vacutainer Systems, Plymouth, UK) con-
taining ethylenediaminetetraacetate (EDTA). Aliquots of
100 ll were placed directly into staining tubes containing
the appropiate volumes of ﬂuorochrome-conjugated mono-
clonal antibodies. The tubes were mixed by gentle vor-
texing and were incubated at room temperature (20�C) for
30 min. in the dark. Two millilitres of commercially avail-
able lysing solution (FACS Lysing Solution; BD Biosciences
Pharmingen, San Diego, CA, USA) diluted 1 in 10 into
water, was added to each tube. The tubes were vortexed
and incubated for exactly 10 min at room temperature in
the dark, after which they were centrifuged for 10 min at
200·g. Subsequently, the supernatant was discarded and
the pellet was washed and centrifuged in phosphate buffer
saline (Braun, Melsungen AG, Germany) for 10 min at
200·g. After the supernatant was discarded again, the
resulting cell pellets were resuspended and ﬁxed in 1%
paraformaldehyde (Cytoﬁx 1:4 diluted, BD Fixation Buffer,
BD Biosciences Pharmingen, San Diego, CA, USA).
Monoclonal antibodies
Fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-,
PE-Cy5 and PE-Cy7-conjugated monoclonal antibodies
were used in various designated combinations. The follow-
ing combinations of FITC-PE-Pc5 and Pc7-conjugated
reagents were arranged to assess the CD26 expression in
peripheral blood: anti-CD3+ (T cells) and anti-CD4+
(T-helper cells), CD8+ (cytotoxic T cells) and CD26
(quadruple staining). Anti-CD45RO+ (memory T cells),
anti-CD25+ (early-activated T cells), and anti-CD26+ were
coupled with either anti-CD4+ or anti-CD8+ (quadruple
staining). Table 1 lists the antibodies used.
Flow cytometry
All assays were run on a FC500 ﬂow cytometer (Beckman
Coulter, Cytomics FC500, Miami, FL, USA) equipped with
an argon ion laser emitting at 488 nm. The ﬂow cytometer
was calibrated routinely, as recommended by the manufac-
turer. List mode data were acquired (CXP Software Version
2.1, 2005, Miami, FL, USA). All samples were processed in
duplo within 24 h of venapuncture.
List mode data analysis
List mode ﬁles were analysed using WinList (Verity Soft-
ware House Inc, Winlist Version 5.0, Topsham, ME, USA)
software. A regional gate was set on CD3+ (FITC) versus
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forward scatter to gate for T lymphocytes in the sample
being studied. At least 20 000 gated events were acquired
for each antibody combination.
Statistical analysis
The statistical signiﬁcance between the two groups involved
the Student’s unpaired two-tailed t-test. P-values below
0.05 were considered statistically signiﬁcant. Data analysis
was performed using SPSS 12.0.1 software.
Results
Participating patients had longstanding psoriasis with a
mean PASI of 16.6 at time of venapuncture. Overall, there
was no signiﬁcant increase with respect to the extent of
lesions during the washout period (mean delta PASI
1.3 ± 1.1 (SEM)).
Distribution of CD26-subsets in T cells in healthy
controls and untreated psoriatic patients
Lymphocyte subsets were measured as a percentage of
total gated T cells (CD3+). The CD26 expression in the
CD3+population showed a negative-, a dim- and a
bright positive fraction. These three fractions were
quantitatively similar in psoriatic patients versus healthy
controls (Fig. 1a,b), without statistically signiﬁcant
differences.
The CD3+ population in the psoriatic patients consisted
of similar proportions of CD4+ and CD8+ T cells com-
pared to healthy controls (Fig. 2). With respect to the
CD4+ population, the intensity of the CD26 expression
(negative ⁄dim ⁄bright) showed no signiﬁcant differences
between psoriatic patients and the healthy controls. How-
ever, the CD26bright expression on CD8+ lymphocytes
revealed a marked and statistically signiﬁcant (P = 0.014)
decrease in psoriatic patients compared to the healthy
volunteers (Fig. 1c,d).
Association of CD45RO+ and CD26bright
expression on T cells in healthy controls
and untreated psoriatic patients
Table 2A summarizes quantitatively the co-expression of
CD45RO and CD26 on either the CD4+ or CD8+ subsets
in psoriatics and healthy controls. These data show that
CD26bright cells are not speciﬁcally restricted to the
CD45RO+ population. In the CD4+ T cells, 72.1% of the
CD26 bright subset are CD45RO+ in psoriatics, corre-
sponding to 67.6% in healthy volunteers.
Of the CD8+ cells, however, only 24.4% of the CD26po-
sitive subset is CD45RO+ in psoriatics, compared to 10.1%
in healthy subjects. Thus, whereas the majority of
Table 1. Monoclonal antibodies (MAb) used
CD MAb ⁄ clone Label Source
CD3 UCTH1 FITC Beckman Coulter
CD4 SFCI12T4D11(T4) PC7 Beckman Coulter
CD8 SFCI12Thy2D3(T8) PC7 Beckman Coulter
CD8 RPA-T8 PC5 Becton Dickinson
CD25 M-A251 FITC Becton Dickinson
CD26 L272 PE Becton Dickinson
CD45RO UCHL1 PC5 Becton Dickinson
FITC, ﬂuorescein isothiocyanate; PC7, phycoerythrin-Cy7; PC5,
phycoerythrin-Cy5; PE, phycoerythrin.
(a) (c)
(d)(b)
Healthy subject
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Figure 1. Expression of CD26 in peripheral
blood of psoriatic patients and healthy
subjects. (a): Lymphocytes were gated based
on morphology by side- and forward scatter
properties as discriminators. Example of
statistically equal CD26-, CD26dim and
CD26bright expression on T cells (CD3+) in
both groups. (b): Representation of
(statistically equal) mean percentages of CD26
fractions on T cells. (c): Representative
example of CD8+CD26 expression in
peripheral blood of psoriatic patients and
healthy subjects. (d) Dispersal of individual
CD8CD26bright expression in both groups.
The CD8+CD26bright population is markedly
reduced in the psoriatic patient group.
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CD4CD26bright cells are CD45RO+, the minority of
CD8CD26bright cells are CD45RO+ in both groups (Fig 3,
Table 2A).
CD26 expression on CD4+CD25+ T cells in
healthy controls and untreated psoriatic patients
In the patients with psoriasis the activation and Treg
marker CD25 was signiﬁcantly elevated (P = 0.006) on
CD4+ T cells compared to healthy subjects althought these
populations were small (6.3 ± 0.6 vs 4.1 ± 0.4). Remark-
ably, this CD4+CD25+ expression was not speciﬁcally
associated with CD26 dim ⁄bright expression (Table 2B).
Discussion
T cells are thought to play a crucial pathogenic role in the
development and maintenance of psoriasis. In this study,
we investigated the T-cell expression of CD26 in untreated
severe psoriatic patients in comparison with healthy sub-
jects, to strive to identify a character proﬁle of CD26
expression in relation to psoriasis-associated T-cell subsets.
The present study demonstrates a substantial decrease in
the CD8+CD26+ T-cell subset in psoriasis which is in
accordance with a previous study (29). Our results extend
this observation, however, by demonstrating that it con-
cerns the ‘CD8+CD26bright T-cell subset’ which is reduced
in psoriasis. Contradictory, the CD4+CD26bright popula-
tion in psoriasis showed no signiﬁcant difference to that of
the healthy subjects. Yet, in other auto-immune processes
increased levels of CD4+CD26bright T cells were actually
prominent ﬁndings. As CD26 is of relevance to transendo-
thelial migration in vitro (11,30), it is attractive to speculate
that such a decrease of CD8+CD26bright T cells is the
result of efﬁcient extravasation and migration into the skin
of this CD26bright subset in patients with widespread
psoriasis. Strikingly, CD8+ T cells are described to be
abundantly present in lesional psoriatic skin (31–36).
Hypothetically, the CX3CL1-CX3CR1 system is suggested
to play a role in the extravasation of leukocytes towards
the psoriatic skin (37) and could be a keyplayer in this
migratory movement of the CD26bright subset. On the
other hand, deﬁcient upregulation of CD26 expression in
CD8+ T cells can be causally related to the decrease as
well. Future investigations could give insight into such a
mechanism.
It is intriguing that psoriasis differs from those autoim-
mune diseases characterized by increased CD26+ T-cell
Table 2. (A): Distribution of CD45RO in the CD26 neg ⁄ dim ⁄ bright subpopulations of CD4+ and CD8+ T cells in psoriatic patients compared to
healthy controls (triple staining). Data reported as mean percentages (ranges). (B): Association of CD26 (negative vs dim ⁄ bright) expression with the
activation and Treg marker CD25 on CD4+ T cells. Overview of Mean percentages (ranges)
CD26 Expression
Psoriasis Healthy controls
Negative Dim Bright Negative Dim Bright
A
CD4+
% CD45RO+ 54.9 (10.4–78.7) 27.6 (8.2–55.3) 72.1 (39.2 –99.7) 33.8 (18–59.2) 19.5 (10.8–30.4) 67.6 (43.4–80.3)
% CD45RO) 45.1 (21.3–89.6) 72.4 (44.7–91.8) 27.9 (0.3–60.8) 66.2 (40.8–82) 80.5 (69.6–89.2) 32.4 (19.7–56.6)
CD8+
% CD45RO+ 16.5 (2.8–39.1) 15.6 (2.8–40.4) 24.4 (3.2–80.9) 9.1 (0.6–15.1) 4.2 (0.7–10) 10.1 (0.005–27.8)
% CD45RO) 83.5 (60.9–97.2) 84.4 (59.6–97.3) 75.6 (19.1–96.8) 90.9 (84.9–99.4) 95.8 (90–99.3) 89.9 (72.3–99.9)
B
Negative Dim ⁄ bright Negative Dim ⁄ bright
CD4+
% CD25+ 47 32.9–65.9) 56.1 (34.1–78.2) 46.2 (33–61) 53.8 (39–67)
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Figure 2. CD4 and CD8 fractions of the overall T-cell population
found in the peripheral blood of psoriatic patients and healthy subjects.
(a): Mean percentages (statistically equal) (b) and (c): Dispersal of
individual CD4 and CD8 expression in both groups. These data show
comparable expression.
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CD4CD26bright cells are CD45RO+, the minority of
CD8CD26bright cells are CD45RO+ in both groups (Fig 3,
Table 2A).
CD26 expression on CD4+CD25+ T cells in
healthy controls and untreated psoriatic patients
In the patients with psoriasis the activation and Treg
marker CD25 was signiﬁcantly elevated (P = 0.006) on
CD4+ T cells compared to healthy subjects althought these
populations were small (6.3 ± 0.6 vs 4.1 ± 0.4). Remark-
ably, this CD4+CD25+ expression was not speciﬁcally
associated with CD26 dim ⁄bright expression (Table 2B).
Discussion
T cells are thought to play a crucial pathogenic role in the
development and maintenance of psoriasis. In this study,
we investigated the T-cell expression of CD26 in untreated
severe psoriatic patients in comparison with healthy sub-
jects, to strive to identify a character proﬁle of CD26
expression in relation to psoriasis-associated T-cell subsets.
The present study demonstrates a substantial decrease in
the CD8+CD26+ T-cell subset in psoriasis which is in
accordance with a previous study (29). Our results extend
this observation, however, by demonstrating that it con-
cerns the ‘CD8+CD26bright T-cell subset’ which is reduced
in psoriasis. Contradictory, the CD4+CD26bright popula-
tion in psoriasis showed no signiﬁcant difference to that of
the healthy subjects. Yet, in other auto-immune processes
increased levels of CD4+CD26bright T cells were actually
prominent ﬁndings. As CD26 is of relevance to transendo-
thelial migration in vitro (11,30), it is attractive to speculate
that such a decrease of CD8+CD26bright T cells is the
result of efﬁcient extravasation and migration into the skin
of this CD26bright subset in patients with widespread
psoriasis. Strikingly, CD8+ T cells are described to be
abundantly present in lesional psoriatic skin (31–36).
Hypothetically, the CX3CL1-CX3CR1 system is suggested
to play a role in the extravasation of leukocytes towards
the psoriatic skin (37) and could be a keyplayer in this
migratory movement of the CD26bright subset. On the
other hand, deﬁcient upregulation of CD26 expression in
CD8+ T cells can be causally related to the decrease as
well. Future investigations could give insight into such a
mechanism.
It is intriguing that psoriasis differs from those autoim-
mune diseases characterized by increased CD26+ T-cell
Table 2. (A): Distribution of CD45RO in the CD26 neg ⁄ dim ⁄ bright subpopulations of CD4+ and CD8+ T cells in psoriatic patients compared to
healthy controls (triple staining). Data reported as mean percentages (ranges). (B): Association of CD26 (negative vs dim ⁄ bright) expression with the
activation and Treg marker CD25 on CD4+ T cells. Overview of Mean percentages (ranges)
CD26 Expression
Psoriasis Healthy controls
Negative Dim Bright Negative Dim Bright
A
CD4+
% CD45RO+ 54.9 (10.4–78.7) 27.6 (8.2–55.3) 72.1 (39.2 –99.7) 33.8 (18–59.2) 19.5 (10.8–30.4) 67.6 (43.4–80.3)
% CD45RO) 45.1 (21.3–89.6) 72.4 (44.7–91.8) 27.9 (0.3–60.8) 66.2 (40.8–82) 80.5 (69.6–89.2) 32.4 (19.7–56.6)
CD8+
% CD45RO+ 16.5 (2.8–39.1) 15.6 (2.8–40.4) 24.4 (3.2–80.9) 9.1 (0.6–15.1) 4.2 (0.7–10) 10.1 (0.005–27.8)
% CD45RO) 83.5 (60.9–97.2) 84.4 (59.6–97.3) 75.6 (19.1–96.8) 90.9 (84.9–99.4) 95.8 (90–99.3) 89.9 (72.3–99.9)
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Figure 2. CD4 and CD8 fractions of the overall T-cell population
found in the peripheral blood of psoriatic patients and healthy subjects.
(a): Mean percentages (statistically equal) (b) and (c): Dispersal of
individual CD4 and CD8 expression in both groups. These data show
comparable expression.
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numbers (25–27,38,39). Indeed, psoriasis may not be
regarded as a classical autoimmune disease. In fact, evi-
dence is accumulating that psoriasis is characterized by an
abnormality in innate immunity (40–42). In contrast to
previous observations in HIV-infected patients and
MS-patients (17,22,28), CD26bright expression was not
speciﬁcally restricted to CD45RO+ T cells. Our results
reveal that both in healthy subjects as psoriatic patients the
vast majority of CD8+CD26bright cells were CD45RO-
(89.9% and 75.6%). Contradictory, the majority of
CD4+CD26bright cells were CD45RO+ in healthy subjects
and psoriatic patients (67.6% and 72.1%). These ﬁndings
insinuate that such a distinct restriction of CD26bright T
cells to the CD45RO+subpopulation in psoriasis is not
requisite for the deﬁned co-stimulatory properties that
CD26bright expression is described to induce in concerted
action with CD45RO.
In conclusion, we demonstrated for the ﬁrst time that
the CD8+CD26bright T cells are reduced in psoriasis. It is
remotely possible that such a decrease in an individual
patient represents inﬂux of activated T cells into the
dermal compartment and that such may represent a posi-
tive sign that some T-cell targeted treatments are indicated
in such a patient. Introcaso et al. suggested, that as some
patients respond to therapy, their CD26cell populations go
through stages of change or alternatively that there is
something different about the pathophysiology of patients
who have CD26- versus CD26dim or CD26bright subpopu-
lations (51). At this point, it is unclear what distinguishes
the three subpopulations from a functional point of view
in psoriasis. The reduction in the CD8+CD26bright sub-
population, however, remains a challenging observation
because it differs from ﬁndings in other (classical) auto-
immune diseases. Further studies are indicated to ﬁnd
out whether patients with a profound reduction of
CD8+CD26bright cells in peripheral blood may be excellent
responders to some T-cell targeted treatments.
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4.1 Introduction
The centre of interest of the present thesis was to study the dynamics of 
on the one hand well-established psoriasis-associated markers of the T-cell 
and on the other hand of a potential novel marker (CD26 / DPPIV) relevant 
to the pathogenesis of psoriasis. In particular we studied these processes 
during treatment with established and innovative anti-psoriatic therapies. 
In order to expand knowledge on the complex puzzle of the pathogenesis 
of psoriasis, corresponding aims and questions were formulated in the gen-
eral introduction of this thesis (1.6). Here, we will discuss and position the 
current observations made in chapters 2 and 3 of this thesis in the light of 
relevant ﬁndings in literature. In the end we will propose some directions
for future investigations.
4.2 AIM I Assessing clinical observations and interference with 
T-cell subsets of pathogenesis-based therapeutic interventions
4.2.1 AIM IA
To deﬁne the eﬀect of immune-targeted therapies on well-established pso-
riasis relevant T-cell subsets in the cutaneous and peripheral blood com-
partment, and to address alleged compartmentalization between them in 
the context of clinical eﬃcacy.
An immune-mediated disease requires immune-targeted therapies. The 
T-cell as central keyplayer (amongst others) is not to be undervalued in the 
pathogenesis of psoriasis. Evaluating the eﬀect of immune-targeted thera-
pies on the T-cell is important in our search for prognostic markers and po-
tential markers to evaluate therapeutic responses. In line, numerous studies 
have addressed the eﬀect of such therapies in the cutaneous and peripheral 
blood compartment separately.1-4 Migration of T-lymphocytes from the cir-
culation to lesional skin and vice versa is a well-known phenomenon (see 
paragraph 1.3.2), even the migration of immune cells to the site of inﬂam-
mation in psoriasis is described to be enhanced.5
In chapter 2.1 & 2.2 we aimed to address shifting of T-cells between the le-
sional skin and circulation under inﬂuence of immune-targeted therapies.
In particular, several well-established subsets, as coworkers have studied 
these in speciﬁc and subsets were found to be of pathogenic relevance in
psoriasis e.g. CD3, CD4, CD8, CD45RO, NKT-cells. When performing observa-
tions and analyses concerning a single compartment and thus with a static
character, no conclusions can be drawn on the interaction between the 
compartments. Correlating disease activity or response to therapy with 
migration of T-cells between compartments is of interest in expanding
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knowledge on the dynamic role of the T-cell in psoriasis. We observed that 
after a 12-week period of treatment with etanercept, adalimumab and 
methotrexate some signiﬁcant reductions in lesional T-cell subsets were
found (see chapter 2.1 and 2.2) in contrast to no signiﬁcant changes in the
T-cell subsets in the peripheral blood. The clinical response to these treat-
ments, reﬂected in a 48-85% reduction of PASI score from baseline, can be
regarded as a good response. Changes in quantities of T-cell subsets in re-
sponse to therapy is hypothesized to cohere with an altered state of im-
mune system activity and in line with a certain extent of clinical eﬃcacy.
Given the low amount of signiﬁcant alterations in T-cell subsets in the cu-
taneous and peripheral blood compartment after these therapies, no cor-
responding T-cell subsets could be detected which in some degree would 
reﬂect a substantial rearrangement of these subsets between the two com-
partments. (Re)compartmentalization of T-cell subsets in response to clini-
cal eﬀective therapy could not be justiﬁed for the immune-targeted thera-
pies etanercept, adalimumab and methotrexate. These three treatments 
indirectly target the T-cell as they primarily target other key aspects of the 
psoriatic pathogenesis. 
Efalizumab, however, showed to act entirely diﬀerent compared to the
aforementioned therapies. Important to note herein is that efalizumab has 
a mode of action primarily targeting the T-cell as it inhibits T-lymphocyte 
activation and traﬃcking of T-cells. The observations in this thesis demon-
strated that a 12-week period treatment with efalizumab caused signiﬁcant
reductions in multiple lesional T-cell subsets in dermis and epidermis and 
partly corresponding shifts of these subsets in the peripheral blood. In par-
ticular a remarkable lymphocytosis was observed after therapy. This nota-
ble (re)compartmentalization of T-cells subsets in response to therapy was 
not reﬂected in an acceptable clinical eﬃcacy as the PASI was not signiﬁ-
cantly reduced in these patients. In addition, the (re)compartmentalization 
of T-cells could not be used as predictive marker for responsiveness to efali-
zumab therapy, as both clinical responders and non-responders had a com-
parable extent of shifting of T-cells.
Therefore, shifts in T-cell subsets in response to immune-targeted thera-
pies, in general, do not represent a prognostic marker for the degree of 
clinical eﬃcacy and consequently cannot be used as a predictive marker.
It is the mode of action of immune-targeted therapies, including biologi-
cals, which seems to play a prominent role in the actual shifting of T-cell 
subsets between the cutaneous and systemic compartment as a marked 
diﬀerence was detected between primarily and secondarily T-cell target-
ing treatments. The fact that one patient responds well to a certain therapy 
and the other does not, still puzzles the researchers in the ﬁeld of dermato-
logy. Consequently, the longing for predictive markers continues to exist 
to date. 
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Lymphocytes are known to acquire a certain predilection, based on the en-
vironment in which they ﬁrst encounter foreign antigen, to home or to re-
circulate through that same environment.6 In skin, cutaneous lymphocyte-
assocated antigen (CLA) is a homing receptor which determines the 
speciﬁc migration of T-cells to the site of (psoriatic) inﬂammation.7 When 
considering (re)compartmentalization of T-cell subsets, the assessment of 
the CLA-expression as a skin-homing marker could be of additional value in 
elucidating the migratory capacity of T-cells. However, literature comprises 
conﬂicting data on the exact amount of CLA+ T-cells that inﬁltrate the pso-
riatic skin varying between approximately 50 to 80 %.8-11 Moreover as in un-
involved skin, distant from the active plaque edge, a signiﬁcant inﬁltration
of CLA+ cells was reported before any signs of epidermal hyperprolifera-
tion were present8 and in an increased extent compared to lesional psori-
atic skin, in our opinion no reliable impression of the extent of homing of 
T-cells can be acquired in order to assess (re)compartmentalization of CLA+ 
T-cells . In peripheral blood, previous studies (also at our own department) 
showed that CLA+ T-cells were present only in relatively small amounts3;11-13 
diﬃcult to analyze in smaller sample sizes of patients. As a result, we rea-
soned to exclude the CLA-marker for evaluating shifting of T-cells between 
the compartments of the skin and peripheral blood in this thesis.
As mentioned, the immune system is organized into distinct functional 
compartments, allowing the extravasation and continuous recirculation 
of speciﬁc populations of lymphocytes into anatomically distinctive sites.
Lymphocytes continually patrol the body for foreign antigen by recircu-
lating from blood, through skin, into lymph and back to blood regulated 
through receptor/ligand pairs.6;14 Besides the peripheral blood and cutane-
ous compartment, a third compartment may comprise amounts of T-lym-
phocytes; the lymphatic system including aﬀerent and eﬀerent lymph.15 
Although it is more diﬃcult to gain access to a lymph node, since one has
to perform a more invasive procedure compared to venapunction or skin 
biopsy, it would be interesting to analyze and quantify the amount of T-cell 
subsets in psoriasis which reside in the lymphatic system in order to create 
a comprehensive view on the occurrence of (re)compartmentalization of 
T-cells in response to therapy. 
4.2.2 AIM IB
To position vascular laser treatment compared to several established treat-
ments in the therapeutic array for psoriasis.
The superﬁcial microvasculature as a key aspect of the psoriatic patho-
genesis represents an interesting underestimated/neglected target in the 
array of antipsoriatic therapies. The presence of dilated, elongated and 
164
increased prominent superﬁcial capillaries in the dermis can facilitate an
increased inﬂux of T-cells and other immune mediators into the skin main-
taining the chronic inﬂammatory reaction and consequently clinical lesions
in psoriasis.16 The exact mechanisms behind the maintenance of this reac-
tion are unclear however. Previous studies have indicated that intervention 
through vascular targeted treatments, such as with vascular lasers, induces 
moderate to good clinical eﬃcacy in chronic plaque type psoriasis with nor-
malization of the epidermal hyperproliferation and of the T-cell inﬂux.16-21 In 
addition, the remission time of the pulsed dye laser in psoriasis is reported 
to be long-lasting up to 6 months after cessation compared to treatment 
with topical therapies.17 Nevertheless, applying the PDL is a time-consum-
ing event and possible side-eﬀects include pain, formation of crusts and
transient hyperpigmentation. In order to underline or expand the clinical 
eﬀect of the PDL, direct comparisons with commonly used therapeutics
extends knowledge on the use and position of PDL in the array of treat-
ment modalities for psoriasis. Especially when two therapies are combined 
each with a diﬀerent mode of action targeting a diﬀerent key aspect in the
pathogenesis of psoriasis, a synergistic additional clinical eﬀect can poten-
tially be achieved.
Chapter 2.3 comprises a study combining PDL- and UVB-therapy thereby 
evaluating the potential synergistic clinical eﬀect in psoriasis as the ﬁrst af-
fects the dermal superﬁcial vessels and the latter aﬀects the keratinocyte
proliferation and induces immunosuppression.22-24 Through combination 
of these divergent modes of action of PDL and UVB, diﬀerent but crucial
pathways in the immunopathogenesis of psoriasis tend to be targeted. Al-
though a comprehensive immunohistochemical study is not available, it 
was found that all tested treatment modalities appeared to be eﬃcacious in
the treatment of localized plaque type psoriasis as no statistically signiﬁcant
diﬀerences were found between the clinical eﬃcacy of PDL treatment and
UVB treatment. A combination of both treatments did not result in syner-
gism with respect to clinical eﬀect. No major insuperable side eﬀects were
detected during or after PDL treatment which makes it a safe therapeutic 
option. Therefore, suitable psoriatic candidates proposed for vascular laser 
therapy include patients with a limited amount of persistent plaques not 
responding to the available medications, who are unﬁt for several therapies
due to side-eﬀects or comorbidity, who are at risk for skin cancer caused
by actinic damage or immunosuppression and patients having plaques on 
non-covered body-sites. 
Chapter 2.4 on the other hand evaluates the position of the Nd:YAG laser 
in the therapeutic array for psoriasis, incorporating immunohistochemical 
studies to shed light on the mode of action of this laser. Although the study 
design had a pilot character, targeting the deeper abnormal vasculature 
in the psoriatic dermis seems justiﬁed in order to achieve a longer lasting
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eﬀect of clearance of psoriatic plaques compared to the more superﬁcial-
ly targeted PDL. Yet, the clinical and immunohistochemical results of this
Nd:YAG study did not lend support for this hypothesis. However, consist-
ent with earlier ﬁndings17;25-27,  the active comparator (CBD ointment) used 
in this study, proved to reduce the clinical severity of the treated plaques 
signiﬁcantly, together with the epidermal thickness.
Taken together, as a result, targeting more superﬁcial located vasculature
in psoriasis (PDL) is likely to be of stronger importance in achieving clinical 
eﬀect than the deeper abnormal vasculature (Nd:YAG).
The need for safe and cost-eﬀective treatments continues to exists as each
patient deserves tailored psoriasis management. Psoriasis is not a single 
disease entity and multiple patterns of expression are observed ranging in 
severity, extent and aspect of the lesions. The option for a speciﬁc treat-
ment is dependent on psoriasis-related factors (type of psoriasis, severity, 
extent, disease duration and localization), but also on treatment-associated 
factors (eﬃcacy, side-eﬀects, contra-indications, availability, duration of 
remission, preceding treatments) and patient-associated factors (age, sex, 
physical and mental health, patients preference) in order to reach induction 
of remission. 
Mostly, at our department, a ‘stepwise approach’ or therapeutic ladder is 
adopted starting with the medications with the least potential toxicity, to 
Figure 13 Proposed positioning of the Pulsed Dye Laser (PDL) on the anti-psoriatic 
treatment ladder.
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deﬁne optimal treatment for the individual psoriatic patient. With respect
to the vascular laser in the treatment of psoriasis, a position in this approach 
or on this ladder has not yet been deﬁned. Based on our own data in this
thesis and the eﬃcacy and safety data in literature on the PDL17;19;21;28, we 
propose PDL next to phototherapy in the treatment ladder after the topical 
therapies and before the systemic and biological treatments (ﬁgure 13). 
However, one should keep in mind the characteristics (for treatment with 
the PDL) of the proposed suitable patient population for this treatment. 
Whereas widespread psoriasis is a proper indication for UVB phototherapy, 
localized (recalcitrant) plaque psoriasis is a proper one for PDL laser treat-
ment.
With regard to the Nd:YAG laser well-designed (comparative) studies are 
required to further delineate the positioning of this laser in the treatment 
array of psoriasis.
4.3  AIM II  Deﬁning the expression of CD26 / DPPIV and char-
acterizing it as a potential novel marker in the immunopatho-
genesis of psoriasis
Studies on the pathogenesis, cause and treatment of psoriasis are continu-
ally arising and considerable progress has been made the last ten years with 
respect to the immunopathogenesis of psoriasis. Whereas the antigen re-
mains undeﬁned, the underlying immunopathogenesis incorporating the
role and function of certain cells equally challenges and puzzles research-
ers to date.
Psoriasis shares many features with other inﬂammatory autoimmune diseas-
es such as multiple sclerosis, rheumatoid arthritis, autoimmune diabetes and 
inﬂammatory bowel disease. Several break-throughs concerning discovery 
of markers or new treatment options in the latter, sooner or later appeared 
to be also of importance in psoriasis. The last two decades, an increasing 
number of articles have focused on the expression of CD26 / DPPIV sharing 
common grounds with or directly focusing on the immunopathogenesis of 
above-mentioned autoimmune diseases and even CD26 / DPPIV inhibitors 
have been developed.29-37 A number of important functions, including the 
regulation of immune reactions, have been attributed to the multifunction-
al CD26 / DPPIV. Altered levels of expression have been found in several au-
toimmune diseases (see table 3, paragraph 1.4.5). In psoriasis, however, less 
is known about the level of expression of CD26 / DPPIV. Given that, on the 
one hand, the regulation of inﬂammatory processes in psoriasis have not
been completely unraveled and, on the other hand, CD26 / DPPIV inhibitors 
are currently being explored as immune modulators in chronic inﬂamma-
tion, mapping the CD26 / DPPIV enzyme in psoriasis was our deﬁned aim.
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In chapter 3, we characterized the pattern of expression of CD26 / DPPIV in 
psoriasis in four divergent studies. In general, the point of focus consisted 
of the psoriatic interplay between cytokines, T-cells and keratinocytes with-
in the ﬁeld of adaptive immunity. Considering the attributed moonlighting
properties of CD26 / DPPIV, two mainstays can be described herein: (1) its
ability to regulate the eﬀect of biological factors through its enzymatic
activity (see paragraph 1.4.4) and (2) its essential role in human T-cell
physiology (see paragraph 1.4.2 & 1.4.3). 
In the ﬁrst paragraph of the third chapter (3.1), we observed a versatile up-
regulation in psoriatic (epi)dermis providing evidence that CD26 / DPPIV is 
expressed on keratinocytes cohering with corresponding enzymatic activ-
ity, and that T-cells express CD26 to an increased extent on their surface 
compared to healthy volunteers. On the whole, considering the common 
grounds of the pattern of expression of CD26 / DPPIV with main pathologi-
cal components of the psoriatic pathogenesis (T-cells, keratinocytes and 
cytokines) and the consequent topographical distribution of CD26 / DPPIV, 
further deﬁning the role and function of CD26 / DPPIV seems valuable in
the attempt to shed light on the psoriatic puzzle. 
 As we found this distinct upregulation and as CD26 / DPPIV is able to trun-
cate several chemokines and can inﬂuence immune responses via modula-
tion of cell adhesion and T-cell activation, inhibition of CD26 / DPPIV could 
possibly represent a promising therapeutic approach. Although one should 
consider whether simultaneous inhibition of both above-deﬁned main-
stays is desirable, as on the one hand the enzyme activity of  CD26 / DPPIV 
can induce the processing of chemokines whereby reducing chemotaxis38 
which is favourable and thus not to be inhibited in the psoriatic inﬂam-
mation process. On the other hand, inhibiting the supposedly regulatory 
role of CD26 / DPPIV in T-cell activation39 brings about a suppressive eﬀect
on T-cell functions in the psoriatic inﬂammation process which may have a
therapeutic potential. Thus, a diﬀerential inhibition of these two main prop-
erties of CD26 / DPPIV should be considered when investigating the thera-
peutic potential of CD26 / DPPIV inhibitors in psoriasis. 
In order to serve as a diagnostic marker, however, CD26 / DPPIV has to show 
an expression which is distinct from other inﬂammatory skin disorders e.g.
lichen planus, atopic dermatitis. Actually, an increased expression of CD26 
/ DPPIV in the skin of these diseases has been reported40, but only small 
patient groups were incorporated not further deﬁned by the extent or type
of disease and thus not comparable with the homogeneous patient group 
in this thesis (chronic plaque type psoriasis). Furthermore, as the enzyme 
activity of CD26 / DPPIV in the skin of healthy volunteers was found to be 
absent, one could hypothesize that the actual activity might be inﬂamma-
tion-related and not speciﬁcally psoriasis-related. Although reports have in-
dicated a relation to hyperproliferative and inﬂammatory skin diseases40;41, 
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no comprehensive data are available concerning the actual disease-speciﬁ-
city of the upregulation of CD26 / DPPIV in psoriasis.
In addition, in order to serve as a prognostic marker, the dynamics of CD26 
/ DPPIV during the disease process in psoriasis has to be investigated. 
Such dynamic studies were integrated in the second paragraph (3.2). We 
observed that upregulation of DPPIV expression and enzyme activity in 
uninvolved skin of psoriatic patients preceded epidermal hyperprolifera-
tion and the presence of an overt psoriatic lesion. Therefore, the increased
DPPIV enzyme activity is involved in an early phase of the lesional psoriatic 
process, possibly inﬂicting a role in the immunological cascade during trig-
gering or initiation of new lesions. Analogue expression with markers for 
aberrant growth and diﬀerentiation of keratinocytes during the develop-
ment of a psoriatic lesion was not observed, as a result of which coherence 
in mechanisms behind the upregulation of CD26 / DPPIV in psoriatic skin 
were improbable taking into account the small sample size in this study 
and the semi-quantitative scoring method for CD26 / DPPIV. 
The third study investigated the (dynamics in) expression of CD26 on pe-
ripheral blood T-cells of psoriatic patients (paragraph 3.3). The CD26 expres-
sion in the T-cell population showed an negative-, a dim- and a bright posi-
tive fraction. Whether the intensity of expression is relevant functionally, 
remains unclear. However, the CD8CD26bright T-cell population showed to 
be markedly decreased compared to healthy volunteers. This reduced pop-
ulation of T-cells in peripheral blood could be speculated to correlate with 
an increased population in the cutaneous compartment, as CD26bright 
expression has been reported to be of relevance to transendothelial migra-
tion in vitro.42;43 Moreover, as CD8+ T-cells are described to be abundantly 
present in lesional psoriatic skin44-47, characterizing and specifying this epi-
dermal CD8+ population with respect to expression of CD26bright would 
further elucidate such a compartmentalization mechanism. Furthermore, 
the speciﬁc migratory capacity of CD26bright T-cells is reported to be pri-
marily exhibited by the CD26bright CD4+CD45RO+ T-cells.48 Interestingly, 
the rather small CD26bright population has been shown to belong to the 
CD45RO+ (memory) T-cell population and CD26 in general showed to be a 
costimulatory protein for CD45RO in vitro and in vivo.48-51 Our results did not 
show such a distinct restriction of CD26 to the CD45RO+ T-cell population 
in peripheral blood, contrasting previous observations in HIV-infected and 
MS-patients33;48;51 and emphasizing the need for additional investigations 
on this issue. 
The dynamics in regulation of CD26 / DPPIV under treatment, was investi-
gated in paragraph 3.4 as inﬂiximab was introduced to further assess the
potential of CD26 / DPPIV to correlate with disease activity. The expression 
of CD26 / DPPIV on keratinocytes on the one hand, and T-cells in the pe-
ripheral blood of psoriatic patients on the other hand, showed to be inde-
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pendent of the major (and rapid) clinical eﬀect of treatment with inﬂixi-
mab. Herewith, the expression of CD26 / DPPIV, though sharing common 
grounds with key players of the psoriatic pathogenesis, showed to be a 
persistent feature of ‘post-treatment’ skin after anti-TNFα therapy, possibly 
encompassing a triggering role in the initiation or maintenance of the lo-
cal immune system in psoriasis. Moreover, because we previously reported 
that in uninvolved skin an upregulation of CD26 / DPPIV enzyme activity 
is present (paragraph 3.2). The previously observed decreased CD26bright 
subpopulation of CD8+T-cells in peripheral blood (paragraph 3.3) showed 
to remain consistently reduced after treatment with inﬂiximab. However,
one should bear in mind that this study only reﬂects data on the expression
of CD26 / DPPIV in response to anti-TNFα therapy. Consequently, the ques-
tion whether CD26 / DPPIV could possibly function as a marker correlating 
with disease activity with respect to anti-psoriatic treatment, needs further 
assessment as the array of available treatment modalities for psoriasis com-
prises several other eﬀective modes of action.
4.4 Concluding comments
Cytokines and chemokines involved in (psoriatic) inﬂammation form a
complex web between cells and support the initiation and perpetuation of 
psoriasis. The chemical modiﬁcation of cytokines and hence the modiﬁca-
tion of their physiological function (as CD26 / DPPIV can exert) is of major 
importance to understand their actual role in the pathophysiology of the 
psoriatic process. In addition, T-cells are considered to be of fundamental 
importance for the initiation and maintenance of a variety of immune dis-
orders, including psoriasis. Moreover, as the robuste keratinocyte changes 
in the epidermis are elemental in the psoriatic pathogenesis, a set of three 
principal keyplayers is appointed within the context of innate and adaptive 
immunity. 
In this thesis, evidence has been provided that (re)compartmentalization 
of T-cell subsets in response to immune targeted anti-psoriatic therapy 
tends to depend on the primary mode of action of the treatment in ques-
tion. (Re)Compartmentalization of T-cell subsets in response to immune-
targeted therapies did not prove to be a valuable marker for the degree 
of clinical eﬃcacy. In order to assess the circulating T-cell subsets between
skin and peripheral blood comprehensively in response to therapy, ideally 
T-cell counts in the lymphatic compartment should be included in future 
studies.
In this thesis, on the one hand pulsed dye laser treatment for psoriasis was 
put forward as a safe and eﬀective treatment option for a selective group
of psoriatic patients primarily characterized by having a limited amount of 
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persistent plaques. Combination with UVB TL-01 therapy did not result in a 
clinical synergistic eﬀect as would the divergent mode of actions suggest.
On the other hand, the Nd:YAG vascular laser did not prove eﬀective in the
treatment for psoriasis. Targeting the more superﬁcial located vasculature
in psoriasis is likely to be of stronger importance in achieving clinical eﬀect
than the deeper abnormal vasculature. With respect to its positioning on 
the anti-psoriatic treatment ladder, we proposed the PDL on the level of 
phototherapy in between the topical and systemic therapies of psoriasis.
In this thesis, CD26 / DPPIV was found to be upregulated on keratinocytes 
and T-cells in lesional psoriatic skin. This upregulated protein expression on 
keratinocytes proved to be enzymatically active and similarly topographi-
cally distributed, present in uninvolved skin well before an overt lesion de-
veloped and independent of the expression of hyperproliferation and dif-
ferentiation markers of keratinocytes. In peripheral blood, in particular the 
CD8CD26bright population was found to decreased as opposed to healthy 
volunteers. In general, CD26 / DPPIV seems to represent a potential novel 
marker with respect to psoriatic key players but it remains to be determined 
whether or not its properties are directly involved in the immunologic pso-
riatic context and in line its speciﬁcity needs further elucidation.
All of these issues are complex and multifactorial in nature. As theories re-
garding the pathogenesis of psoriasis have changed over decades, the fu-
ture tells us to be open to new hypotheses as researchers are continuously 
investigating psoriatic aspects in order to contribute to the ongoing discus-
sion and understanding of this complex disease. 
4.5 Future outlooks
Research generates additional research. It is an intriguing question whether 
diﬀerent patterns of skin involvement in psoriasis imply distinct pathogenic
mechanisms and consequently whether the expression of distinct patho-
genic principles may explain the interindividual diﬀerences between the
responses to treatment. In order to further evaluate and deﬁne the posi-
tion of the vascular laser and the expression of CD26 / DPPIV in psoriasis, 
well-designed larger studies assessing patterns of skin involvement and 
functional properties respectively are required to further expand on the 
ﬁndings of this thesis.
As the PDL has proven to generate a good clinical eﬀect for a selected
group of patients, immunohistochemical assessments after PDL-therapy 
evaluating the response in terms of pathogenic aspects could further in-
spire the search for optimal time-intervals between successive treatments 
as no data exist on ideal time-intervals,  or substantiate and expand insights 
into the mode of action. Regarding the Nd:YAG laser, the study in this thesis 
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presents preliminary ﬁndings which promotes further research elucidating
the possible position of the Nd:YAG in the array of treatment modalities 
for psoriasis. In particular, the settings should be optimized and validated 
in a larger population in order to judge on the anti-psoriatic therapeutic 
potential.
In studies on the pathogenesis of psoriasis, the search for diagnostic and 
prognostic markers represents an important approach as the responsible 
antigen still has to be identiﬁed. In this thesis, mapping the expression of
CD26 / DPPIV and deﬁning its position in the pathogenesis of psoriasis is an
attempt to contribute to this search. The initial trigger for the investigations 
done, was the pattern of expression of CD26 / DPPPIV observed in several 
autoimmune diseases. As our ﬁndings were not always compatible and
comparable to those in other autoimmune diseases, further research could 
incorporate analyses on peripheral blood of patients with RA, MS, psoriasis 
and IBD to make a direct comparison and judge on whether the expression 
of CD26 / DPPIV in these autoimmune diseases is of similar nature.
The results of this thesis give emphasis to the observed upregulation of CD26 
/ DPPIV in psoriasis. Due to its moonlighting properties, we feel we have only 
touched upon the tip of the iceberg considering the complex nature, proper-
ties, functions and relevance of the expression of CD26 / DPPIV in psoriasis. In 
line, the exact picture of all biological functions of CD26 / DPPIV is diﬃcult to
compose as CD26 / DPPIV exerts its diﬀerent functions in diﬀerent cell types
and thus in diﬀerent cellular contexts. Further research should involve other 
inﬂammatory dermatoses in order to shed light on the speciﬁcity of the up-
regulation of CD26 / DPPIV in psoriasis. In addition, it would be fascinating 
to work out a method to typify CD26dim or CD26bright T-cells in psoriatic 
skin to investigate whether the reduced amount of CD8CD26bright T-cells 
in peripheral blood is caused by an increased expression of CD8CD26bright 
T-cells in lesional skin. Besides, performing experiments addressing the role 
of CD26 / DPPIV for cellular functions, e. g. T cell activation, proliferation and 
cytokine production in vitro would add functional information to our ob-
servations. In the end, CD26 / DPPIV expression and -activity measurement 
may be useful for the assessment of the severity of various inﬂammatory
diseases, the response to therapy or the prognosis.
In this thesis, we have studied the eﬀect of the anti-TNF treatment inﬂiximab
on the expression of CD26 / DPPIV in lesional skin and peripheral blood. 
The eﬀect of other anti-psoriatic therapies such as topical therapies or UVB-
treatment, is still to be investigated to create a comprehensive view on dy-
namics in CD26 / DPPIV expression and to further investigate its potential 
to function as a diagnostic and prognostic marker in response to therapy.
As DASH-proteins, exhibiting DPPIV-like enzyme activity, have been intro-
duced in inﬂammatory conditions with potential abilities to complement
and/or associate to DPPIV on the level of its enzymatic activity, future studies 
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should assess the DASH-proteins in psoriasis in order to deﬁne the exact
place of CD26 / DPPIV within the array of DASH-proteins.
 To conclude, the everlasting question in psoriasis remains as 
(immuno)dermatologists and researchers in the ﬁeld still wonder whether
the aberrant keratinocyte diﬀerentiation is a primary defect or that it is the
consequence of an inﬂux of pathogenic immunocytes, or maybe both. Per-
haps an even more intriguing question is the nature of the factor(s) that 
trigger psoriasis because that answer is still wide open. A better apprecia-
tion and approach is needed to understand not only the pathogenesis but 
also the role of CD26 / DPPIV in psoriasis. Although a new Th17 T-cell para-
digm with potential relevance is precautiously gaining ground in psoriasis, 
it will probably still take years and certainly further research eﬀorts until all
the pieces of the psoriatic puzzle fall into their places and reveal a compre-
hensive view on this disease.
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5.1 Summary and conclusions
Chapter 1, the general introduction, gives an overview of subjects relevant 
to creating an all-embracing / comprehensive background to consider the 
observations made in chapters 2 and 3. First, the epidemiology, clinical 
presentation and course, histopathological features and aspects of the im-
munopathogenesis of psoriasis are set out in detail. Subsequently, special 
reference is made to the expression of CD26 / DPPIV as its structural proper-
ties, distribution of expression, multifunctional character and role in auto-
immune diseases and inﬂammation are being addressed. Consequently,
the array of available anti-psoriatic treatment modalities are reviewed. In 
particular, the use of vascular lasers and their application in psoriasis is ad-
dressed.
Before the investigational approach is reﬂected, the aims of the present
thesis are presented (as below): 
AIM I Assessing clinical observations and interference with T-cell 
subsets of pathogenesis-based therapeutic interventions
AIM II Deﬁning the expression of CD26 / DPPIV and characterizing it
as a potential novel marker in the immunopathogenesis of psoriasis
  
In chapter 2, in four studies several clinical observations are made in co-
herence with pathogenic aspects of psoriasis in reference to innovative 
anti-psoriatic treatments. In the ﬁrst two studies, two major compartments
in which T-cells can reside e.g. the cutaneous and peripheral blood com-
partment, were evaluated on shifting of T-cells (compartmentalization) in 
response to immune-targeted therapies. It was concluded that shifts in T-cell 
subsets between the skin and peripheral blood under inﬂuence of immune-
targeted therapies, in general, do not represent a prognostic marker for the 
degree of clinical eﬃcacy. More likely, it is the mode of action which seems
to play a prominent role in the actual compartmentalization of T-cells as 
a marked diﬀerence was detected between primary and secondary T-cell
targeting treatments.
Secondly, we sought to position vascular lasers in general, and the PDL and 
Nd:YAG laser in particular, in the array of available anti-psoriatic treatments 
as the expansion of the superﬁcial psoriatic microvasculature forms an op-
To deﬁne the eﬀect of immune-targeted therapies on well-established
psoriasis relevant T-cell subsets in the cutaneous and peripheral blood 
compartment, and to address alleged compartmentalization between 
them in the context of clinical eﬃcacy
To position vascular laser treatment compared to several established treat-
ments in the therapeutic array for psoriasis
A 
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timal target for therapy. Although the PDL proved to be a an eﬀective treat-
ment for psoriatic patients with a limited amount of persistent plaques, we 
also concluded that the combination of PDL and UVB-TL01 therapy, both 
having divergent modes of action, did not result in synergism with respect 
to clinical eﬀect as compared to the monotherapy with either one of the
treatments. PDL therapy was positioned next to phototherapy but after the 
topical therapies and before the systemic therapies on the treatment lad-
der for psoriasis. Conversely, the Nd:YAG laser targets the deeper dermal 
vasculature in psoriasis but in our study did not prove to reduce the clini-
cal severity of the treated plaques. Therefore, from these results it could be 
concluded that targeting more superﬁcial located vasculature in psoriasis
with the PDL is likely to be of stronger importance in achieving remarkable 
clinical eﬀect than the deeper abnormal vasculature with the Nd:YAG.
In chapter 3, the expression of CD26 / DPPIV in psoriasis was investigated, 
especially in relation to two main key players in the pathogenesis of pso-
riasis: keratinocytes and T-cells. CD26 / DPPIV proved to be upregulated on 
keratinocytes and T-cells in the psoriatic (epi)dermis compared to skin of 
healthy volunteers. The observed pattern of expression on keratinocytes 
topographically cohered with the enzymatic activity of  CD26 / DPPIV. The 
expression and enzyme activity of CD26 / DPPIV in uninvolved skin of pso-
riatic patients showed to precede epidermal hyperproliferation and the ac-
tual presence of an overt psoriatic lesion. Furthermore, the expression of 
CD26 / DPPIV on peripheral blood T-cells was analyzed in psoriatic patients 
and healthy volunteers. We concluded that the CD8CD26bright T-cell pop-
ulation was markedly decreased compared to healthy volunteers. Finally, 
the dynamics in regulation of CD26 / DPPIV under inﬂuence of treatment
with an anti-TNFα agent (inﬂiximab) and thus its potential as a marker cor-
relating with disease activity, was further investigated. It was demonstrated 
that the expression of CD26 / DPPIV on keratinocytes on the one hand, and 
on T-cell subsets in the peripheral blood of psoriatic patients on the other, 
showed to be independent of the major (and rapid) clinical eﬀect of treat-
ment with inﬂiximab. The potential of the expression of CD26 / DPPIV as
a marker for clinical eﬃcacy could not convincingly be substantiated nor
refuted. Future research could lead to clariﬁcation on this.
In chapter 4, the general discussion portrays the results of the various in-
vestigations of the present thesis in light of relevant literature. The aims for-
mulated in chapter 1 are being addressed. Subsequently, concluding com-
ments and future outlooks for further research are outlined which bring the 
current thesis to an end.
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5.2 Samenvatting en conclusies
Allereerst wordt in hoofdstuk 1, de algemene introductie, een overzicht 
gegeven van onderwerpen die relevant zijn als allesomvattende achter-
grondinformatie om vervolgens de bevindingen in de hoofdstukken 2 en 
3 te kunnen interpreteren en plaatsen. Hiertoe worden de epidemiologie, 
klinische presentatie en beloop, histopathologische kenmerken en di-
verse aspecten (van de immunopathogenese) van psoriasis nauwkeurig 
uiteengezet. Vervolgens wordt de expressie van CD26 / DPPIV speciﬁek be-
licht te weten de structurele eigenschappen, de distributie van de expres-
sie, het multifunctionele karakter en de rol ervan in de context van auto-im-
muun aandoeningen en inﬂammatie. Aansluitend volgt een overzicht van
de beschikbare behandelingsmogelijkheden voor psoriasis.
Alvorens de toegepaste onderzoeksmethoden in dit eerste hoofdstuk 
worden toegelicht, zijn de doelstellingen van het proefschrift uiteengezet 
zoals hierna nog eens kort weergegeven:
Doel I Inzicht krijgen in het klinisch eﬀect en de beïnvloeding van T-cel
subsets in respons op therapeutische interventies welke speciﬁek ge-
baseerd zijn op de pathogenese van psoriasis
 
Doel II De expressie van CD26 / DPPIV te deﬁniëren en te karakteri-
seren als een nieuwe potentiële marker in de immunopathogenese 
van psoriasis
In hoofdstuk 2 worden, in vier uiteenlopende studies, klinische 
waarnemingen gedaan betreﬀende pathogenetische aspecten van pso-
riasis in relatie tot innovatieve behandelingen voor psoriasis. In de eerste 
twee studies worden de twee belangrijkste compartimenten waar T-cellen 
zich kunnen bevinden, te weten het cutane en het perifere bloed comparti-
ment, nader bekeken op het shiften van die T-cellen (zgn. compartimen-
talisatie) in respons op therapieën die aangrijpen op het immuunsysteem. 
Deze studies lieten zien dat het shiften van T-cel subsets tussen de huid 
en het perifere bloed onder invloed van immuun-gemedieerde thera-
Het eﬀect van immuun-gemedieerde therapieën te bepalen op speci-
ﬁeke T-cel subsets (welke geassocieerd worden met psoriasis) in ener-
zijds de huid en anderzijds het perifere bloed van psoriasis patiënten, 
om zodoende de veronderstelde compartimentalisatie van deze T-cel 
subsets tussen de huid en het perifere bloed in de context van klinische 
eﬀectiviteit van deze therapieën te analyseren
Het positioneren van vasculaire laserbehandeling ten opzichte van 
enkele gevestigde behandelingen in het therapeutisch arsenaal voor 
psoriasis
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pieën over het algemeen niet van prognostische waarde is voor de mate 
van klinische eﬀectiviteit van de desbetreﬀende therapie. Het is eerder het
werkingsmechanisme van de therapieën welke een prominente rol lijkt te 
spelen in het feitelijke compartimentaliseren van T-cel subsets, aangezien 
een duidelijk verschil werd gevonden tussen therapieën die primair ofwel 
secundair op de T-cel aangrijpen.
Daarnaast is gepoogd vasculaire lasers in het algemeen en de Pulsed Dye 
Laser (PDL) en Nd:YAG laser speciﬁek, een plek te geven in de reeks van
beschikbare behandelingen voor psoriasis aangezien de uitbreiding van de 
oppervlakkig gelegen microvasculatuur in psoriasis een optimaal doelwit 
vormt als aangrijpingspunt. Alhoewel werd gevonden dat de PDL een eﬀec-
tieve behandeling is voor juist die patiënten die maar een beperkt aantal 
hardnekkige psoriasis plekken hebben, konden we ook concluderen dat de 
combinatie van PDL met UVB-TL01 lichttherapie, allebei met uiteenlopende 
aangrijpingspunten in de pathogenese, niet uitmondde in synergisme met 
betrekking tot klinisch eﬀect of in vergelijking tot het afzonderlijk geven
van deze twee therapieën. In de stapsgewijze benadering van de behande-
ling van psoriasis werd behandeling middels de PDL naast lichttherapie ge-
plaatst, dus nà de topicale behandelingen en vóór de systemische behan-
delingen. De Nd:YAG laser grijpt daartegenover juist aan op de meer dieper 
gelegen dermale vasculatuur in psoriasis. Echter, de resultaten van onze 
studie lieten niet zien dat de klinische ernst van de behandelde plaques 
afnam na behandeling met de Nd:YAG laser. Zodoende werd uit deze twee 
laserstudies afgeleid dat het richten op de meer oppervlakkig gelegen vas-
culatuur in psoriasis door middel van de PDL waarschijnlijk belangrijker is 
in het bereiken van een goed klinisch eﬀect dan het richten op de dieper
gelegen abnormale vasculatuur door middel van de Nd:YAG laser.
In hoofdstuk 3 werd de expressie van CD26 / DPPIV in psoriasis bestudeerd, 
met name in relatie tot de twee voornaamste participanten in de patho-
genese van psoriasis: de keratinocyten en T-cellen. CD26 / DPPIV bleek 
toegenomen tot expressie te komen op keratinocyten en T-cellen in de 
psoriatisch aangedane (epi)dermis in vergelijking tot de huid van gezonde 
vrijwilligers. Het waargenomen patroon van expressie op keratinocyten cor-
releerde topograﬁsch met de enzymactiviteit van CD26 / DPPIV. Daarnaast 
bleek de expressie en enzymactiviteit van CD26 / DPPIV in niet-aangedane 
huid van psoriasispatiënten aanwezig en tevens vooraf te gaan aan enige 
mate van epidermale hyperproliferatie en het ontwikkelen van een feitelijke 
psoriasis plaque. Ook werd de expressie van CD26 / DPPIV geanalyseerd op
T-cellen in het perifere bloed van psoriasis patiënten en gezonde vrijwilligers. 
Uit deze analyse konden we concluderen dat de CD8CD26bright T-cel po-
pulatie aanzienlijk verlaagd was ten opzichte van gezonde vrijwilligers. Als 
laatste, werd de dynamiek in de regulatie van de expressie van CD26 / DPPIV 
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onder invloed van een anti-TNFα behandeling (inﬂiximab) en de potentie
ervan als marker voor ziekte-activiteit nader onderzocht. Aangetoond werd 
dat enerzijds de expressie van CD26 / DPPIV op keratinocyten en anderzijds 
op T-cel subsets in het perifere bloed van psoriasis patiënten, onafhankelijk 
was in relatie tot het snelle en aanzienlijke klinische eﬀect van behandeling
met inﬂiximab. De mogelijke potentie van de expressie van CD26 / DPPIV
als een marker voor klinische eﬀectiviteit kon niet afdoende worden aange-
toond danwel ontkracht. Verder onderzoek in de toekomst zou uitsluitsel 
kunnen geven hierover.
In hoofdstuk 4, de algemene discussie, worden de resultaten van de di-
verse onderzoeken weergegeven en gebundeld in het licht van relevante 
literatuur. De doelstellingen zoals geformuleerd in hoofdstuk 1 worden 
nader toegelicht. Tot besluit worden enkele slotopmerkingen en sugges-
ties gedaan voor verder onderzoek.
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CURRICULUM VITAE
Op 26 juli 1979 werd Rosanne Gwendolyn van Lingen geboren in ’s-Graven-
hage. Al snel verhuisde de familie van Lingen naar Halsteren te Noord-Bra-
bant. Tussen 1983 en 1987 bezocht ze daar de katholieke basisschool ‘De 
Biezenhof’. Een volgende verhuizing bracht haar naar Bergen te Noord-Hol-
land alwaar zij haar tienerjaren aan de Europese School doorbracht.
Na het Europees Baccalaureaatsexamen in 1997 meldde zij zich tot tweemaal 
toe aan voor de studie Geneeskunde en werd even zo veel keer uitgeloot. 
Als “tweede keus” werd met de studie Psychologie aan de Rijksuniversiteit 
Groningen aangevangen en het jaar daarop in 1998 met de studie Bedrijfs-
kunde eveneens in Groningen. Gelukkig was het in 1999 raak, werd drie-
maal scheepsrecht beloond, en begon zij aan de studie Geneeskunde ook 
in Groningen. Tijdens de coschappen in het Medisch Spectrum Twente te 
Enschede, werd haar interesse voor het vakgebied van de dermatologie ge-
prikkeld, waarna zij gedurende een half jaar een wetenschappelijke stage 
vervulde op de afdeling Dermatologie en Venereologie van het Erasmus 
MC te Rotterdam. Haar interesse in de Dermatologie werd bevestigd en 
spoorde haar aan om ook haar 3-maanden keuze coschap te vervullen in 
het specialisme van de Dermatologie en Venereologie, maar nu in het UMC 
St. Radboud te Nijmegen. Na het behalen van haar artsexamen in 2005 
werd zij aangenomen als junior-onderzoeker aan de afdeling Dermatolo-
gie en Venereologie van het UMC St. Radboud en werd aangevangen met 
het verrichten van onderzoek onder begeleiding van professor dr. dr. PCM 
van de Kerkhof, dr. EMGJ de Jong, dr. PEJ van Erp en dr. MMB Seyger. Het 
proefschrift dat voor u ligt is hier het resultaat van.
Sinds 1 januari 2008 is zij in opleiding tot dermatoloog in het UMC St. Rad-
boud te Nijmegen.
Op 23 juni 2007 trouwde zij met Joep van Roermund.
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DANKWOORD       “YOU MADE THE DIFFERENCE!!”
Mijn onderzoeksperiode was één groot avontuur en jullie hebben het leuk 
gemaakt! 
Na vele PASI’s, CRF’s en CRA’s maar ook na veel pipetteren, ﬂowen, over-
leggen, afstemmen, denken, schrijven en liters thee kon het samenbunde-
len van de data gaan beginnen naar het eindproduct in de vorm van het 
proefschrift dat voor u ligt. Een eindproduct waar velen een bijdrage aan 
geleverd hebben. Daar hoort een plek in de schijnwerpers bij!
Allereerst ben ik veel dank verschuldigd aan mijn promotor, prof.dr.dr. PCM 
van de Kerkhof. Beste Professor, het was altijd een feest om bij u langs te 
komen. Door uw enthousiaste en creatieve inbreng tijdens onze besprekin-
gen, leerde u mij in de loop der tijd een wetenschappelijke feeling te krij-
gen en uw enthousiasme werkte aanstekelijk…! Onderzoek doen in hèt 
grote psoriasiscentrum van Nederland was dan ook een groot genot. De 
aanwezigheid van veel expertise en kennis, maar ook de ﬁjne samenwer-
king en gemoedelijke sfeer onderling maakt het hier tot een echt weten-
schappelijk Eldorado. Bedankt voor deze ervaring. Het is een geweldige tijd 
geweest, ik had het niet willen missen.  
Daarnaast wil ik mijn copromotoren dr. MMB Seyger en dr. PEJ van Erp 
bedanken. 
Marieke, waar zal ik beginnen. Waar wij begonnen zijn…? In de periode 
van mijn oudste coschap 2005 tijdens het schrijven van een stuk voor het 
NTvDV. Door jouw juiste zet op het juiste moment is mijn promotietraject 
op de rol gekomen. Tja, wat moet je dan nog zeggen in een dankwoord… 
Simpelweg “bedankt” is wat droog, “ik ben je eeuwig dankbaar” veel te 
dramatisch. Maar je snapt dat het daar wel dichtbij ligt. Je betrokkenheid, 
enthousiasme en luisterend oor zijn een grote steun geweest, je was letter-
lijk en ﬁguurlijk altijd met 2 stappen in de buurt.
Piet, voor jouw adviezen en begeleiding hoefde ik ook altijd maar een deurtje 
verder, en die stond altijd open! Als brein achter CD26 / DPPIV heb je me vanaf 
‘scratch’ ingewijd in de wondere wereld van het lab. Erg waardevol waren 
je praktische adviezen en kritische blik naar manuscripten. Dat heb ik bij-
zonder gewaardeerd. Dank voor alles, het was ﬁjn samenwerken met je.
In de volgende plaats wil ik dr. EMGJ de Jong enorm bedanken! Mijn 
schaduw-copromotor! Elke, met raad en daad heb je me bijgestaan ge-
durende mijn hele promotietraject. Je niet aﬂatende optimisme, betrokken-
heid en steun zijn voor mij erg belangrijk geweest in het plezier wat ik heb 
ervaren tijdens mijn onderzoek. Hoe jij in oplossingen en mogelijkheden 
kan denken, daar kan menigeen nog veel van leren!
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Maar er waren nog meer die het verschil hebben gemaakt afgelopen 
jaren…
Jaap de Leeuw, jij was degene die me als eerste liet kennismaken met het 
opzetten en uitvoeren van een klinisch onderzoek in een dermatologische 
setting. Uiteindelijk heeft het geleid tot één van de artikelen dat is opge-
nomen in dit proefschrift! Dank voor de ﬁjne en gezellige samenwerking
in Rotterdam. Ik kijk er met veel plezier op terug en… kijk uit naar jouw 
promotie!
Matthijs Poll en Arjan Bergsma, dank voor jullie inzet tijdens jullie weten-
schappelijke stages over CD26  / DPPIV. Het was leuk om samen met jullie 
het pad verder te verkennen rondom de expressie van dit o-zo-veelzijdige 
eiwitje. Het heeft zeker zijn vruchten afgeworpen!
Marisol Kooijmans-Otero, onze one-and-only onderzoeksverpleegkundige. 
Dank voor de hulp en gezellige samenwerking! Samen met Rieke vormden 
we het inﬂiximab- trio waarin jij als -i- de onmisbare schakel vormde tus-
sen inﬂix (Rieke) en mab (ikke). Altijd in voor een geintje, ik heb erg met je
gelachen.
Ook mijn collega onderzoekers / ex-labgenoten wil ik danken voor de 
hulp en goede sfeer: Tsing, Patrick2, David, Mieke, Sandra, Marijke, Judith B, 
Maartje, John, Jeanette, Michelle en Haike. In het bijzonder Ivonne, Desiree, 
Diana en Roelie voor de ondersteuning bij het verwerken van biopten en 
“bloedjes”. Zonder jullie was het nooit zo vlot gegaan.
Mijn collega assistenten in opleiding en de leden van de staf wil ik bedan-
ken voor hun steun en collegialiteit. Speciﬁek mijn kamergenoten Maartje,
Jorn, Tim en Haike; het was erg belangrijk en bijdragend om met elkaar 
vooral eens nìet over dat “onderzoek doen” te praten...! Alle secretaresses, 
de fotografen, iedereen van de administratie en verplegend personeel: 
dank voor jullie hulp en interesse. “De mensen van het CHL”: dank voor jul-
lie ondersteuning met de ﬂow cytometer. Zonder patiënten was er boven-
dien niets terecht gekomen van dit proefschrift, dus ook naar hen gaat een 
woord van dank uit.
Jan Boezeman, je adviezen hebben mij geholpen wegwijs te worden in de 
wir-war van statistische toetsen. Dank daarvoor. Matthijs Poll, 2x genoemd 
worden in een dankwoord, dan moet je toch wel een verschil hebben ge-
maakt…! Dank voor het realiseren van de fraaie lay-out. We hebben er wat 
moois van gemaakt.
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Mijn vrienden en collega-dr-in-spé’s, drs. RJB Driessen en drs. HM Kroon. 
Niet voor niks heb ik jullie gevraagd voor de ceremoniële taak van een para-
nimf. Rieke, mijn onderzoeksmaat, het was erg gezellig om met elkaar in 
hetzelfde schuitje te zitten. We vaarden er wel bij en vormden een goed 
team. Bedankt voor alle adviezen maar ook gezellige mailtjes en klets-
praatjes als collega en vriendin. Hidde, mijn studiemaat, beiden meermalig 
uitgeloot en dan beginnen aan een studie geneeskunde. Van begin tot eind 
hebben we elkaar gevolgd door de studie heen, en nu ook erna. Ik waar-
deer je vriendschap enorm en ben blij dat je weer “op tijd” terug in NL bent 
om mijn paranimf te zijn. 
Dan natuurlijk, wil ik mijn dierbare (schoon)familie, Wouter, Matthia, vrien-
den en vriendinnen ontzettend bedanken voor hun belangstelling, morele 
boosts en niet aﬂatende steun. Misschien dat de Nederlandse samenvatting
enigszins helder heeft gemaakt wat ik nu afgelopen jaren heb gedaan…! 
Voor het kritisch doorlezen van mijn manuscript was ik overigens aan het 
juiste adres bij “de Harry’s”. Dank voor jullie aanvullingen en opmerkingen! 
Pauline, Willem, dank voor jullie betrokkenheid en bemoedigende woorden. 
Helaas hebben jullie dit eindproduct niet meer uit mijn handen kunnen 
ontvangen, maar ik weet dat jullie daarboven mee aan het glunderen zijn 
en het fantastisch zouden vinden. 
Lief sissie, besef dat ik net zo trots op jou ben. 
Lieve ouders, dank voor jullie niet aﬂatende vertrouwen, steun en de moge-
lijkheden die jullie tot op de dag van vandaag bieden en hebben geboden, 
en dat al bijna 30 jaar! Ik had me geen liever koppel kunnen wensen om 
onvoorwaardelijk op terug te kunnen vallen. Dit eindproduct dat voor jullie 
ligt, moet dan ook als een product van jullie gezien worden. 
Tja lieverd, en dan moet ik woorden zien te vinden om jou te bedanken. Voor 
mij heb jij hét verschil gemaakt. Relativeringsvermogen en opbeurende 
woorden kwamen onuitputtelijk van jouw kant ondanks een roerige tijd. 
Daar heb ik je ontzettend lief om, en om nog veel meer. 
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COLOUR ILLUSTRATIONS
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I. Chapter 1, paragraph 1.1.2, p. 21
Figure 1 Typical clinical presentation of psoriasis vulgaris with sharply 
delineated erythematous plaques covered by silvery white scales.
II. Chapter 1, paragraph 1.1.2, p. 22
Figure 2 Clinical pictures of patients with psoriasis unguium, psoriasis 
pustulosis (palmo)plantaris and psoriasis inversa.
III. Chapter 2, paragraph 1.2, p. 25
Figure 3 Histopathological characteristics of psoriasis. 
Top left: normal skin of healthy volunteer, Top right: psoriatic skin (both 
HE-staining). Bottom left: T-cell inﬁltrate in psoriasis (CD3; red stained),
Bottom right: Prominent vasculature in psoriasis (CD31; red stained).
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IV. Chapter 1, paragraph 1.3.2, p. 33
Figure 5 Five steps in skin homing of leukocytes.
VI. Chapter 1, paragraph 1.4.5, p. 44
Figure 7 Hypothesized position of CD26 / DPPIV in psoriasis.
V. Chapter 1, paragraph 1.4.2, p. 38
Figure 6 Various characteristics of T-cells in peripheral blood expressing 
high levels of CD26 on their surface, the CD26bright T-cells.
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VII.a Chapter 1, paragraph 1.5.3, p. 52
Figure 9 Sites of action of major biologics.
Interactions between APCs and T-cells are crucial in the pathogenesis of 
psoriasis. Several immunomodulatory biological therapies can target the 
molecules expressed on the surface of both cells. 
VII.b
Figure 9 Modes of action of major biologics.
Alefacept blocks the interaction between LFA-3 on APCs and CD2 on
T-lymphocytes. Moreover, alefacept functions as a bridging molecule be-
tween CD2 that is upregulated on CD45RO+ T-lymphocytes and the Fc y 
III receptor (CD16) on NK cells which induces apoptosis of T-lymphocytes 
through the release of granzyme by NK cells. Efalizumab blocks the in-
teraction between LFA-1 and ICAM-1 thereby inhibiting the T-cell acti-
vation and migration into the skin. Etanercept antagonizes the eﬀects
of endogenous TNF by competitively inhibiting its interactions with cell-
surface receptors. Inﬂiximab binds to and inhibits the activity of trans-
membrane-bound and soluble TNF-α with high speciﬁcity, aﬃnity and
activity. Finally, adalimumab is directed against TNF-α as well and blocks 
its interaction with the p55 and p75 cell-surface receptors thereby lysing 
the cells that express surface TNF-α. 
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IX. Chapter 1, paragraph 1.5.4, p. 61
Figure 12 Depth of penetration by diﬀerent medical lasers.
KTP=potassium titanyl phosphate; Nd= neodymium; PDL= pulsed dye 
laser; YAG= yttrium-aluminium-garnet
VIII. Chapter 1, paragraph 1.5.4, p. 61
Figure 11 Absorption spectra of tissue chromophores with wavelengths 
of medical lasers.
Nd:YAG=neodymium:yttrium-aluminium-garnet; PDL= pulsed dye laser; 
Er:YAG= erbium:YAG 
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X. Chapter 2, paragraph 2.1, p. 93
Figure 1 Fluctuations in T-cell subset counts in response to treatment 
with efalizumab or etanercept. 
(a) Signiﬁcant changes in CD markers and peripheral blood lymphocytes
in response to a 12-week treatment with efalizumab and corresponding 
Psoriasis Area and Severity Index (PASI) reduction (%). (b) Changes in CD 
markers and peripheral blood lymphocytes in response to efalizumab 
through the ﬁrst 4 weeks of treatment. (c) Changes in CD markers and 
peripheral blood lymphocytes in response to efalizumab between 4 and 
12 weeks of treatment. (d) Changes in CD markers and peripheral blood 
lymphocytes in response to a 12-week treatment with etanercept and 
corresponding PASI reduction (%). Data are shown in mean percentag-
es ± SEM. ED, epidermis; D, dermis; BL, peripheral blood; *, signiﬁcantly
changed (P < 0,05).
XII. Chapter 2, paragraph 2.3, 
p. 110
Figure 7 For each therapy, the dis-
tribution of the degree of change 
in physician’s global assessment 
score at week 13. Proportion of 
plaques (%) (n = 27).
XI Chapter 2, paragraph 2.3, 
p. 109
Figure 6 For each therapy, the 
distribution of physician’s global 
assessment-scores at baseline 
(T0) and after 13 weeks (T13) of 
treatment.
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XIII Chapter 3, paragraph 3.1, p. 129
Figure 2 Equal topographical immunohistochemical and enzyme histo-
cytometric staining of psoriatic skin vs. normal skin with CD26/dipepti-
dylpeptidase IV (DPP-IV).
(a) Immunohistochemical staining of normal skin with CD26/DPP-IV; (b) 
in psoriatic skin a clearly distinguishable column-like staining pattern in 
the suprabasal compartment in the rete ridges was observed; and (c) a 
patchy suprapapillary staining of the psoriatic epidermis extending from 
the stratum basale up to several keratinocyte layers of the stratum spino-
sum was observed. (d) In addition, a distinct focal honeycomb-like struc-
ture in the suprabasal layers of the psoriatic epidermis was noted. (e) 
The dermal reactivity for CD26/DPP-IV shows a complex staining pattern 
not suitable for a clear-cut analysis of T-cell bound CD26/DPP-IV expres-
sion in the dermis. (f,g,i) Enzyme histocytometric staining of psoriatic 
skin vs. normal skin (h) with CD26/DPP-IV (clone BA-5) revealed an equal 
topographical staining pattern compared with the immunohistochemi-
cal staining pattern of CD26/DPP-IV (a–e). (j) Enzyme histocytometric re-
activity was absent in serial sections using the DPP-IV inhibitor diprotin 
A. (k, l) Frozen sections of murine kidney were stained with CD26/DPP-IV 
as a positive control (m) and with diprotin A.
202
X
XIIXI
A
B C
D
120,00
100,00
80,00
60,00
40,00
20,00
0,00
-20,00
-40,00
-60,00
-80,00
-100,00
Response to 12-week treatment with efalizumab (%) Response to 12-week treatment with etanercept (%)
Response through ﬁrst 4 weeks of treatment with efalizumab (%) Response between 4  and 12 weeks of treatment with efalizumab (%)
PASI 0<>12
CD3 ED *
CD3 D *
CD4 ED *
CD4 D*
CD8 ED *
CD8 D *
CD8 BL *
CD25 ED *
CD25 D *
CD45RO ED *
CD45RO D*
Lymphocytes BL *
PASI 0<>12
CD3 ED
CD3 D
CD4 ED
CD4 D
CD8 ED
CD8 D *
CD25 ED
CD25 D *
CD45RO ED *
CD45RO D*
Lymphocytes BL
PASI 0<>12
PASI 0<>4
CD3 ED 
CD3 D *
CD4 ED
CD4 D*
CD8 ED *
CD8 D *
CD8 BL *
CD25 ED *
CD25 D *
CD45RO ED *
CD45RO D*
Lymphocytes BL *
PASI 0<>12
PASI 4<>12
CD3 ED 
CD3 D
CD4 ED
CD4 D*
CD8 ED
CD8 D
CD8 BL
CD25 ED
CD25 D *
CD45RO ED *
CD45RO D*
Lymphocytes BL
120,00
100,00
80,00
60,00
40,00
20,00
0,00
-20,00
-40,00
-60,00
-80,00
-100,00
120,00
100,00
80,00
60,00
40,00
20,00
0,00
-20,00
-40,00
-60,00
-80,00
-100,00
120,00
100,00
80,00
60,00
40,00
20,00
0,00
-20,00
-40,00
-60,00
-80,00
-100,00
203
XIII
204
XIV. Chapter 3, paragraph 3.1, p. 131
Figure 3 Phenotyping of CD26+ T cells in lesional psoriatic (epi)dermis 
using the Zenon immunoﬂuorescence labelling technique.
Sections of lesional psoriatic skin were double stained using direct im-
munoﬂuorescence labelling for CD3 and CD26/dipeptidyl-peptidase IV
(DPP-IV). (a) Costaining of CD3 (green) and CD26 (red) in lesional psori-
atic skin revealed colocalization of these two proteins (merge; yellow) in 
the dermis (inset). (b) Monoclonal anti-CD26 antibody. (c) Monoclonal 
anti-CD3 antibody. (d) DAPI counterstaining of nuclei. (e, f) Colocaliza-
tion of CD3 (green) and CD26 (red) was also evident in lesional psoriatic 
epidermis (merge; yellow).
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XVI. Chapter 3, paragraph 3.2, p. 138
Figure 1 Expression of DPPIV protein expression, enzyme activity, Kera-
tin 16 and Ki-67 throughout the margin zone of a psoriatic lesion com-
pared to normal skin. 
Plaque centre, inner margin, clinically uninvolved skin (UIS): x200 magni-
ﬁcation. Healthy volunteers skin (HV): x100 magniﬁcation. Noticeably, in
the skin of healthy volunteers the DPPIV enzymeactivity staining creates 
a brownish background staining.
XVII. Chapter 3, paragraph 3.4, p. 154
Figure 2 Phenotyping of CD8+CD26+ T-cells in lesional psoriatic epider-
mis using the Zenon immunoﬂuorescence double-labeling technique.
(Top panel) Costaining of CD8 (green) and CD26 (red) in lesional psoriatic 
skin revealed colocalization of these two proteins (merge; yellow) in the 
epidermis (white arrows). (Panel below) Overview of mean changes in re-
spectively the percentage of (epi)dermal double-labeled CD3+CD26+ T-
cells, and the percentage of (epi)dermal double-labeled CD8+CD26+ T-cells 
during treatment with inﬂiximab. T= timepoint in weeks, ED=epidermis,
D=dermis. Error bars indicate standard error of the mean.
XV. Chapter 2, paragraph 2.4, p. 118
Figure 2: A) Results for the clinical eﬃcacy of treatment with CBD-oint-
ment and the Nd:YAG laser compared to no treatment (No Tx) reﬂected in
mean SUM-scores. 
B) Results for experienced pain during Nd:YAG treatment with diﬀerent
spotsizes reﬂected in mean VAS-scores. The VAS-scores at the diﬀerent
points in time are taken together. Error bars indicate the Standard Error of 
the Mean.
 * = signiﬁcantly decreased compared to baseline (p<0.05).
** = signiﬁcantly increased compared to week 12 (p<0.05).
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